Page last updated: 2024-12-05

triclosan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5564
CHEMBL ID849
CHEBI ID164200
SCHEMBL ID3269
MeSH IDM0021945

Synonyms (587)

Synonym
MLS001066347
smr000471847
S00100
triclosan; irgasan
5-chloro-2-(2,4-dichlorophenoxy)phenol
ch 3565
lexol 300
2-hydroxy-2',4,4'-trichlorodiphenyl ether
stri-dex face wash
triclosanum [inn-latin]
einecs 222-182-2
brn 2057142
c12h7cl3o2
stri-dex cleansing bar
phenyl ether, 2'-hydroxy-2,4,4'-trichloro-
2,4,4'-trichloro-2'-hydroxydiphenyl ether
hsdb 7194
phenol, 5-chloro-2-(2,4-dichlorophenoxy)-
irgasan dp300
2,4,4'-trichloro-2'-hydroxy diphenyl ether
caswell no. 186a
ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl
epa pesticide chemical code 054901
cloxifenolum
dp-300
bdbm8726
chembl849 ,
TCL ,
irgasan
stri-dex cleansing bar (tn)
D06226
triclosan (usp/inn)
TCS ,
3380-34-5
triclosan ,
5-chloro-2-(2,4-dichlorophenoxy)phenol, 97%
NCGC00159417-02
NCGC00159417-03
NCGC00159417-04
sapoderm
aquasept
MLS001074876
MLS001335937
MLS001335938
irgasan, >=97.0% (hplc)
AC-10667
HMS2093L17
5-chloro-2-(2,4-dichloro-phenoxy)-phenol
CHEBI:164200 ,
triclosanum
ch-3565
cloxifenol
dndi1246774
nsc-759151
DB08604
T1872
NCGC00159417-05
NCGC00159417-07
NCGC00159417-06
HMS3259K19
nsc 759151
neostrata antibacterial facial cleanser
ccris 9253
4nm5039y5x ,
triclosan [usan:usp:inn:ban]
unii-4nm5039y5x
dtxcid3012498
cas-3380-34-5
dtxsid5032498 ,
tox21_400079
tox21_111648
2-[2,4-bis(chloranyl)phenoxy]-5-chloranyl-phenol
A821950
BRD-K41731458-001-09-4
nsc759151
pharmakon1600-01505465
HMS2270M06
S4541 ,
FT-0609773
NCGC00159417-08
triclosan [usp monograph]
triclosan [vandf]
triclosan [orange book]
triclosan [inci]
triclosan [mi]
triclosan [who-dd]
triclosan [hsdb]
triclosan [usp-rs]
colgate total component triclosan
triclosan [inn]
triclosan component of colgate total
triclosan [mart.]
triclosan [usan]
EPITOPE ID:119683
AKOS015850380
CCG-213459
5-chloro-2-(2,4-di-chloro-phenoxy)-phenol
NC00516
SCHEMBL3269
tox21_111648_1
3P9T
1NHG
CS-4718
F2173-0825
Q-201866
triclosan, antibiotic for culture media use only
ch-3635
sterzac
dp 300
KS-5356
HY-B1119
AB00698074_08
mfcd00800992
4W9N
STL451034
triclosan, certified reference material, tracecert(r)
SR-01000762974-3
sr-01000762974
SR-01000762974-2
triclosan, united states pharmacopeia (usp) reference standard
triclosan, pharmaceutical secondary standard; certified reference material
triclosan 10 microg/ml in cyclohexane
SBI-0206807.P001
HMS3715H11
irgasan dp 30
5-chloro-2-(2, 4-dichlorophenoxy)phenol
Q408646
BRD-K41731458-001-04-5
HMS3872N03
D70549
2,4,4'-trichloro-2'-hydroxydiphenylethe
EN300-1272333
dalan therapy antibacterial and odor neutralizer
antibacterial foamingcomplete
personal care antibacterial foaming hand wash
bacti-free tmantibacterial hand
d09aa06
pacific anti-bacterial hand cleanse peach essence
rite aid renewalantibacterial
health-stat foam
antibacterial foamingplumeria
tricolsan
prevens
antibacterial foaming hand sp lemongrass
purgo satin foam
equatespring showers antibacterial
health smart antibacterial cucumber melon
antibacterialwith light moisturizers
antibac foam wash
antibacterial foaming hand sp cucumber and melon
simply rightantibacterial
hand guard foaming antimicrobial
topcareantibacterial foaming
lever 2000 antibacterial
hfs antimicrobial foam hand so ap with triclosan-triclosan liquid
holiday elegance
hill country essentialslavender and jasmine
antibacterial foamingpear scent
bodycologywhite gardenia
xtracare antibacterial hand cleanseoriginal
pier 1 imports cool watermelon anti-bacterial hand washn/a
triclosan, 0.30%
dt antibacterial hand
antibacterial foamingoriginal
antibacterial foamingfresh pear
auroraantibacterial vanilla brown sugar
antibacterial gel hand wash
soft care foaming antibacterial hand
auroraantibacterial basil key lime
antibacterial foamingcucumber melon
antibacterial hand-ocean fresh scent
fredsantibacterial fresh pear
antibacterial hsoapfresh and light scent-refill
ecocare 250
irgasan dp-300r
tork premium
triclosanum (inn-latin)
antibaceterial hand soap golden sunflower
dial pomeganate and tangerine antibacterial soapwith moisturizer
antibacterial foaminggreen tea
rite aidantibacterial
publix ultradish detergent green apple scent
antibacterial foamingolive and aloe
antibacterial hand soapfor sensitive skin
hand cleansecitrus blast scent
dial complete antibacterial foaming hand wash with lotionfresh pear with lotion
clean and refreshing body washspring fresh
anti-bacterial fresh aloe hand
dial mountain fresh antibacterial soapwith moisturizers
dalan golden tropics antibacterial deodorant
pear blossom antibacterial gel hand wash
dial clear and refresh antibacterial hand soapclear
all day freshness antibacterial body wash with moisturizer
my essentials citrus scent
royal antibacterial tropical fruit hand cleanse
kiwi crate liquid hand
kindest kare antimicrobial foaming handwashhealthcare personnel handwash
royal antibacterial (apple and pear) moisturizing hand cleanse
dial complete antibacterial foaming hand wash with lotiongentle on skin, frosted pear with lotion
care one antibacterial foaming hand soapgreen tea
dial complete antibacterial foaming hand wash with lotionoriginal scent, gentle on skin
satin pink
home 360 ultra dish detergent green apple scent
orchid by h e bwhite lavender and mint
dg bodyantibacterial hand
hand antibacterial premium
anti-bacterial hand wash
dg bodyantibacterial
foaming antimicrobial
smith and johnson antibacterial
triclosan (usp monograph)
simply rightsparkling mist
hand wash nettoyant pour les mains citrus cilantronone
piranha brand foaming antibacterial hand
antibacterial hand-aloe vera
wegmansantibacterial cucumber melon
foaming antibacterial
antibacterialcucumber melon
deluxe dish detergent
antibacterial mandarin and grapefruit handsoapgentle cleansing formula
pier 1 imports warm vanilla anti-bacterial hand washn/a
cardinal health antimicrobial soap with triclosan
antibacterial body washmoisturizing
simply right body care
medspa antibacterial bar
pier 1 imports citrus and sunflowers anti-bacterial hand washn/a
aromafields lavender scented antibacterial hand wash
gojo antibacterial plum scent foam handwash triclosan liquid
pro advantage antibacterial
healing waters cucumber mint antibacterial hand soap
antibacterial bar
aire-masterfoaming ab handsoap
health care personnel handwash
bobbarker antibacterial bar
clean and refresh body washmoisturizing
dial gold antibacterial soapwith moisturizer
le techniqmorning mist antibacterial hand
personal care antibacterial hand-fresh melon
rite aidliquid
wegmans
foaming hand wash antibacterial
skintegrity antibacterial handblue
lucky supersoft antibacterialhand
antibacterial foamingpomegranate
dalan antibacterial deodorant spring freshness
ben e. keithantibacterial hand cleaner
antibacterial amber hand soap
pier 1 imports ocean water anti-bacterial hand washn/a
naturals cucumber and melonanti bacterial hand
cactus flower and mango antibacterial deep cleansing hand sp
triclosan 0.46%
stoko refresh
theochem white tea hand and body wash
therazcream
white tea hand and body wash
price chopperpumpkin spice antibacterial foaming
wegmansantibacterial with moisturizers
anti-bacterial foaming
naturals pomegranate and mangoanti-bacterial hand
handtastic foamy mango
ecosave grapefruit and lemongrass soap antibacterial hand soap
shop rite ultra so-soft
cvs phramacy antibacterialmelon
pier 1 imports lily flower anti-bacterial hand washn/a
clario foaming antibacterial skin cleanser
antibacterial foamingcranberry
safeway carerefill
proformance series antibacterial
husky 575 foaming antiseptic hand cleaner
deb gold
panacheantibacterial body wash
harris teeterantibacterial
auroraantibacterial japanese flower garden
white tea antibacterial
soft care foam antibacterial hand soap
bodycologycherry blossom
servo-stat t
foaming antibacterialplumeria
jisberry antibacterial handlotion
dalan ocean breeze antibacterial deodorant
perfect purity antibacterial gold
dial complete antibacterial foaming hand wash with lotioncool plum, gentle on skin
pier 1 imports sweet orange anti-bacterial hand washn/a
soft care foam select antibacterial triclosan
dalan covex antibacterial deodorant soft hygiene
cvs pharmacymandarin citrus
hand cleanserefill
bodycologycucumber melon
orchid by h e bcactus flower and mango antibacterial gentle foaming hand
liquid nature antibacterial hand soap
prevail pomegranate scented antibacterial hand
topcareantibacterial fresh pear
hand cleansefresh peach scent
clearskinpore penetrating cleanser
antibacterial foaming
servo-stat te
proformance antibacterial
berkley jensen hypoallergenic antibacterial hand soap soapenriched with vitamin e and aloe vera moisturizers
chinese herb essence bacteriostatic foaming agent
gold antibacterial hand soap with moisturizer
aromafields plumeria scented antibacterial hand wash
image essentialsantibacterial
studio 35spring morning
holiday elegancefrosted gingerbrefrosted gingerbread
hand cleanse-strawberry pomegranate
lucky antibacterial hand soapsupersoft
oil free foaming facial cleanser
antibacteriallight moisturizers refill
health smart antibacterial sweet pea orchid
xtracare foaming facial cleanser
equalineliquid
purgo ultra foam
bodycology peppermint sugar anti-bacterial scrubbing hand soap
sparkling mistantibacterial cleanser with moisturizers
antibacterialfresh pear
aromafields plumeria scented anti-bacterial hand
1014 foaming antimicrobial
fresh citrus
orchid by h e bantibacterial hand white lavender and mint
healing waters sweet pea antibacterial hand soap
thera rx
antibacterialpamegranate apple
antibacterial citrus fresh
mango madness anti bacterial foaming hand
caribbean escape anti bacterial foaming hand
dignity health medspa antibacterial
pacific anti-bacterial hand cleanse blueberry essence
anti-bacterial bubble gum hand
anchor foaming mango
dermacen foaming antimicrobial-t hand
ecosave lavender antibacterial hand soap
rite aidfoaming hand
antibacterial hand soapwith light moisturizers
antibacterial foaming hand sp cherry and almond
topcoantibacterial
pier 1 imports coconut breeze anti-bacterial hand washn/a
aeroscent milk and honey antibacterial moisturizing
jabonito fresh
cvs pharmacypear white tea
fresh picked strawberries anti bacterial foaming hand
hand cleanse-ocean fresh
antibacterialcitrus coconut
aromafields jasmine scented antibacterial hand wash
quiksan
nutri vetmedicated dog
triclotrex-bantibacterial (neutral)
triclosan (usan:usp:inn:ban)
meijerantibacterial foaming
medicated soft n surehealthcare personnel handwash
le techniqspring fresh
spasoap liquid antibacterial
antibacterialsunblossom
antibacterial foaming hand cleanser
aromafields lavender scented anti-bacterial hand
pacific anti-bacterial hand cleanse kiwi essence
image essentialsantibacterial hand gold
signature care antibacterial foaming moisturizing
antibacterial foamingpear
hand wash nettoyant pour les mains plum grapefruitnone
nu skinantibacterial body cleansing
usepa/opp pesticide code: 054901
dermaprottriclotrex-b
healthy accents antibacterial body washspring fresh
lysol i.c.antimicrobial
dial mountain fresh antibacterial body wash
triclosan (mart.)
foamy mango
bebelle for kids antibacterial hand
dial complete antibacterial foaming hand washholiday line holiday lineholiday line
xtracare antibacterial hand cleanse
natural extensions antibacterial foaming hand wash
protect antibacterial bar
enmotionantimicrobial with moisturizers, tranquil aloe, green
antibacterial hand sp with light moisturizers
dalan antibacterial deodorant ocean breeze regenerating
scott clear antibacterial skin cleanser
dial complete antibacterial foaming hand washhello kitty
white lavendar and mint antibacterial gentle foaming hand sp
antibacterial body washspring water 2 in 1
le techniq antibacterialvanilla brown sugar
shopko antibacterial deep cleansing hand
harris teeterfoaming
dermacen antimicrobial-t hand
debmed antimicrobial body wash and shampoo
ecosave japanese cherry blossom soap antibacterial hand soap
tc enrichedlotionantibacterial hand wash
astound antibacterial
dial spring water antibacterial soapwith moisturizer
antibacterialmandarin and pomelo
antibacterialrefill
foaming antibacterial hand soap with aloe and vitamin e
body washclear spring
sbs ultragreen
healing waters mandarin vanilla antibacterial hand soap
health smart antibacterial original
rite aid renewalpear
safeway home orange scent
anti-bacterial moisturizing handpumpkin caramel latte
roccos old school tattoo balmanti bacterial wash
orchid
antibacterial foamingrefill
signature care antibacterial foaming hand pear scent
image essentialsantibacterial gold
lemon zest antibacterial hand
deluxe all-purpose
pier 1 imports sweet cherry anti-bacterial hand washn/a
pacific gardenantimicrobial, fragrance free, dye free
rite aid renewalwhite tea
antibacterialfoaming
candy apple anti bacterial foaming hand
dalan antibacterial deodorant ocean breeze
publix ultradish detergent
dial country orchard antibacterial soapwith moisturizer
instant hand sanitizing spray with aloe vera
stoko refresh 4in1 food handler foam
personal care antibacterial hand-raspberry
careonevanilla brown sugar
le techniqfoaming antibacterial hand
aromafields tiger lily scented antibacterial hand wash
simply right body careantibacterial
dalan spring freshness antibacterial deodorant
spasoap liquid antibacterial 2x ultra
cvs antibacterial foamingkitchen
wegmans orange scent
dalan covex antibacterial deodorant natural hygiene
pier 1 imports sweet grape anti-bacterial hand washn/a
health smart antibacterial spring rain
antibacterial foamingberry medley
natural extensions antibacterial liquid hand wash
health stat
dial complete antibacterial foaming hand wash with lotionsoothing white tea, gentle on skin
hand wash nettoyant pour les mains orange pekoenone
rite aid renewalantibacterial clear spring
ecolabdigiclean
hill country essentialsantibacterial foaming
antibacterial hand sp with light moisturizers refill
antibacterial foaming hand spclean and mild
antibacterial liquid soap refill
prevail lemongrass scented antibacterial hand
antibacteriallight moisturizers
royal antibacterial (coconut and lime) moisturizing hand cleanse
dalan antibacterial deodorant golden tropics
dial complete antibacterial foaming hand wash with lotioncranberry with antioxidants
cotton candy anti bacterial foaming hand
source antibacterial foaming hand original
soft care foam select antibacterial hand
scott antibacterial
dalan covex antibacterial deodorant maximum hygiene
fu er jie
red apple antibacterial hand
orchid by h e bantibacterial moisturizing vanilla and apple blossom
natural concept body washspring breeze
pacific
royal antibacterial raspberry hand cleanse
dial complete antibacterial foaming hand wash with lotionclean citrus, gentle on skin
xtracare antibacterial hand cleansemountain spring
personal care antibacterial hand
safeway home lemon scent
anti-bacterial lemon drop hand
moisturizing anti-bacterial hand soap
enmotionantimicrobial with moisturizers, fragrance free, dye free
cactus flower and mango antibacterial gentle foaming hand sp
spa originals antibacterial gold hand
bodycology white gardenia anti-bacterial scrubbing hand soap
simple pleasuresantibacterial foaming hand
antibacterialmandarin and grapefruit
royal antibacterial orange berry hand cleanse
dt antibacterial foaming hand wash
family dollar antibacterial hand
vanilla cream and apple blossom antibacterial moisturizing hand sp
raggedy ann and andycotton candy
simply right body caresparkling mist
freshands
aromafields jasmine scented anti-bacterial hand
lynx medi foam
triclosano
le techniqpear
image essentialsspring fresh
aromafields tiger lily scented anti-bacterial hand
triclosan (usp-rs)
pear barlet antibacterial hand
sbs ultrapink
zep professional healthcare worker
deb med antibacterial foam hand wash
pier 1 imports granny smith apple anti-bacterial hand washn/a
gojo antibacterial foam handwash triclosan liquid
xtracare antibacterial hand cleansefresh citrus
antibacterial hand cleanse
antibaceterial hand soap rose
exchange select ultra citrus scent
essential everyday orange scent
servo-stat t foam
royal antibacterial passion plum hand cleanse
orchidcactus flower and mango
hand cleanse
triclosanum (latin)
antibacterial hand-strawberry pomegranate scent
careoneantibacterial
our family dish and antibacterial citrus burst scent
aire-masterantibacterial liquid handsoap
vanilla cream
dial complete antibacterial foaming hand washwhite tea and vitamin e
dial aloe antibacterial soapwith moisturizer
germicidaantimicrobial
soft care neutra germ antibacterial
antibacterialfor the kitchen
dial lavender and twilight jasmine antibacterial body wash
soft care foam antibacterial hand
kooboos instant hand sanitizer
equateantibacterial foaming
holiday elegancepeppermint twist peppermint twistpeppermint twist
auroraantibacterial apple summer berry
antibaceterial hand soap lavender
irgaguard b1000
xtracare antibacterial hand cleansestrawberry pomegranate
dermacare
image essentialsantibacterial hand mandarin and grapefruit
antibacterial foamy mango
germasidol
cvs pharmacyantibacterial
personal care oil free foaming facial cleanser
wegmansantibacterial
white lavender and mint antibacterial moisturizing hand sp
royal antibacterial (coconut and lime)
royal antibacterial (mango)
dial complete antibacterial foaming hand wash with lotioniced cranberry, gentle on skin
rite aid renewalclear spring
antibacterialpassion flower
anti-bacterial blue raspberry hand
tc enrichedfoamantibacterial
holiday elegancefrosted gingerbrefrosted gingerbrefrosted gingerbread
naturalsantibacterial liquid soap vanilla
shopko antibacterial foaming hand sanitizer
auroraantibacterial coconut tropical island
pacific gardenantimicrobial, pacific citrus, mandarin
antibacterialmandarin
dial complete antibacterial foaming hand washkitchen crisp limkitchen crisp limkitchen crisp lime
tc spraysoap
provon medicated ltion s oap with triclosan
personal care antibacterial hand-fresh peach
cv medicated
forest fresh
foaming antiseptic hand cleaner
prevail white tea scented antibacterial hand
health smart antibacterial lavender chamomile
softone luxury foam antibacterial skin cleanser
hill country essentialsantibacterial
antibacterial clean and smoothgentle skin cleanser
foaming antibacterialcucumber melon
pacific anti-bacterial hand cleanse strawberry essence
family dollarfoaming antibacterial hand wash
vanilla cupcake anti bacterial foaming hand
noxzemabacteria fighting cleanser
raggedy ann and andytropical breeze
elf milk and honey cleansing anti-bacterial hand
triclotrex-bantibacterial
foaming antibacterialpear
gojo e2 foam sanitizing so ap
antibacterialsparkling mist
purgo ultra
simple pleasuresantibacterial hand
soft care neutra-germ antibacterial fragrance free
reeva antibacterial green apple
bodycology sparkling cranberry anti-bacterial scrubbing hand soap
stoko refresh food handler foam
soft care neutra germ fragrance free antibacterial
cvs pharmacyclean antibacterial
shopko antibacterial foaming hand cleanser
dial white tea and vitamin e antibacterial hand soap
jasmine tea and basil antibacterial hand sp
market basket ultra
ez foam 6793
wegmans ultra dishwashing orange scent
island spring antibacterial body washwith moisturizers
d08ae04
powerhouse fresh scent ultra dish
dial tropical escape antibacterial body wash
anti-bacterial strawberry kiss hand
antibacterial hand-vanilla brown sugar
soft care antiseptic skin cleanser ii
jasmine rose hand wash nettoyant pour les mainsnone
liquid hand cleanse
bodycologycoconut lime
bodycology white gardenia anti-bacterial foaming hand soap
hand cleansewater melon scent
hand wash nettoyant pour les mains vallina tuberosenone
mandarin orange antibacterial hand

Research Excerpts

Overview

Triclosan (1) is a slow, tight-binding inhibitor of FabI, interacting specifically with the E.NAD(+) form of the enzyme with a K(1) value of 7 pM. Triclosan is a widely used biocide against microorganisms and is ubiquitously distributed in the environment.

ExcerptReferenceRelevance
"Triclosan (1) is a slow, tight-binding inhibitor of FabI, interacting specifically with the E.NAD(+) form of the enzyme with a K(1) value of 7 pM."( Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
Cui, G; Johnson, F; Novichenok, P; Simmerling, C; Sivaraman, S; Sullivan, TJ; Tonge, PJ, 2004
)
1.3
"Triclosan is a potent inhibitor of Toxoplasma gondii enoyl reductase (TgENR), which is an essential enzyme for parasite survival. "( Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
Afanador, GA; Auschwitz, JM; Cheng, G; Fomovska, A; Hickman, MR; Lai, BS; Lee, PJ; Leed, SE; McLeod, R; Muench, SP; Mui, EJ; Prigge, ST; Rice, DW; Roberts, CW; Woods, S; Zhou, Y, 2013
)
1.83
"Triclosan is an antimicrobial chemical used in healthcare settings that can be absorbed through the skin. "( Dermal Exposure to the Immunomodulatory Antimicrobial Chemical Triclosan Alters the Skin Barrier Integrity and Microbiome in Mice.
Anderson, SE; Baur, R; Gandhi, J; Hu, G; Lukomska, E; Marshall, NB; Shane, HL; Weatherly, LM, 2021
)
2.3
"Triclosan (TCS) is an antimicrobial and antimycotic agent widely used in personal care products. "( Multibiomarker responses in Danio rerio after exposure to sediment spiked with triclosan.
Loughlin, TM; Marino, D; Rossi, A; Sager, E; Torre, F, 2021
)
2.29
"Triclosan is a widely used biocide against microorganisms and is ubiquitously distributed in the environment. "( Distinct uptake and accumulation profiles of triclosan in youdonger (Brassica campestris subsp. Chinensis var. communis) under two planting systems: Evidence from
Akhtar, K; Chen, Y; Lu, Y; Nie, E; Riaz, M; Wang, H; Ye, Q; Yu, Z; Zhang, S, 2022
)
2.42
"Triclosan (TCS) is a phenolic compound with broad-spectrum antimicrobial action that has been incorporated into a variety of personal care products and other industry segments such as toys, textiles, and plastics. "( Developmental and Reproductive Outcomes in Male Rats Exposed to Triclosan: Two-Generation Study.
Anselmo-Franci, JA; Costa, NO; Forcato, S; Gerardin, DCC; Montagnini, BG; Monteiro, MC; Moreira, EG; Pereira, MRF; Pernoncine, KV, 2021
)
2.3
"Triclosan (TCS) is a broad-spectrum antimicrobial agent commonly used in pharmaceuticals and personal care products (PPCPs). "( Research on freshwater water quality criteria, sediment quality criteria and ecological risk assessment of triclosan in China.
Hou, Y; Liu, X; Tu, M; Wang, J; Wang, S; Wang, Y; Yan, Z; Zheng, X, 2022
)
2.38
"Triclosan (TCS) is an organic substance showing antibacterial action, which is commonly used in many branches of industry, including, among others, cosmetics, pharmaceuticals and the food industry. "( The Presence of Triclosan in Human Hair Samples in Poland-A Pilot Study.
Gonkowski, S; Makowska, K; Tsatsakis, AM; Tzatzarakis, M; Vakonaki, E; Wojtkiewicz, J, 2022
)
2.51
"Triclosan is an antimicrobial chemical present in consumer products that is frequently detected in aquatic environments. "( Triclosan uptake and transformation by the green algae Euglena gracilis strain Z.
Flick, R; Lam, KY; Noble, AJ; Passeport, E; Yu, ZH, 2022
)
3.61
"Triclosan is a broad-spectrum antibacterial agent and widely exists in environmental media and organisms. "( Preimplantation triclosan exposure alters uterine receptivity through affecting tight junction protein†.
Dong, G; Du, G; Lu, C; Qin, Y; Sun, R; Wang, X; Xia, Y; Zhang, R, 2022
)
2.51
"Triclosan (TCS) is a widely used synthetic antibacterial compound with ubiquitous human exposure. "( Association between triclosan exposure and obesity measures among 7-year-old children in northern China.
Ao, J; Ding, G; Gao, Y; Hu, Y; Lv, C; Tian, Y; Xia, Y; Yu, X; Yuan, T; Zhang, Q; Zhang, Y, 2022
)
2.49
"Triclosan (TCS) is an antimicrobial agent, which participates in the process of multiple human diseases, including spontaneous abortion."( Triclosan activates c-Jun/miR-218-1-3p/SLC35C1 signaling to regulate cell viability, migration, invasion and inflammatory response of trophoblast cells in vitro.
Cao, T; Chen, T; Hou, S; Huo, W; Shi, Z; Wang, Y; Zhang, Y, 2022
)
2.89
"Triclosan is an antibacterial agent suspected to disrupt the endocrine system. "( The Influence of Triclosan on the Thyroid Hormone System in Humans - A Systematic Review.
Feldt-Rasmussen, U; Homburg, M; Ramhøj, L; Rasmussen, ÅK, 2022
)
2.5
"Triclosan (TCS) is a broad-spectrum antimicrobial agent widely used in personal care, healthcare, and clinical practice. "( Effect of Triclosan and Silver Nanoparticles on DNA Damage Investigated with DNA-Based Biosensor.
Blaškovičová, J; Labuda, J, 2022
)
2.57
"Triclosan (TCS) is an antibacterial compound used mainly in personal care products. "( Effect of triclosan exposure on ovarian hormones, trace elements and growth in female rats.
Alanis, C; Arismendi, D; Paredes, AH; Richter, P, 2022
)
2.57
"Triclosan is an antimicrobial agent added in pharmaceuticals and personal care products."( Reduced graphene oxide accelerates the dissipation of
Chen, Y; Lu, Y; Nie, E; Wang, H; Xu, L; Ye, Q; Yu, Z; Zhang, S, 2022
)
1.44
"Triclosan is a broad-spectrum antimicrobial, and was thought to affect intrauterine development, but the mechanism remains unclear."( Multiple mediation effects on association between prenatal triclosan exposure and birth outcomes.
Cao, Y; Chang, X; Dai, Y; Guo, J; Liang, W; Lu, D; Lv, S; Qi, X; Wang, Z; Wu, C; Zhang, J; Zhang, L; Zhou, Z, 2022
)
2.41
"Triclosan (TCS) is a ubiquitous antimicrobial used in daily consumer products. "( Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders.
Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023
)
2.68
"Triclosan (TCS) is a widespread antimicrobial agent that is associated with many adverse health outcomes. "( Microbiota-mediated reactivation of triclosan oxidative metabolites in colon tissues.
Cai, Z; Haggerty, TD; Hu, C; Lin, Y; Parsonnet, J; Sanidad, KZ; Wang, G; Zhang, G; Zhang, H; Zhang, J; Zhang, R; Zheng, Y, 2023
)
2.63
"Triclosan is an anti-microbial chemical incorporated into products that are applied to the skin of healthcare workers. "( Exposure to the anti-microbial chemical triclosan disrupts keratinocyte function and skin integrity in a model of reconstructed human epidermis.
Anderson, SE; Baur, R; Kashon, M; Lukomska, E; Shane, HL; Weatherly, LM, 2023
)
2.62
"Triclosan (TCS) is a commonly used antibacterial agent present in personal care and household products. "( Prenatal triclosan exposure impairs mammalian lung branching morphogenesis through activating Bmp4 signaling.
Ge, H; Li, Q; Qiao, Y; Wang, F; Wu, L; Xu, S; Zhao, J, 2023
)
2.77
"Triclosan (TCS) is an antiseptic incorporated in consumer goods and personal care products that can be absorbed via the skin, raising public health concerns for its continuous detection in human biofluids and tissues. "( Long-term percutaneous triclosan exposure induces thyroid damage in mice: Interpretation of toxicity mechanism from metabolic and proteomic perspectives.
Cai, Z; Dai, Q; Lei, B; Li, L; Liang, Y; Xie, G; Yang, Z; Zhang, H, 2023
)
2.66
"Triclosan is an antimicrobial agent that has been used in common household products and can be detected in water environment. "( Environmentally relevant concentrations of triclosan induce lethality and disrupt thyroid hormone activity in zebrafish (Danio rerio).
Horie, Y, 2023
)
2.62
"Triclosan (TCS) is an antimicrobial agent and frequently detected in wastewater or water body. "( Insights into roles of triclosan in microalgal-bacterial symbiosis system treating wastewater.
Gan, Z; He, ZW; Li, ZH; Tang, CC; Varrone, C; Wang, R; Wang, TY; Wang, XC, 2023
)
2.66
"Triclosan (TCS) is an antibacterial agent that often co-exists with SUC in personal care products and sewage environments."( Insight into the evolution of microbial communities and resistance genes induced by sucralose in partial nitrification system with triclosan pre-exposure.
Cui, Y; Fu, X; Gao, J; Wang, Z; Xu, H; Yuan, Y; Zeng, L; Zhao, Y, 2024
)
2.37
"Triclosan (TCS) is an antimicrobial agent used in many personal care and cleaning products. "( Occurrence and removal of triclosan in Canadian wastewater systems.
Albert, A; Gewurtz, SB; Guerra, P; Shah, A; Smyth, SA; Teslic, S, 2019
)
2.26
"Triclosan (TCS) is a kind of chronic toxicity to aquatic organisms. "( A novel strategy for selective removal and rapid collection of triclosan from aquatic environment using magnetic molecularly imprinted nano-polymers.
Cao, M; Lu, YC; Mao, JH; Wang, C; Wang, KY; Wang, XD; Xiong, XH; Zhang, W, 2020
)
2.24
"Triclosan (TCS) is a chlorophenol which is highly bacteriostatic and used in a wide array of consumer products. "( Salicylic acid application alleviates the adverse effects of triclosan stress in tobacco plants through the improvement of plant photosynthesis and enhancing antioxidant system.
Guan, C; Ji, J; Jin, C; Li, Q; Wang, C; Wang, G; Wu, H; Zhang, Y, 2020
)
2.24
"Triclosan is an antimicrobial compound with direct links to antibiotic resistance that was widely used in soaps in the U.S."( Benzalkonium chloride alters phenotypic and genotypic antibiotic resistance profiles in a source water used for drinking water treatment.
Harrison, KR; Kappell, AD; McNamara, PJ, 2020
)
1.28
"Triclosan (TCS) is an antibacterial and antifungal compound found in many hygiene products, including toothpaste, soap, and detergents. "( In vitro metabolism of triclosan studied by liquid chromatography-high-resolution tandem mass spectrometry.
Guesmi, A; Sleno, L, 2020
)
2.31
"Triclosan (TCS) is a broad-spectrum antibacterial and anti-fungal agent used in a broad variety of personal care products (PCPs) throughout the world. "( Effects of triclosan on antioxidant- and apoptosis-related genes expression in the gill and ovary of zebrafish.
Liu, F; Wang, F; Zheng, F, 2020
)
2.39
"Triclosan (TCS) is a personal care product widely used as an antiseptic or preservative in cosmetics, hand wash, toothpaste and deodorant soaps."( Potential formation of PCDD/Fs in triclosan wastewater treatment: An overall toxicity assessment under a life cycle approach.
Aldaco, R; Irabien, A; Laso, J; Margallo, M; Ortiz, I; San-Román, MF; Schröder, S; Solá-Gutiérrez, C; Vázquez-Rowe, I, 2020
)
1.56
"Triclosan is an emerging contaminant, commonly used as antibacterial agent in personal care products."( Emerging organic contaminants in wastewater: Understanding electrochemical reactors for triclosan and its by-products degradation.
Magro, C; Mateus, EP; Paz-Garcia, JM; Ribeiro, AB, 2020
)
1.5
"Triclosan (TCS) is a synthetic antimicrobial compound that has been widely used in consumer products. "( Rapid capture and SERS detection of triclosan using a silver nanoparticle core - protein satellite substrate.
He, L; Mills, AJ; Qu, Y; Yang, T; Zhang, G; Zhao, B, 2020
)
2.28
"Triclosan (TCS) is a potent antibacterial and antifungal compound that is extensively used in various daily products. "( miR-142-5p/DAX1-dependent regulation of P450c17 contributes to triclosan-mediated testosterone suppression.
Duan, P; Ha, M; Huang, X; Li, L; Liu, C, 2020
)
2.24
"Triclosan is an antimicrobial agent that is ubiquitously present in water, biosolids and soil. "( Uptake, translocation and accumulation of
Chen, Y; Gao, X; Nie, E; Wang, H; Ye, Q, 2020
)
2
"Triclosan (TCS) is an antimicrobial compound ubiquitously found in surface waters throughout the world. "( Tracking photodegradation products and bond-cleavage reaction pathways of triclosan using ultra-high resolution mass spectrometry and stable carbon isotope analysis.
Carena, L; Gligorovski, S; Jin, B; Liu, Y; Mekic, M; Vione, D; Zhang, G, 2020
)
2.23
"Triclosan (TCS) is an antibacterial agent used in personal care and household products."( Does salinity variation increase synergistic effects of triclosan and carbon nanotubes on Mytilus galloprovincialis? Responses on adult tissues and sperms.
Andrade, M; Chiellini, F; Costa, M; Cuccaro, A; De Marchi, L; Freitas, R; Leite, C; Manzini, C; Morelli, A; Oliva, M; Pretti, C; Tardelli, F, 2020
)
1.53
"Triclosan (TCS) is an extensively used antibacterial agent which has been frequently detected in different environmental compartments. "( Effect of Pleurotus ostreatus and Trametes versicolor on triclosan biodegradation and activity of laccase and manganese peroxidase enzymes.
Haghnia, GH; Khodaverdi, E; Lakzian, A; Maadani Mallak, A; Mahmoudi, S, 2020
)
2.25
"Triclosan (TCS) is a widespread environmental endocrine-disrupting chemical. "( Triclosan exposure and in vitro fertilization treatment outcomes in women undergoing in vitro fertilization.
Jurewicz, J; Kaleta, D; Klimowska, A; Krasiński, R; Radwan, M; Radwan, P; Wielgomas, B; Zajdel, R, 2021
)
3.51
"Triclosan is a high-production volume chemical, which has become widely detected in environmental systems because of its widespread usage. "( Linking Triclosan's Structural Features to Its Environmental Fate and Photoproducts.
Apell, JN; Kliegman, S; McNeill, K; Solá-Gutiérrez, C, 2020
)
2.44
"Triclosan (TCS) is a widespread antimicrobial agent with many adverse health risks. "( Frequent occurrence of triclosan hydroxylation in mammals: A combined theoretical and experimental investigation.
Cai, Z; Haggerty, TD; Parsonnet, J; Sanidad, KZ; Zhang, G; Zhang, H; Zhu, L, 2021
)
2.37
"Triclosan (TCS) is a highly effective antibacterial agent, which is widely distributed in wastewater and sludge. "( Comparative transcriptome combined with transgenic analysis reveal the involvement of salicylic acid pathway in the response of Nicotiana tabacum to triclosan stress.
Guan, C; Ji, J; Jin, C; Li, X; Liu, A; Peng, D; Wang, G; Wang, W; Zhang, Y, 2021
)
2.26
"Triclosan (TCS) is an emerging contaminant that threatens the environment and human health. "( Degradation of triclosan by anodic oxidation/in-situ peroxone process: Kinetics, pathway and reaction mechanism.
Li, AR; Li, XH; Li, YG; Liang, DW; Meng, SJ; Qu, C; Ren, N; Wang, SQ; Zhang, SJ, 2021
)
2.42
"Triclosan (TCS) is a ubiquitous antimicrobial used in many daily consumer products. "( Integrated Proteomics and Metabolomics Assessment Indicated Metabolic Alterations in Hypothalamus of Mice Exposed to Triclosan.
Cai, Z; Cao, G; Chen, X; Huang, J; Huang, W; Song, Y; Xie, P; Zhu, L, 2021
)
2.27
"Triclosan is a commonly used biocide effective against bacterial and fungal infections. "( Sensitive and selective determination of triclosan using visual spectroscopy.
Ghosh, R; Gopalakrishnan, S; Pushpavanam, S; Renganathan, T, 2021
)
2.33
"Triclosan (TCS) is a well-known compound that can be found in disinfectants, personal care products. "( Triclosan affects the expression of nitric oxide synthases (NOSs), peroxisome proliferator-activated receptor gamma (PPARγ), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in mouse neocortical neurons in vitro.
Skóra, B; Szychowski, KA; Wójtowicz, AK, 2021
)
3.51
"Triclosan is an antimicrobial agent widely used in personal care products and an emerging contaminant with potential to have harmful effects to edaphic organisms. "( Ecotoxicity of triclosan in soil: an approach using different species.
da Silva Júnior, FMR; da Silva, AB; de Lima Brum, R; Escarrone, AL; Honscha, LC; Ramires, PF; Tavella, RA; Volcão, LM, 2021
)
2.42
"Triclosan (TCS) is a broad-spectrum antibacterial agent widely used as antiseptic and disinfectant."( An investigation of the impact of triclosan adaptation on Proteus mirabilis clinical isolates from an Egyptian university hospital.
Abdelaziz, A; Elbanna, T; Elekhnawy, E; Sonbol, F, 2021
)
1.62
"Triclosan (TCS) is an endocrine-disrupting chemical (EDC), which is used ubiquitously as an antimicrobial ingredient in healthcare products and causes contamination in the environment such as air, water, and biosolid-amended soil. "( The triclosan-induced shift from aerobic to anaerobic metabolism link to increased steroidogenesis in human ovarian granulosa cells.
Cai, Z; Du, Y; Liang, W; Ouyang, F; Wang, B; Wang, W; Zhang, H; Zhou, G, 2021
)
2.62
"Triclosan is a promising candidate of fatty acid synthase (FASN) inhibitor by blocking FASN activity, but its effect on FASN expression and the underling epigenetic mechanism remain elusive. "( Triclosan down-regulates fatty acid synthase through microRNAs in HepG2 cells.
Long, K; Sun, D; Wu, M; Zhang, Z; Zhao, T, 2021
)
3.51
"Triclosan is a chlorinated phenolic antimicrobial agent having a wide application in commercial and healthcare products. "( Effect of triclosan (TCS) on the protein content and associated histological changes on tilapia, Oreochromis mossambicus (Peters, 1852).
Deepika, S; Jawahar, P; Padmavathy, P; Srinivasan, A; Sugumar, G, 2021
)
2.47
"Triclosan (TCS) is an antibacterial and antifungal agent used in many consumer products and exhibits a chemical structure similar to non-steroidal estrogen, which is known to induce endocrine disruption. "(
Kwack, SJ; Yoon, KS, 2021
)
2.06
"Triclosan (TCS) is an antimicrobial ingredient that has been widely incorporated in consumer products. "( Gut microbiota exaggerates triclosan-induced liver injury via gut-liver axis.
Duan, Y; Gao, H; Gao, Y; Luo, Y; Mao, D; Zhang, P; Zheng, L, 2022
)
2.46
"Triclosan (TCS) is an antibacterial agent that has been used in many products since 1960s. "( Is Triclosan a neurotoxic agent?
Aschner, M; Li, S; Rodriguez, MB; Ruszkiewicz, JA, 2017
)
2.52
"Triclosan is an antimicrobial chemical used in consumer products, and exposure is ubiquitous among pregnant women in the United States. "( Urinary triclosan concentrations during pregnancy and birth outcomes.
Braun, JM; Calafat, AM; Chen, A; Etzel, TM; Lanphear, BP; Savitz, DA; Ye, X; Yolton, K, 2017
)
2.33
"Triclosan is an extensively applied antimicrobial agent which has been frequently detected in the environment. "( Degradation of triclosan and its main intermediates during the combined irradiation and biological treatment.
Wang, J; Wang, S, 2018
)
2.28
"Triclosan (TCS) is an antimicrobial agent that has been widely dispersed and detected in the marine environment. "( Effects of triclosan (TCS) on fecundity, the antioxidant system, and oxidative stress-mediated gene expression in the copepod Tigriopus japonicus.
Han, J; Lee, JS; Lee, MC; Park, JC; Seo, JS, 2017
)
2.29
"Triclosan (TCS) is a broad spectrum antibacterial agent widely used in personal care products and present in most aquatic ecosystems. "( Impacts of triclosan exposure on zebrafish early-life stage: Toxicity and acclimation mechanisms.
Falisse, E; Silvestre, F; Voisin, AS, 2017
)
2.29
"Triclosan (TCS) is an emerging contaminant of concern in environmental studies due to its potential adverse effects on fish behavior. "( Potential effects of triclosan on spatial displacement and local population decline of the fish Poecilia reticulata using a non-forced system.
Araújo, CVM; López-Doval, JC; Neto, MB; Paiva, TCB; Pompêo, MLM; Silva, DCVR; Silva, FT, 2017
)
2.22
"Triclosan is a personal care product widely used in North America, Europe and Asia as antimicrobial ingredient in many consumer chemical products. "( Multigenerational effects of triclosan on the demography of Plationus patulus and Brachionus havanaensis (ROTIFERA).
Castellanos-Páez, ME; González-Pérez, BK; Nandini, S; Sarma, SSS, 2018
)
2.21
"Triclosan (TCS) is an antimicrobial compound found in personal care products, and consequently in greywater. "( Investigation of triclosan contamination on microbial biomass and other soil health indicators.
Horne, D; Horswell, J; Lowe, H; Siggins, A; Zaayman, M, 2017
)
2.24
"Triclosan (TCS) is a suspected endocrine disrupting chemical which is widely used in consumer products as an antibacterial agent. "( Urinary level of triclosan in a population of Chinese pregnant women and its association with birth outcomes.
Chen, Z; Hu, J; Huo, W; Jiang, Y; Li, Y; Liu, H; Qian, Z; Wan, Y; Wu, C; Xia, W; Xu, B; Xu, S; Zhang, B; Zhou, A; Zhu, Y, 2018
)
2.26
"Triclosan is a common antibacterial agent widely applied in various household and personal care products. "( Proteome and phospholipid alteration reveal metabolic network of Bacillus thuringiensis under triclosan stress.
Li, C; Li, Y; Long, Y; Ou, H; Qin, H; Yang, M; Ye, J, 2018
)
2.14
"Triclosan (TCS) is an antibacterial and antifungal agent widely used in personal care products (PCPs). "( Triclosan-induced transcriptional and biochemical alterations in the freshwater green algae Chlamydomonas reinhardtii.
Hu, LX; Pan, CG; Peng, FJ; Shi, WJ; Wei, XD; Ying, GG, 2018
)
3.37
"Triclosan (TCS) is an emerging organic contaminant in the environment. "( Anoxic biodegradation of triclosan and the removal of its antimicrobial effect in microbial fuel cells.
Liu, Y; Ma, J; Mahadeva, GD; Wang, C; Wang, L; Wu, Y; Zhao, F; Zhao, X, 2018
)
2.23
"Triclosan (TCS) is a broad spectrum antimicrobial agent which has been widely dispersed and determinated in the aquatic environment. "( Effects of triclosan (TCS) on hormonal balance and genes of hypothalamus-pituitary- gonad axis of juvenile male Yellow River carp (Cyprinus carpio).
Chen, W; Liu, F; Wang, F; Wang, W; Xu, R, 2018
)
2.31
"Triclosan (TCS) is an antimicrobial used so ubiquitously that 75% of the US population is likely exposed to this compound via consumer goods and personal care products. "( Triclosan exposure, transformation, and human health effects.
Gosse, JA; Weatherly, LM, 2017
)
3.34
"Triclosan (TCS) is an antibacterial agent used in a variety of consumer products such as: soaps, deodorant, and toothpaste, among others. "( Evaluation of reproductive toxicity in rats treated with triclosan.
de Góes, MLM; Garcia, PC; Gerardin, DCC; Montagnini, BG; Pernoncini, KV, 2018
)
2.17
"Triclosan is a synthetic chemical with broad antimicrobial activity that has been used extensively in consumer products, including personal care products, textiles, and plastic kitchenware, although the exposure which is widespread evidence from human studies is scarce. "( Environmental levels of triclosan and male fertility.
Hanke, W; Jurewicz, J; Kałużny, P; Klimowska, A; Radwan, M; Radwan, P; Wielgomas, B, 2018
)
2.23
"Triclosan is a phenolic biocide used in a multitude of consumer products and in health care settings. "( Associations between maternal triclosan concentrations in early pregnancy and gestational diabetes mellitus, impaired glucose tolerance, gestational weight gain and fetal markers of metabolic function.
Arbuckle, TE; Ashley-Martin, J; Bouchard, MF; Dodds, L; Ettinger, AS; Fisher, M; Fraser, WD; Monnier, P; Morisset, AS; Shapiro, GD, 2018
)
2.21
"Triclosan (TCS) is an antimicrobial agent used in a range of personal care and consumer products and is commonly detected in aquatic ecosystems. "( Response of detoxification system genes on Chironomus riparius aquatic larvae after antibacterial agent triclosan exposures.
Martínez-Paz, P, 2018
)
2.14
"Triclosan is a widely used broad-spectrum biocidal agent."( Triclosan and its derivatives as antimycobacterial active agents.
Krátký, M; Vinšová, J; Vosátka, R, 2018
)
2.64
"Triclosan (TCS) is an antibacterial chemical widely used in personal-care products and an endocrine disruptor. "( Maternal urinary triclosan level, gestational diabetes mellitus and birth weight in Chinese women.
Cheng, W; Ouyang, F; Tang, N; Wang, W; Wang, X; Zhang, HJ; Zhang, J; Zhao, S, 2018
)
2.26
"Triclosan (TCS) is an antibacterial and antifungal agent widely used in personal care products, and it has been frequently detected in the aquatic environment. "( The pH-dependent toxicity of triclosan to five aquatic organisms (Daphnia magna, Photobacterium phosphoreum, Danio rerio, Limnodrilus hoffmeisteri, and Carassius auratus).
Ajarem, J; Allam, AA; Chen, J; Li, C; Qu, R; Wang, Z; Zhang, S, 2018
)
2.21
"Triclosan (TCS) is a broad range antimicrobial agent used in many personal care products, which is commonly discharged to wastewater treatment facilities (WWTFs). "( Evaluating the impacts of triclosan on wastewater treatment performance during startup and acclimation.
Gardner, CM; Gunsch, CK; Holzem, RM, 2018
)
2.22
"Triclosan (TCS) is an organic compound with a wide range of antibiotic activity and has been widely used in items ranging from hygiene products to cosmetics; however, recent studies suggest that it has several adverse effects. "( Triclosan affects axon formation in the neural development stages of zebrafish embryos (Danio rerio).
Jung, CR; Kim, CY; Kim, J; Kim, U; Lee, JM; Oh, H; Park, JH; Ryu, B, 2018
)
3.37
"Triclosan (TCS) is an antibacterial widely used in personal care products that exhibits endocrine disrupting activity in several species, with reports of altered thyroid, estrogen and androgen signaling pathways. "( Evaluation of triclosan in the Hershberger and H295R steroidogenesis assays.
Buckalew, AR; Farmer, WT; Hallinger, DR; Louis, GW; Stoker, TE, 2018
)
2.28
"Triclosan is an antimicrobial agent that may affect the gut microbiome and endocrine system to influence adiposity. "( Early life Triclosan exposure and child adiposity at 8 Years of age: a prospective cohort study.
Braun, JM; Calafat, AM; Chen, A; Kalloo, G; Lanphear, BP; Yolton, K, 2018
)
2.31
"Triclosan is an antibacterial and antifungal chemical used in a variety of consumer products, including soaps, detergents, moisturizers, and cosmetics. "( Deriving a water quality guideline for protection of aquatic communities exposed to triclosan in the Canadian environment.
Breton, RL; Capdevielle, M; Hill, KL; Manning, GE; Slezak, B; Teed, RS, 2018
)
2.15
"Triclosan (TCS) is an antimicrobial agent that is used extensively in personal care and in sanitising products. "( Triclosan-Evoked Neurotoxicity Involves NMDAR Subunits with the Specific Role of GluN2A in Caspase-3-Dependent Apoptosis.
Kajta, M; Leszczyńska, T; Rzemieniec, J; Szychowski, KA; Wnuk, A; Wójtowicz, AK, 2019
)
3.4
"Triclosan is an antimicrobial agent, which is widely used in personal care products including toothpaste, soaps, deodorants, plastics, and cosmetics. "( Degradation of triclosan by environmental microbial consortia and by axenic cultures of microorganisms with concerns to wastewater treatment.
Bester, K; Chen, X; Zhuang, J, 2018
)
2.28
"Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in more than 2000 consumer products, such as toothpaste, cosmetics, kitchenware, and toys. "( A common antimicrobial additive increases colonic inflammation and colitis-associated colon tumorigenesis in mice.
Bolling, BW; Gu, M; Kim, D; Liu, Z; Martin, DA; Minter, LM; Ozay, EI; Panigrahy, D; Pei, R; Rey, FE; Romano, KA; Sanidad, KZ; Schmidt, B; Song, M; Wang, W; Wang, Y; Xiao, H; Yang, GY; Yang, H; Yang, J; Zhang, G, 2018
)
1.92
"Triclosan (TCS) is a common antimicrobial found in many personal care products. "( A triclosan turn-ON fluorescence sensor based on thiol-capped core/shell quantum dots.
Forbes, PBC; Montaseri, H, 2018
)
2.64
"Triclosan (TCS) is an antibacterial agent that is commonly used in personal care products. "( Fate and effects of sediment-associated triclosan in subtropical freshwater microcosms.
Bracewell, SA; Diepens, NJ; Pan, CG; Peng, FJ; Salvito, D; Selck, H; Van den Brink, PJ; Ying, GG, 2018
)
2.19
"Triclosan (TCS) is a broad-spectrum antimicrobial used in a variety of consumer products. "( Metagenomics reveal triclosan-induced changes in the antibiotic resistome of anaerobic digesters.
Carey, DE; Fujimoto, M; McNamara, PJ, 2018
)
2.25
"Triclosan (TCS) is a broad-spectrum antibacterial agent which is widely used in various personal care products and cosmetics. "( Exposure to triclosan changes the expression of microRNA in male juvenile zebrafish (Danio rerio).
Chen, W; Liu, F; Wang, F, 2019
)
2.34
"Triclosan (TCS) is a phenolic compound with antimicrobial action widely used in cosmetics and other personal care products and other industry segments. "( Investigation of the potential effects of triclosan as an endocrine disruptor in female rats: Uterotrophic assay and two-generation study.
Anselmo-Franci, JA; Borges, LI; Costa, NO; Gerardin, DCC; Kiss, ACI; Montagnini, BG; Moreira, EG; Pernoncine, KV, 2018
)
2.19
"Triclosan (TCS) is a broad-spectrum antibacterial agent and has been widely used in a diversity of personal care products. "( Gene expression profiles in brain of male juvenile zebrafish (Danio rerio) treated with triclosan.
Chen, W; Liu, F; Wang, F; Wang, R, 2019
)
2.18
"Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in over 2000 consumer products such as toothpastes, cosmetics, and toys. "( Consumer Antimicrobials on Gut Microbiota and Gut Health.
Wang, W; Yang, H; Zhang, G, 2019
)
1.96
"Triclosan is a widely used antimicrobial agent and may pose health risks to many aquatic organisms. "( Effects of inorganic anions on the photolysis of triclosan under UV irradiation.
Chen, L; He, Y; Qian, C; Wang, Z, 2018
)
2.18
"Triclosan (TCS) is a phenolic antimicrobial chemical used in consumer products and medical devices. "( Non-Ionic Surfactants Antagonize Toxicity of Potential Phenolic Endocrine-Disrupting Chemicals, Including Triclosan in
Alfhili, MA; Cha, DS; Faten, TA; Francis, JA; Lee, MH; Pan, X; Yoon, DS; Zhang, B, 2018
)
2.14
"Triclosan (TCS) is an antimicrobial compound incorporated into more than 2,000 consumer products. "( Triclosan, a common antimicrobial ingredient, on gut microbiota and gut health.
Sanidad, KZ; Xiao, H; Zhang, G, 2019
)
3.4
"Triclosan (TCS) is an endocrine disruptor which may affect endocrine function, antibiotic resistance, and thyroid hormone homeostasis. "( Triclosan in over the counter medicines of South China.
Gao, CJ; Guo, Y; Jia, LL, 2018
)
3.37
"Triclosan is a broad-spectrum antimicrobial additive in consumer products that has been detected in human populations globally. "( Exposure to triclosan among the Canadian population: Results of the Canadian Health Measures Survey (2009-2013).
Chan, HM; Hu, XF; Juric, A; Singh, K, 2019
)
2.34
"Triclosan (TCS) is a prevalent anthropogenic contaminant in aquatic environments and its chronic exposure can lead to a series of neurotoxic effects in zebrafish. "( Neurotoxicological effects induced by up-regulation of miR-137 following triclosan exposure to zebrafish (Danio rerio).
Dahlgren, RA; Huang, W; Ling, Y; Liu, J; Mei, J; Sun, L; Wang, C; Wang, H; Wang, X; Xiang, C, 2019
)
2.19
"Triclosan (TCS) is an antimicrobial agent used in diverse personal care products that is considered as an emerging contaminant of both aquatic and terrestrial ecosystems. "( Embryotoxic effects of in-ovo triclosan injection to the yellow-legged gull.
Caprioli, M; Covaci, A; De Felice, B; Defossé, S; Parolini, M; Poma, G; Possenti, CD; Romano, A; Saino, N, 2019
)
2.25
"Triclosan (TCS) is a well-known emerging contaminant got wide use in daily use products of domestic purpose, which provides the way to enter the ecological cycle, and is preferably detected in sewage treatment plants. "( Isolation and identification of Pseudomonas from wastewater, its immobilization in cellulose biopolymer and performance in degrading Triclosan.
Devatha, CP; Pavithra, N, 2019
)
2.16
"Triclosan is an important emerging pollutant. "( Eco-friendly rapid removal of triclosan from seawater using biomass of a microalgal species: Kinetic and equilibrium studies.
Abalde, J; Santaeufemia, S; Torres, E, 2019
)
2.25
"Triclosan is an antibacterial added to consumer products including toothpastes, cosmetics, and plastic cutting boards. "( Use of antibacterial toothpaste is associated with higher urinary triclosan concentrations in Asian immigrant women living in Vancouver, Canada.
Dix-Cooper, L; Kosatsky, T, 2019
)
2.19
"Triclosan (TCS) is an effective broad-spectrum antimicrobial agent that is widely used in personal care products. "( Research Progress on Toxic Effects and Water Quality Criteria of Triclosan.
Fan, J; Liu, P; Wang, P; Wang, S; Yan, Z; Zhang, T; Zheng, X, 2019
)
2.19
"Triclosan (TCS) is a biocide commonly used in household and personal care items to prevent the microbial growth and is currently considered as an emerging pollutant. "( Triclosan exposure induces varying extent of reversible antimicrobial resistance in Aeromonas hydrophila and Edwardsiella tarda.
Abraham, TJ; Karmakar, S; Kumar, K; Kumar, S; Roy, U; Shukla, SP, 2019
)
3.4
"Triclosan (TCS) is a broad-spectrum antibacterial compound which is used in many cosmetic products, medical devices and house hold products. "( Neurobehavioral toxicity of triclosan in mice.
Esfahani, ML; Hosseini, SM; Rahimi, A; Tabari, SA, 2019
)
2.25
"Triclosan (TCS) is a synthetic, chlorinated phenolic antimicrobial agent commonly used in commercial and healthcare products. "( Triclosan: An Update on Biochemical and Molecular Mechanisms.
Alfhili, MA; Lee, MH, 2019
)
3.4
"Triclosan (TCS) is an antibiotic that is added to household and personal care products. "( Metabolomics and phenotype assessment reveal cellular toxicity of triclosan in Caenorhabditis elegans.
Kim, HM; Kwon, SW; Long, NP; Nguyen, HT; Yoon, SJ, 2019
)
2.19
"Triclosan is an antibacterial substance that reduces the growth of bacteria by inhibiting fatty acid synthesis."( Triclosan-coated sutures reduce surgical site infection after open vein harvesting in coronary artery bypass grafting patients: a randomized controlled trial.
Friberg, Ö; Gudbjartsson, T; Jeppsson, A; Roman-Emanuel, C; Scherstén, H; Thimour-Bergström, L, 2013
)
2.55
"Triclosan is an antimicrobial agent that is discharged to soils with land-applied wastewater biosolids, is persistent under anaerobic conditions, and yet its impact on anaerobic microbial communities in soils is largely unknown. "( Triclosan enriches for Dehalococcoides-like Chloroflexi in anaerobic soil at environmentally relevant concentrations.
Krzmarzick, MJ; McNamara, PJ, 2013
)
3.28
"Triclosan (TCS) is a chemical compound used in household products as biocide. "( Pulmonary toxicity screening of triclosan in rats after intratracheal instillation.
Choi, K; Kang, MS; Kim, HM; Kim, P; Kwon, JT; Lee, DH; Lee, K; Seo, GB; Shim, I; Yang, MJ; Yang, YS, 2013
)
2.12
"Triclosan (TCS) is a broad-spectrum antimicrobial compound that is incorporated into numerous consumer products. "( Triclosan exposure increases triclosan resistance and influences taxonomic composition of benthic bacterial communities.
Drury, B; Kelly, JJ; Rosi-Marshall, EJ; Scott, J, 2013
)
3.28
"Triclosan is an antimicrobial agent, an endocrine disrupting compound, and an emerging contaminant in the environment. "( Effects of growth substrate on triclosan biodegradation potential of oxygenase-expressing bacteria.
Chu, KH; Lee, DG, 2013
)
2.12
"Triclosan (TCS) is an antimicrobial agent which is used as a broad-spectrum bacteriostatic and found in personal care products, and due to this it is widely spread in the aquatic environment. "( Development of aquatic life criteria for triclosan and comparison of the sensitivity between native and non-native species.
Liu, ZT; Pei, SW; Wang, WL; Wang, XN; Yan, ZG; Zhang, C; Zhou, JL, 2013
)
2.1
"Triclosan (TCS) is a broad-spectrum bactericide, highly toxic to algae, which is released into the environment via wastewater effluents. "( Occurrence and potential risk of triclosan in freshwaters of São Paulo, Brazil--the need for regulatory actions.
Jardim, WF; Montagner, CC; Umbuzeiro, GA; Von der Ohe, PC, 2014
)
2.13
"Triclosan is an active agent that is commonly found in biocide formulations which are used by the food industry to control microbial contamination. "( Transcriptomic analysis of triclosan-susceptible and -tolerant Escherichia coli O157:H19 in response to triclosan exposure.
Burgess, CM; Duffy, G; Fanning, S; Lenahan, M; Morris, D; Sheridan, Á, 2014
)
2.14
"Triclosan is a broad-spectrum antibacterial agent that is present in many consumer products and has been found to be a therapeutic aid in human allergic skin disease(7-11), although the mechanism for this effect is unknown."( A microplate assay to assess chemical effects on RBL-2H3 mast cell degranulation: effects of triclosan without use of an organic solvent.
Gosse, JA; Kennedy, RH; Shim, J; Weatherly, LM, 2013
)
1.33
"Triclosan is an antibacterial agent with low toxicity, which, along with a copolymer for aiding retention, can be added to toothpastes to reduce plaque and gingivitis (inflammation of the gums)."( Triclosan/copolymer containing toothpastes for oral health.
Lamont, T; Riley, P, 2013
)
2.55
"Triclosan (TCS) is a synthetic antibacterial chemical that is used in personal care products and is measurable in urine. "( Reliability of triclosan measures in repeated urine samples from Norwegian pregnant women.
Aase, H; Bertelsen, RJ; Calafat, AM; Eggesbø, M; Engel, SM; Guidry, VT; Hoppin, JA; Jusko, TA; Knudsen, GP; London, SJ; Longnecker, MP; Reichborn-Kjennerud, T; Zeiner, P,
)
1.93
"Triclosan (TCS) is a broad-spectrum antimicrobial agent used in personal care products, and as a result, is widespread in the environment. "( Assessment of toxic effects of triclosan on the terrestrial snail (Achatina fulica).
Chen, L; Liu, Z; Wang, W; Wang, X; Yan, Z; Zhang, C, 2014
)
2.13
"Triclosan is a general membrane-active agent with a broad-spectrum antimicrobial activity that is commonly used in oral care products. "( Subinhibitory concentrations of triclosan promote Streptococcus mutans biofilm formation and adherence to oral epithelial cells.
Bedran, TB; Grenier, D; Grignon, L; Spolidorio, DP, 2014
)
2.13
"Triclosan is a broad-spectrum antibacterial commonly used in cosmetics, dentifrices, and other consumer products. "( Recent evidence regarding triclosan and cancer risk.
Chen, J; Dinwiddie, MT; Terry, PD, 2014
)
2.15
"Triclosan (TCS) is a widely used antimicrobial agent found at high concentrations in biosolids produced during municipal wastewater treatment. "( Effects of triclosan and biosolids on microbial community composition in an agricultural soil.
Ogunyoku, TA; Park, I; Scow, KM; Young, TM; Zhang, N, 2013
)
2.22
"Triclosan is a broad-spectrum antimicrobial agent used in toothpaste to reduce dental plaque, gingivitis and oral malodor. "( Community-level assessment of dental plaque bacteria susceptibility to triclosan over 19 years.
Haraszthy, VI; Sreenivasan, PK; Zambon, JJ, 2014
)
2.08
"Triclosan is a widespread antimicrobial agent that accumulates in anaerobic digesters used to treat the residual solids generated at municipal wastewater treatment plants; there is very little information, however, about how triclosan impacts microbial communities in anaerobic digesters. "( The impacts of triclosan on anaerobic community structures, function, and antimicrobial resistance.
LaPara, TM; McNamara, PJ; Novak, PJ, 2014
)
2.2
"Triclosan is a broad spectrum anti-bacterial agent widely used in many personal care products, household items, medical devices, and clinical settings. "( Extracellular signal-regulated kinases 1/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41-5a cells.
Beland, FA; Chen, S; Fang, JL; Wu, Y, 2015
)
2.1
"Triclosan is an anti-bacterial agent used in many personal care products, household items, medical devices, and clinical settings. "( Differential effects of triclosan on the activation of mouse and human peroxisome proliferator-activated receptor alpha.
Beland, FA; Fang, JL; Ge, P; Manjanatha, MG; Wu, Q; Wu, Y, 2014
)
2.15
"Triclosan (TCS) is a widely-used antimicrobial agent in many consumer products around the world, and China is a major producer and consumer of TCS. "( Substance flow analysis and assessment of environmental exposure potential for triclosan in mainland China.
Huang, CL; Ma, HW; Yu, CP, 2014
)
2.07
"Triclosan (TCS) is a commonly used antimicrobial agent in personal care and sanitizing products, as well as in household items. "( Triclosan induces Fas receptor-dependent apoptosis in mouse neocortical neurons in vitro.
Sitarz, AM; Szychowski, KA; Wojtowicz, AK, 2015
)
3.3
"Triclosan (TCS) is a broad-spectrum synthetic antimicrobial agent that is toxic to microbes and other aquatic organisms. "( Bacterial community variation and microbial mechanism of triclosan (TCS) removal by constructed wetlands with different types of plants.
Hu, Z; Liang, S; Liu, C; Wang, J; Wang, Q; Xie, H; Xu, J; Xu, X; Zhang, J; Zhao, C, 2015
)
2.1
"Triclosan (TCS) is a ubiquitous antibacterial agent found in soaps, scrubs, and consumer products. "( Resilience and recovery: the effect of triclosan exposure timing during development, on the structure and function of river biofilm communities.
Korber, DR; Lawrence, JR; Leavitt, P; Paule, A; Roy, J; Swerhone, GD; Topp, E; Tumber, V; Waiser, MJ, 2015
)
2.13
"Triclosan is a synthetic biocide found in many household products, including antimicrobial hand soap. "( Efficacy of triclosan as an antimicrobial hand soap and its potential impact on antimicrobial resistance: a focused review.
Giuliano, CA; Rybak, MJ, 2015
)
2.24
"Triclosan is an antimicrobial chemical commonly used occupationally and by the general public. "( Investigations of immunotoxicity and allergic potential induced by topical application of triclosan in mice.
Anderson, SE; Long, CM; Lukomska, E; Marshall, NB; Meade, BJ, 2016
)
2.1
"Triclosan (TCS) is a broad-spectrum antibacterial agent widely used in household and personal care products and is frequently detected in the environment. "( Transformation of triclosan to 2,8-dichlorodibenzo-p-dioxin by iron and manganese oxides under near dry conditions.
Ding, J; Lin, K; Su, M; Wu, C, 2015
)
2.19
"Triclosan is a widely used antibacterial agent that has become a ubiquitous contaminant in freshwater, estuary, and marine environments. "( Long-term effects of the antibacterial agent triclosan on marine periphyton communities.
Andersson, MX; Arrhenius, Å; Backhaus, T; Blanck, H; Eriksson, KM; Fihlman, V; Grehn, A; Johansson, CH; Sanli, K; Sircar, T, 2015
)
2.12
"Triclosan (TCS) is a multi-purpose antimicrobial agent used as a common ingredient in everyday household personal care and consumer products. "( Triclosan: current status, occurrence, environmental risks and bioaccumulation potential.
Brar, SK; Cledón, M; Dhillon, GS; Kaur, S; Pulicharla, R; Surampalli, RY; Verma, M, 2015
)
3.3
"Triclosan (TCS) is an antibacterial agent commonly added to personal care products. "( Temporal variability and sources of triclosan exposure in pregnancy.
Arbuckle, TE; Dumas, P; Fisher, M; Hauser, R; Lang, C; LeBlanc, A; Mallick, R; Ramsay, T; Walker, M; Weiss, L, 2015
)
2.13
"Triclosan is an antimicrobial chemical incorporated into many personal, medical and household products. "( Triclosan Induces Thymic Stromal Lymphopoietin in Skin Promoting Th2 Allergic Responses.
Anderson, KL; Anderson, SE; Jean Meade, B; Kashon, ML; Long, CM; Lukomska, E; Marshall, NB; Nayak, AP; Sharpnack, DD, 2015
)
3.3
"Triclosan (TCS) is a potential threat to the environment and human health. "( Photocatalytic reduction of triclosan on Au-Cu2O nanowire arrays as plasmonic photocatalysts under visible light irradiation.
Crittenden, JC; Dai, Y; Niu, J; Shang, J; Yin, L, 2015
)
2.15
"Triclosan is a broad-spectrum biocide used in personal-care products that is suspected to be linked to the emergence of antibiotic-resistant bacteria. "( A comparison between the oxidation with laccase and horseradish peroxidase for triclosan conversion.
Dezotti, M; Marques, MR; Melo, CF, 2016
)
2.1
"Triclosan (TCS) is an antimicrobial used widely in hospitals and personal care products, at ~10 mm. "( Antimicrobial agent triclosan is a proton ionophore uncoupler of mitochondria in living rat and human mast cells and in primary human keratinocytes.
Gosse, JA; Hashmi, HN; Hess, ST; Kennedy, RH; Shim, J; Weatherly, LM, 2016
)
2.2
"Triclosan (TCS) is an important broad-spectrum antimicrobial agent widely utilized in a range of personal care products, and is therefore commonly found in the environment. "( Development of predicted no effect concentration (PNEC) for TCS to terrestrial species.
Chen, L; Liu, Z; Wang, W; Wang, X; Zhang, C, 2015
)
1.86
"Triclosan is an antimicrobial agent which is widely used in many personal care products. "( Accumulation and Risk of Triclosan in Surface Sediments Near the Outfalls of Municipal Wastewater Treatment Plants.
Cao, S; Chen, L; Jing, Z; Wang, Z; Yu, T, 2015
)
2.16
"Triclosan is an effective inhibitor for enoyl acyl carrier protein reductase (ENR) in fatty acid biosynthesis. "( An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.
Demissie, RD; Fung, LW; Kabre, P; Tuntland, ML, 2016
)
2.13
"Triclosan (TCS) is a broad-spectrum antimicrobial agent that has been added to personal care products, including hand soaps and cosmetics, and impregnated in numerous different materials ranging from athletic clothing to food packaging. "( Triclosan: A Widespread Environmental Toxicant with Many Biological Effects.
Tukey, RH; Yueh, MF, 2016
)
3.32
"Triclosan (TCS) is an antimicrobial and is an aquatic contaminant. "( Full life-cycle toxicity assessment on triclosan using rotifer Brachionus calyciflorus.
Niu, J; Wang, Y; Zhang, L, 2016
)
2.15
"Triclosan (TCS) is an active antimicrobial ingredient used in many household products, such as skin creams and toothpaste. "( Triclosan (TCS) exposure impairs lipid metabolism in zebrafish embryos.
Ho, JCH; Hsiao, CD; Kawakami, K; Tse, WKF, 2016
)
3.32
"Triclosan is an example of a chemical contained in high contact products (e.g., soaps, lotions, and toothpaste) not necessarily designed for children."( Consumer products as sources of chemical exposures to children: case study of triclosan.
Balk, SJ; Ginsberg, GL, 2016
)
1.38
"Triclosan (TCS) is an ionizable synthetic antimicrobial that has been found to be a persistent environmental contaminant with potential for bioaccumulation. "( Developmental Toxicity of Triclosan in the Presence of Dissolved Organic Carbon: Moving Beyond Standard Acute Toxicity Assays to Understand Ecotoxicological Risk.
Carmosini, N; Grandstrand, S; King-Heiden, TC, 2016
)
2.18
"Triclosan (TCS) is an antimicrobial agent found in personal care products that has become prevalent in surface waters. "( Cardiac Toxicity of Triclosan in Developing Zebrafish.
Hess, M; Howard, D; King-Heiden, TC; Miller, K; Saley, A, 2016
)
2.2
"Triclosan (TCS) is a broad-spectrum antimicrobial agent that is frequently used in pharmaceuticals and personal care products. "( Endocrine Disrupting Effects of Triclosan on the Placenta in Pregnant Rats.
Feng, Y; Jiao, Z; Shao, B; Shi, J; Zhang, P; Zhang, Z, 2016
)
2.16
"Triclosan (TCS) is a broad spectrum antibacterial agent mainly used in Pharmaceutical and Personal Care Products. "( Triclosan: A review on systematic risk assessment and control from the perspective of substance flow analysis.
Abass, OK; Huang, CL; Yu, CP, 2016
)
3.32
"Triclosan is an antimicrobial agent and a persistent pollutant. "( Effects of different culture media on biodegradation of triclosan by Rhodotorula mucilaginosa and Penicillium sp.
Ertit Taştan, B; Özdemir, C; Tekinay, T,
)
1.82
"Triclosan (TCS) is a ubiquitous contaminant in municipal biosolids, which has also been detected in soils and earthworms sampled from agricultural fields amended with biosolids. "( Lethal and sub-lethal effects of triclosan toxicity to the earthworm Eisenia fetida assessed through GC-MS metabolomics.
Gillis, JD; Prasher, S; Price, GW, 2017
)
2.18
"Triclosan (TCS) is an antimicrobial agent that is used extensively in personal care and in sanitizing products, such as soaps, toothpastes, and hair products. "( Triclosan activates aryl hydrocarbon receptor (AhR)-dependent apoptosis and affects Cyp1a1 and Cyp1b1 expression in mouse neocortical neurons.
Kajta, M; Szychowski, KA; Wnuk, A; Wójtowicz, AK, 2016
)
3.32
"Triclosan (TCS) is an antimicrobial agent commonly found in a variety of personal care products and cosmetics. "( Phenotypically anchored transcriptome profiling of developmental exposure to the antimicrobial agent, triclosan, reveals hepatotoxicity in embryonic zebrafish.
Haggard, DE; Noyes, PD; Tanguay, RL; Waters, KM, 2016
)
2.09
"Triclosan (TCS) is a widely used antimicrobial agent and TCS resistance is considered to have evolved in diverse organisms with extensive use of TCS, but distribution of TCS resistance has not been well characterized. "( Triclosan Resistome from Metagenome Reveals Diverse Enoyl Acyl Carrier Protein Reductases and Selective Enrichment of Triclosan Resistance Genes.
Baek, KY; Choi, J; Hwang, EC; Jung, YH; Khan, R; Kong, HG; Lee, SW, 2016
)
3.32
"Triclosan (TCS) is a broad-spectrum antimicrobial agent that is found extensively in natural aquatic environments. "( Laccase-mediated transformation of triclosan in aqueous solution with metal cations and humic acid.
Gao, Y; Huang, Q; Kang, F; Sun, K; Waigi, MG, 2017
)
2.17
"Triclosan is an antimicrobial agent which has been frequently detected in the environment. "( Enhanced biodegradation of triclosan by means of gamma irradiation.
Wang, J; Wang, S; Yin, Y, 2017
)
2.19
"Triclosan is a widely used broad-spectrum anti-bacterial agent. "( Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Beland, FA; Chitranshi, P; Fang, JL; Gamboa da Costa, G; Loukotková, L; Wu, Y; Zhang, J, 2017
)
2.17
"Triclosan (TCS) is an antimicrobial ingredient found in personal care products that include soaps, shampoos, and other sanitation goods. "( Comparative evaluation of four biosolids formulations on the effects of triclosan on plant-arbuscular mycorrhizal fungal interactions in three crop species.
Lissemore, L; Prosser, RS; Shahmohamadloo, RS; Sibley, PK, 2017
)
2.13
"Triclosan is an antimicrobial agent used in a range of consumer products, such as deodorants, oral care, clothing, and household items. "( Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
Capdevielle, M; Mihaich, E; Slezak, B; Urbach-Ross, D, 2017
)
2.11
"Triclosan (TCS) is an antibacterial agent widely used in personal care and consumer products and commonly detected in aquatic ecosystems. "( Endocrine-related genes are altered by antibacterial agent triclosan in Chironomus riparius aquatic larvae.
Martínez-Guitarte, JL; Martínez-Paz, P; Morales, M; Morcillo, G; Urien, J, 2017
)
2.14
"Triclosan (TCS) is an antimicrobial chemical widely used in different commercial preparations. "( Disruption of LH-induced testosterone biosynthesis in testicular Leydig cells by triclosan: probable mechanism of action.
Balomajumder, C; Kumar, V; Roy, P, 2008
)
2.01
"Triclosan is an antimicrobial agent widely used in many contemporary consumer and health care products. "( Terrestrial ecotoxicological effects of the antimicrobial agent triclosan.
Liu, F; Yang, LH; Ying, GG; Zhou, QX, 2009
)
2.03
"Triclosan (TCN) is a commonly used antiplaque agent in toothpastes."( PAMAM dendrimers for the delivery of the antibacterial Triclosan.
Alcock, J; D'Emanuele, A; Freeman, S; Gardiner, J; Green, A; Leach, M, 2008
)
1.31
"Triclosan is a lypophilic chlorophenol biocide with broad-spectrum antibacterial and antifungal activity. "( Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema.
Girolomoni, G; Papagrigoraki, A; Schena, D, 2008
)
2.09
"Triclosan is a broad-spectrum antimicrobial agent currently used in numerous products including surgical scrubs and ureteral stents. "( The effects of triclosan on uropathogen susceptibility to clinically relevant antibiotics.
Cadieux, PA; Chew, BH; Denstedt, JD; Goneau, LW; Wignall, GR, 2008
)
2.14
"Triclosan is a broad-spectrum antimicrobial in numerous consumer and medical products and has been incorporated into a ureteral stent."( Use of triclosan-eluting ureteral stents in patients with long-term stents.
Cadieux, PA; Chew, BH; Denstedt, JD; Elwood, CN; Goneau, LW; Nott, L; Seney, S; Wignall, GR, 2009
)
1.53
"Triclosan is an antibacterial compound commonly used in cosmetics and personal care products for everyday use. "( Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones.
Allmyr, M; Diczfalusy, U; Panagiotidis, G; Sandborgh-Englund, G; Sparve, E, 2009
)
2.13
"Triclosan is a biocide whose wide use has raised a debate about the potential benefits vs. "( The synergistic activity of triclosan and ciprofloxacin on biofilms of Salmonella Typhimurium.
Chikindas, ML; Scher, K; Tabak, M; Yaron, S, 2009
)
2.09
"Triclosan is an antimicrobial agent added to a wide array of consumer goods and personal care products. "( Temporal trends of triclosan contamination in dated sediment cores from four urbanized estuaries: evidence of preservation and accumulation.
Burgess, RM; Cantwell, MG; King, JW; Olsen, CR; Smith, JP; Wallace, GT; Wilson, BA; Zhu, J, 2010
)
2.13
"Triclosan (TCS) is an antimicrobial agent which is used as a broad-spectrum bacteriostatic and found in personal care products, and due to this it is spread in the environment. "( Predicted no effect concentration (PNEC) for triclosan to terrestrial species (invertebrates and plants).
Amorim, MJB; Oliveira, E; Scott-Fordsmand, JJ; Soares, AMVM, 2010
)
2.06
"Triclosan (TC) is an antimicrobial agent used in a large number of antibacterial soaps."( Immunosuppressive effects of triclosan, nonylphenol, and DDT on human natural killer cells in vitro.
Etherton, R; Martin, T; Udoji, F; Whalen, MM,
)
1.14
"Triclosan is a biocide that is commonly found in human excrement and is considered an emerging pollutant in wastewater and the environment."( Toxicogenomic response of Rhodospirillum rubrum S1H to the micropollutant triclosan.
De Wever, H; Leys, N; Mergeay, M; Monsieurs, P; Pycke, BF; Vanermen, G; Verstraete, W, 2010
)
1.31
"Triclosan is a widely used broad-spectrum antibacterial agent that acts by specifically inhibiting enoyl-acyl carrier protein reductase. "( Determination of triclosan metabolites by using in-source fragmentation from high-performance liquid chromatography/negative atmospheric pressure chemical ionization ion trap mass spectrometry.
Cai, Z; Liu, J; Wu, JL, 2010
)
2.14
"Triclosan is an antimicrobial found in personal care and sanitizing products, such as soaps, toothpaste, and hair products. "( Triclosan exposure modulates estrogen-dependent responses in the female wistar rat.
Gibson, EK; Stoker, TE; Zorrilla, LM, 2010
)
3.25
"Triclosan (TCS) is an antibacterial agent used in a variety of personal care and industrial products. "( Triclosan has endocrine-disrupting effects in male western mosquitofish, Gambusia affinis.
Angus, RA; Raut, SA, 2010
)
3.25
"Triclosan is an antimicrobial compound found in many consumer products including soaps and personal care products. "( Terrestrial ecological risk evaluation for triclosan in land-applied biosolids.
Barber, T; Bock, M; Capdevielle, M; Fuchsman, P; Lauren, D; Leigh, K; Lyndall, J; Perruchon, E, 2010
)
2.07
"Triclosan is a commonly used bactericide that survives several degradation steps in WWTP (wastewater treatment plants) and potentially reaches fluvial ecosystems. "( Triclosan persistence through wastewater treatment plants and its potential toxic effects on river biofilms.
Alberch, M; Barceló, D; Bonnineau, C; Farré, Ml; Ferrer, J; Geiszinger, A; Guasch, H; Morin, S; Proia, L; Ricart, M; Ricciardi, F; Romaní, AM; Sabater, S; Sala, L; Sureda, D, 2010
)
3.25
"Triclosan is a broad-spectrum antimicrobial agent having low toxicity which facilitates its incorporation into numerous personal and health care products. "( Triclosan-induced modification of unsaturated fatty acid metabolism and growth in Pseudomonas aeruginosa PAO1.
Bullard, JW; Burkus, J; Champlin, FR; Conrad, RS; Millar, SY, 2011
)
3.25
"Triclosan is known to be an effective inhibitor for this enzyme."( Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum.
Banerjee, T; Maity, K; Prabakaran, N; Suguna, K; Surolia, A; Surolia, N, 2011
)
1.09
"Triclosan is an inhibitor of FabI and forms a stable ternary complex in the presence of NADH."( Crystallization and preliminary X-ray crystallographic studies of enoyl-acyl carrier protein reductase (FabI) from Psuedomonas aeruginosa.
Chi, YM; Lee, JH; Lee, KS; Moon, JH; Park, AK, 2011
)
1.09
"Triclosan (TCS) is an antimicrobial agent used widely in household products such as soaps, household cleaners, cosmetics, sportswear, mouthwash and toothpaste. "( Triclosan: its occurrence, fate and effects in the Australian environment.
Kookana, RS; Waller, NJ; Ying, GG, 2011
)
3.25
"Triclosan is an antibacterial agent widely used in periodontal therapy, the effectiveness of triclosan in the management of radiation induced oral mucositis is evaluated here."( Effectiveness of triclosan in the management of radiation-induced oral mucositis: a randomized clinical trial.
Balan, A; Bhatathiri, VN; Bose, T; Chamba, MS; Satheeshkumar, PS; Sreelatha, KT,
)
1.19
"Triclosan is an antimicrobial agent that is currently incorporated into hundreds of consumer and medical products. "( Triclosan-resistant bacteria isolated from feedlot and residential soils.
Gillock, ET; Welsch, TT, 2011
)
3.25
"Triclosan is an antimicrobial agent which is widely used in household and personal care products. "( Biodegradation of triclosan and formation of methyl-triclosan in activated sludge under aerobic conditions.
Bester, K; Chen, X; Furgal, K; Liu, Y; Lolas, IB; Nielsen, JL, 2011
)
2.15
"Triclosan (TCS) is a multi-purpose biocide. "( Triclosan--the forgotten priority substance?
Brack, W; Schmitt-Jansen, M; Slobodnik, J; von der Ohe, PC, 2012
)
3.26
"Triclosan is a broad-spectrum antimicrobial compound commonly used in oral hygiene products. "( Triclosan antagonizes fluconazole activity against Candida albicans.
Coleman, DC; Higgins, J; Kelly, SL; Martel, CM; Moran, GP; Oltean, HN; Pinjon, E; Sullivan, DJ; White, TC, 2012
)
3.26
"Triclosan is a chlorinated phenol ether that has been in widespread use as a broad-spectrum antibacterial agent for four decades. "( Triclosan in individual human milk samples from Australia.
Adolfsson-Erici, M; Allmyr, M; Harden, FA; McLachlan, M; Mueller, JF; Murby, J; Toms, LM, 2011
)
3.25
"Triclosan is a broad-spectrum antibacterial agent, which has been shown previously to alleviate human allergic skin disease. "( Antibacterial agent triclosan suppresses RBL-2H3 mast cell function.
Burpee, BT; Evans, BL; Gosse, JA; Hopke, AR; Hutchinson, LM; Kormendy, Z; Malay, ET; Palmer, RK; Pelletier, JH; Tupper, EJ; Velez, A, 2012
)
2.15
"Triclosan (TCS) is a broad-spectrum antibacterial agent widely used in many personal care products. "( [Kinetics modeling and reaction mechanism of ferrate(VI) oxidation of triclosan].
Yang, B; Ying, GG; Zhao, JL, 2011
)
2.05
"Triclosan (TCS) is a common constituent of personal care products and is frequently present in biosolids. "( Toxicity and bioaccumulation of biosolids-borne triclosan in terrestrial organisms.
O'Connor, GA; Pannu, MW; Toor, GS, 2012
)
2.08
"Triclosan is a broad spectrum antibacterial agent widely used in numerous healthcare products and has been previously shown to reduce inflammation on the skin and in the oral cavity."( The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial.
Cadieux, PA; Chew, BH; Denstedt, JD; Elwood, CN; Goneau, LW; Lange, D; MacDonald, KW; Mendez-Probst, CE; Nott, L; Seney, S, 2012
)
1.49
"Triclosan is an antimicrobial agent widely used in many household and personal care products. "( Ozonation products of triclosan in advanced wastewater treatment.
Bester, K; Chen, X; Dopp, E; Liu, Y; Richard, J; Tuerk, J, 2012
)
2.14
"Triclosan is an antimicrobial compound that has been widely used in consumer products such as toothpaste, deodorant, and shampoo. "( Effects of triclosan on marine benthic and epibenthic organisms.
Burgess, RM; Cantwell, MG; Ho, KT; Pelletier, MC; Perron, MM, 2012
)
2.21
"Triclosan is an antimicrobial agent frequently used in pharmaceuticals and personal care products. "( The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells.
Honkisz, E; Wojtowicz, AK; Zieba-Przybylska, D, 2012
)
2.18
"Triclosan (TCS) is a broad-spectrum bactericide that is used for a variety of antimicrobial functions. "( Biochemical and genotoxic effect of triclosan on earthworms (Eisenia fetida) using contact and soil tests.
Lin, D; Liu, Y; Xie, X; Zhou, Q, 2012
)
2.1
"Triclosan (TCS) is an antimicrobial compound commonly found in biosolids. "( Toxicity and bioaccumulation of biosolids-borne triclosan in food crops.
O'Connor, GA; Pannu, MW; Toor, GS; Wilson, PC, 2012
)
2.08
"Triclosan is an antimicrobial additive in many personal care and household products, and evidence indicates that it can be estrogenic. "( Disruption of blastocyst implantation by triclosan in mice: impacts of repeated and acute doses and combination with bisphenol-A.
Crawford, BR; Decatanzaro, D, 2012
)
2.09
"Triclosan is a widely used biocide effective against different microorganisms. "( Genome-wide enrichment screening reveals multiple targets and resistance genes for triclosan in Escherichia coli.
Choi, SK; Hwang, SJ; Ju, HM; Kim, E; Kim, JA; Pan, JG; Park, S; Yu, BJ, 2012
)
2.05
"Triclosan (TCS) is an antimicrobial compound being increasingly used in personal care products (PCPs) over the last 40 years, and as a result is present in wastewater treatment plant (WWTP) effluents. "( Factors regulating the accumulation and spatial distribution of the emerging contaminant triclosan in the sediments of an urbanized estuary: Greenwich Bay, Rhode Island, USA.
Burgess, RM; Cantwell, MG; Charpentier, MA; Ho, KT; Katz, DR; Perron, MM; Sullivan, JC, 2013
)
2.05
"Triclosan (TCS) is a common antimicrobial agent that has been detected in wastewater treatment plant (WWTP) effluent outflows. "( Antibiotic resistance in triclosan tolerant fecal coliforms isolated from surface waters near wastewater treatment plant outflows (Morris County, NJ, USA).
Middleton, JH; Salierno, JD, 2013
)
2.14
"Triclosan is a biocidal active agent commonly used in domestic and industrial formulations. "( Proteomic and phenotypic analysis of triclosan tolerant verocytotoxigenic Escherichia coli O157:H19.
Bonilla-Santiago, R; Burgess, CM; Condell, O; Duffy, G; Fanning, S; Lenahan, M; Nally, JE; Renaut, J; Sergeant, K; Sheridan, A, 2013
)
2.11
"Triclosan (TCN) is a long-standing, proven antibacterial and anti-inflammatory agent found in the only Food and Drug Administration-approved dentifrice for the treatment of plaque and gingivitis."( Triclosan blocks MMP-13 expression in hormone-stimulated osteoblasts.
Barnes, VM; Jefcoat, S; Nakatani, T; Partridge, NC; Qin, L; Shimizu, E; Vasilov, A; Xu, T, 2013
)
2.55
"Triclosan is a broad-spectrum antimicrobial agent widely used in oral care products. "( Effects of triclosan/copolymer dentifrice on dental plaque and gingivitis in a 3-month randomized controlled clinical trial: influence of baseline gingivitis on observed efficacy.
Bartizek, RD; McClanahan, SF, 2002
)
2.15
"Triclosan (TCS) is an anti-microbial agent used in down-the-drain consumer products. "( A field study of triclosan loss rates in river water (Cibolo Creek, TX).
Eckhoff, W; Hauk, A; Inauen, J; Jacob, M; McAvoy, D; Morrall, D; Schatowitz, B, 2004
)
2.11
"Triclosan is a hydrophobic antibacterial agent used in dermatological preparations and oral hygiene products. "( Location and orientation of Triclosan in phospholipid model membranes.
Bernabeu, A; Guillén, J; Shapiro, S; Villalaín, J, 2004
)
2.06
"Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, where ACP stands for acyl carrier protein), which catalyses the last step in a sequence of four reactions that is repeated many times with each elongation step in the type II fatty acid biosynthesis pathway. "( Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan.
Kapoor, M; Krishnasastry, MV; Reddy, CC; Surolia, A; Surolia, N, 2004
)
1.98
"Triclosan is a broad spectrum antibacterial agent used in many household products. "( Triclosan as a substrate and inhibitor of 3'-phosphoadenosine 5'-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions.
Falany, CN; James, MO; Wang, LQ, 2004
)
3.21
"Triclosan is a broad spectrum antimicrobial agent, with additional anti-metabolic and anti-inflammatory properties."( The role of Triclosan in dentifrice formulations, with particular reference to a new 0.3% Triclosan calcium carbonate-based system.
Beasley, T; Brading, MG; Cromwell, VJ; DeBrabander, S; Green, AK; Marsh, PD, 2004
)
1.42
"Triclosan is an agent that was found to have an antibacterial effect against oral bacteria."( Sustained-release delivery systems of triclosan for treatment of Streptococcus mutans biofilm.
Friedman, M; Steinberg, D; Tal, T, 2006
)
1.33
"Triclosan is a broad-spectrum antimicrobial agent with activity against a wide range of both gram-negative and gram-positive bacteria that has found increasing popular use in personal care products."( Correlation between in vitro release from topical delivery vehicles and microbicidal activity of triclosan.
De Villiers, MM; Du Preez, JL; Liebenberg, W; Lötter, AP; Swart, HC, 2006
)
1.27
"Triclosan is a broad-spectrum antibacterial agent, marketed for use in oral products. "( Advanced oral antibacterial/anti-inflammatory technology: A comprehensive review of the clinical benefits of a triclosan/copolymer/fluoride dentifrice.
Davies, RM; DeVizio, W; Panagakos, FS; Petrone, ME; Proskin, HM; Volpe, AR, 2005
)
1.98
"Triclosan is a biocide currently used in a plethora of consumer and medical products that has recently been loaded into a ureteral stent."( Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model.
Cadieux, PA; Chew, BH; Dejong, K; Denstedt, JD; Knudsen, BE; Reid, G; Rowe, E, 2006
)
2.5
"Triclosan is a widely used biocide that is considered as an effective antimicrobial agent against different microorganisms. "( Triclosan and antimicrobial resistance in bacteria: an overview.
Fotland, TØ; Heir, E; Høiby, EA; Kruse, H; Lunestad, BT; Naterstad, K; Scheie, AA; Yazdankhah, SP, 2006
)
3.22
"Triclosan is an established bacteriostatic compound widely used in topical and dental preparations. "( Risk assessment of triclosan [Irgasan] in human breast milk.
Dayan, AD, 2007
)
2.11
"Triclosan (TCS) is an antimicrobial agent widely used in many personal care products. "( Triclosan in wastewaters and biosolids from Australian wastewater treatment plants.
Kookana, RS; Ying, GG, 2007
)
3.23
"Triclosan was found to be a potent inhibitor of the F(H+)-ATPase of the oral pathogen Streptococcus mutans and to increase proton permeabilities of intact cells. "( Triclosan inhibition of membrane enzymes and glycolysis of Streptococcus mutans in suspensions and biofilms.
Marquis, RE; Phan, TN, 2006
)
3.22
"Triclosan is an antimicrobial commonly used in consumer and medical products that inhibits bacterial fatty-acid synthesis."( In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens.
Cadieux, PA; Chew, BH; Denstedt, JD; Reid, G, 2006
)
1.37
"Triclosan is a common antibacterial chemical currently in widespread use in household and health care-related products. "( Triclosan.
Campbell, L; Zirwas, MJ, 2006
)
3.22
"Triclosan is a potent biocide that is included in a diverse range of products. "( Effect of triclosan on Salmonella typhimurium at different growth stages and in biofilms.
Chikindas, ML; Hartog, E; Matthews, KR; Romling, U; Scher, K; Tabak, M; Yaron, S, 2007
)
2.18
"Triclosan is a widely used antibacterial agent found in many personal hygiene products. "( Formation of chloroform and other chlorinated byproducts by chlorination of triclosan-containing antibacterial products.
Fiss, EM; Rule, KL; Vikesland, PJ, 2007
)
2.01
"Triclosan is a widely accepted broad spectrum antimicrobial agent proven to be effective against many gram-positive and gram-negative bacteria."( Antimicrobial effect of triclosan and triclosan with Gantrez on five common endodontic pathogens.
Begole, EA; Fayad, MI; Johnson, BR; Nudera, WJ; Wenckus, CS; Wu, CD; Zhu, M, 2007
)
1.37
"Triclosan is an antimicrobial agent commonly used in consumer and medical products that inhibits bacterial fatty acid synthesis. "( Triclosan inhibits uropathogenic Escherichia coli-stimulated tumor necrosis factor-alpha secretion in T24 bladder cells in vitro.
Cadieux, PA; Chew, BH; Denstedt, JD; Elwood, CN; Jass, J; Seney, S, 2007
)
3.23
"Triclosan is an antimicrobial agent found in many consumer products. "( A triclosan-ciprofloxacin cross-resistant mutant strain of Staphylococcus aureus displays an alteration in the expression of several cell membrane structural and functional genes.
Aris, VM; Bello, A; Joy, A; Londono, I; Marku, J; Peteroy-Kelly, MA; Shepard, J; Soteropoulos, P; Tkachenko, O,
)
2.3
"Triclosan (TCS) is a broad-spectrum antimicrobial used in consumer products including toothpaste and hand soap. "( Consideration of exposure and species sensitivity of triclosan in the freshwater environment.
Capdevielle, M; Cunningham, V; Hofmann-Kamensky, M; Inauen, J; Van Egmond, R; Versteeg, D; Whelan, M; Woltering, D, 2008
)
2.04
"Triclosan is a synthetic chemical with broad antimicrobial activity that has been used extensively in consumer products, including personal care products, textiles, and plastic kitchenware."( Urinary concentrations of triclosan in the U.S. population: 2003-2004.
Calafat, AM; Needham, LL; Reidy, JA; Wong, LY; Ye, X, 2008
)
2.09
"Triclosan is a lipid-soluble, antibacterial substance which is added to toothpastes and mouthwashes to inhibit plaque."( Experiments with a toothpaste containing polydimethylsiloxan/triclosan.
Ellingsen, JE; Gaare, D; Rölla, G, 1993
)
1.25
"Triclosan monophosphate is a phosphorylated derivative of the antimicrobial agent, triclosan. "( Hydrolysis of triclosan monophosphate by dental plaque and selected species of oral micro-organisms.
Greenman, J; Nelson, DG, 1996
)
2.1
"Triclosan (Irgasan) is a broad spectrum antimicrobial agent used in handsoaps, toothpastes, fabrics, and plastics. "( Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli.
Levy, SB; McMurry, LM; Oethinger, M, 1998
)
1.98
"Triclosan is a broad-spectrum antibacterial agent that inhibits bacterial fatty acid synthesis at the enoyl-acyl carrier protein reductase (FabI) step. "( Mechanism of triclosan inhibition of bacterial fatty acid synthesis.
Heath, RJ; Holland, DR; Rock, CO; Rubin, JR; Snow, ME; Zhang, E, 1999
)
2.12
"Triclosan is a nonionic, broad-spectrum, antimicrobial agent that has been incorporated into a variety of personal hygiene products, including hand soaps, deodorants, shower gels, mouthwashes, and toothpastes. "( The effectiveness of triclosan-incorporated plastic against bacteria on beef surfaces.
Cutter, CN, 1999
)
2.07
"Triclosan is a widely accepted antimicrobial ingredient because of its safety and antimicrobial efficacy. "( Triclosan: a review of effectiveness and safety in health care settings.
Jampani, HB; Jones, RD; Lee, AS; Newman, JL, 2000
)
3.19
"Triclosan is an antiseptic frequently added to items as diverse as soaps, lotions, toothpaste, and many commonly used household fabrics and plastics. "( Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ.
Becher, A; Beinlich, K; Chuanchuen, R; Hoang, TT; Karkhoff-Schweizer, RR; Schweizer, HP, 2001
)
2.06
"Triclosan is a broad-spectrum hydrophobic antibacterial agent used in dermatological preparations and oral hygiene products. "( Membranotropic effects of the antibacterial agent Triclosan.
Aranda, FJ; Mateo, CR; Micol, V; Shapiro, S; Villalaín, J, 2001
)
2.01
"Triclosan is a lipophilic antimicrobial agent which, when present in an aqueous dentifrice vehicle, is complexed by or in close contact with polymers and surface-active molecules, emulsifying agents, flavoring oils and other hydrophobic ingredients. "( Plaque regrowth effects of a triclosan/pyrophosphate dentifrice in a 4-day non-brushing model.
Beiswanger, BB; Bollmer, BW; Court, LK; Crisanti, MM; Majeti, S; Mau, MS; McClanahan, SF; McClary, JM, 2000
)
2.04
"Triclosan is an antibacterial agent commonly used in industry and often detected in waste-water effluent. "( Developmental evaluation of a potential non-steroidal estrogen: triclosan.
Bennett, ER; Benson, WH; Foran, CM,
)
1.81
"Triclosan is a broad-spectrum antimicrobial agent that has been incorporated into many household and medical products. "( Soil bacteria Pseudomonas putida and Alcaligenes xylosoxidans subsp. denitrificans inactivate triclosan in liquid and solid substrates.
Callahan, TM; Meade, MJ; Waddell, RL, 2001
)
1.97
"If triclosan is an inhibitor of human fatty acid synthase and if inhibition of fatty acid synthase is toxic to breast cancer cell lines, triclosan could prove to be a lead compound for the treatment of breast cancer."( Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.
Anderson, VE; Fillgrove, KL; Liu, B; Wang, Y, 2002
)
2.27

Effects

Triclosan exposure has a profound impact on the mouse gut microbiome. Triclosan has a propensity to adhere to organic carbon in biosolids and biosolid-amended soils.

Triclosan (TCS) has been widely used as a disinfectant and antiseptic. Triclosan mouthrinse has continuous disinfecting effect and help control the formation and adhesion of dental plaque.

ExcerptReferenceRelevance
"Triclosan exposure has a profound impact on the mouse gut microbiome by inducing perturbations at both compositional and functional levels. "( Profound perturbation induced by triclosan exposure in mouse gut microbiome: a less resilient microbial community with elevated antibiotic and metal resistomes.
Bian, X; Chi, L; Gao, B; Lu, K; Ru, H; Tu, P, 2017
)
2.18
"Triclosan has a propensity to adhere to organic carbon in biosolids and biosolid-amended soils."( Human health risk assessment of triclosan in land-applied biosolids.
Capdevielle, M; Mayfield, DB; Slezak, B; Tabony, JA; Verslycke, T, 2016
)
1.44
"Triclosan has a relatively rapid clearance from the oral cavity, and attempts have been made to increase its oral retention."( Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer.
Barkvoll, P; Kjaerheim, V; Rölla, G; Skaare, A,
)
1.09
"Triclosan has potential to accumulate in sediment and aquatic organisms."( Comprehensive insight into triclosan-from widespread occurrence to health outcomes.
Milanović, M; Milić, N; Milošević, N; Đurić, L, 2023
)
1.93
"Triclosan exposure has been reported to have adverse effects on reproduction including embryo implantation disorder."( Preimplantation triclosan exposure alters uterine receptivity through affecting tight junction protein†.
Dong, G; Du, G; Lu, C; Qin, Y; Sun, R; Wang, X; Xia, Y; Zhang, R, 2022
)
1.79
"Triclosan (TCS) has been widely used in daily life because of its broad-spectrum antibacterial activities. "( Triclosan and related compounds in the environment: Recent updates on sources, fates, distribution, analytical extraction, analysis, and removal techniques.
Bian, Y; Feng, XS; Liu, ZF; Sun, C; Zhang, T; Zhang, Y; Zhou, Y, 2023
)
3.8
"Triclosan has been widely used as an antimicrobial agent. "( Detection of triclosan using 2-domain hemoglobin promoter of Daphnia magna.
Kim, YH; Min, J; Shin, HY; Vu Le, QA; Yu, J, 2023
)
2.72
"Triclosan (TCS) has become widely distributed due to its widespread use. "( Mechanism-based understanding of the potential cellular targets of triclosan in zebrafish larvae.
Liu, F; Wang, F, 2023
)
2.59
"Triclosan (TCS) has been increased in the water during the COVID-19 pandemic because it cannot remove by conventional water treatment. "( Human health risk assessment of Triclosan in water: spatial analysis of a drinking water system.
Ebrahimi, A; Ebrahimpour, K; Heidari, Z; Moazeni, M; Mohammadi, F, 2023
)
2.64
"Triclosan (TCS) has been manufactured as an antibacterial compound for half a century. "( Chronic administration of triclosan leads to liver fibrosis through hepcidin-ferroportin axis-mediated iron overload.
Liu, J; Song, Y; Xu, F; Zhang, L; Zhang, P, 2024
)
3.19
"Triclosan (TCS) has potentially toxic effects on humans and animals. "( Triclosan stimulates human vascular endothelial cell injury via repression of the PI3K/Akt/mTOR axis.
Zhang, L; Zhang, M; Zhu, R, 2020
)
3.44
"Triclosan (TCS) has been widely used as an antibacterial agent for the last several decades in personal care products. "( PI3K/Akt/FoxO pathway mediates glycolytic metabolism in HepG2 cells exposed to triclosan (TCS).
An, J; He, H; Jiang, Y; Shang, Y; Yao, W; Yu, Z, 2020
)
2.23
"Triclosan (TCS) has been immensely employed in health care products and consumer items, as an active agent with fungicidal and bactericidal potentialities, such as soaps, sanitizers, tubes of toothpaste, deodorants, skin creams, and so on for over last five decades. "( Persistence, ecological risks, and oxidoreductases-assisted biocatalytic removal of triclosan from the aquatic environment.
Barceló, D; Bilal, M; Iqbal, HMN, 2020
)
2.23
"Triclosan has been found in human plasma, urine and milk, demonstrating that it is present in human tissues."( Triclosan has a robust, yet reversible impact on human gut microbial composition in vitro.
Arango-Argoty, G; Bittinger, K; Bobokalonov, J; Fett, B; Firrman, J; Lee, JJ; Liu, LS; Mahalak, KK; Mattei, LM; Nuñez, A; Zhang, G; Zhang, H; Zhang, L, 2020
)
2.72
"Triclosan (TCS) has been widely used in daily life for its broad-spectrum antibacterial property and subsequently detected frequently in aquatic waterborne. "( Effects of triclosan on the RedoximiRs/Sirtuin/Nrf2/ARE signaling pathway in mosquitofish (Gambusia affinis).
Bao, S; He, C; Ku, P; Lin, J; Lu, S; Nie, X; Xie, M, 2021
)
2.45
"Triclosan (TCS) has attracted increasing concern due to its ubiquitous occurrence in aquatic environments as well as its potential adverse effects on human health. "( Toxicity evaluation and by-products identification of triclosan ozonation and chlorination.
Li, L, 2021
)
2.31
"Triclosan has potential risks in the Pearl River watershed."( A review of distribution and risk of pharmaceuticals and personal care products in the aquatic environment in China.
Li, L; Lin, A; Qie, H; Ren, M; Wu, H; Xiang, Y, 2021
)
1.34
"Triclosan has been found in human plasma, urine, and breast milk, and the safety of TCS-containing products has been disputed."(
Kwack, SJ; Yoon, KS, 2021
)
1.34
"Triclosan (TCS) has been used as an antiseptic, disinfectant, and preservative in various media."( Triclosan alterations of estuarine phytoplankton community structure.
Hylton, S; Pinckney, JL; Thompson, L, 2017
)
2.62
"Triclosan exposure has a profound impact on the mouse gut microbiome by inducing perturbations at both compositional and functional levels. "( Profound perturbation induced by triclosan exposure in mouse gut microbiome: a less resilient microbial community with elevated antibiotic and metal resistomes.
Bian, X; Chi, L; Gao, B; Lu, K; Ru, H; Tu, P, 2017
)
2.18
"Triclosan has been widely used as an antibacterial agent in consumer and industrial products, and large quantities continue to be discharged to natural waters annually. "( The impact of antibacterial handsoap constituents on the dynamics of triclosan dissolution from dry sand.
Kibbey, TCG; Koehler, DA; Papelis, C; Strevett, KA, 2017
)
2.13
"Triclosan (TCS) has been widely detected in pregnant women. "( Impacts of prenatal triclosan exposure on fetal reproductive hormones and its potential mechanism.
Chen, L; Gao, Y; Hu, Y; Tian, Y; Wang, C; Wang, W; Zhang, J; Zhao, S; Zhou, Y, 2018
)
2.25
"Triclosan has been shown to have endocrine-disrupting effects in aquatic organisms. "( Effects of triclosan on Japanese medaka (Oryzias latipes) during embryo development, early life stage and reproduction.
Horie, Y; Iguchi, T; Takahashi, H; Tatarazako, N; Yamagishi, T, 2018
)
2.31
"Triclosan (TCS) has been detected in human tissues. "( The effects and possible mechanisms of triclosan on steroidogenesis in primary rat granulosa cells.
Chen, W; Wang, B; Wang, L; Yang, X; Yu, X, 2019
)
2.23
"Triclosan (TCS) has been used widely in personal care products for its broad-spectrum antimicrobial activity. "( Low-dose exposure to triclosan disrupted osteogenic differentiation of mouse embryonic stem cells via BMP/ERK/Smad/Runx-2 signalling pathway.
Cheng, W; Feng, Y; Li, Y; Liang, F; Wang, W; Wang, Y; Yang, S; Zhou, R, 2019
)
2.28
"Triclosan has been used in a large number of consumer products and concerns have been raised over regarding potential genotoxicity. "( Evaluation of DNA and chromosomal damage in two human HaCaT and L02 cells treated with varying triclosan concentrations.
Li, X; Sun, D; Zhang, Z; Zhao, T, 2019
)
2.18
"Triclosan (TCS) has been widely used as a disinfectant and antiseptic in multiple consumer and healthcare products due to its clinical effectiveness against various bacteria, fungi and protozoa. "( Triclosan induces PC12 cells injury is accompanied by inhibition of AKT/mTOR and activation of p38 pathway.
Aschner, M; Chen, P; Li, SJ; Miah, MR; Peres, TV; Villahoz, BF; Zhang, Z, 2019
)
3.4
"Triclosan has received extensive attention as it has been frequently detected in the aquatic environment. "( Faster photodegradation rate and higher dioxin yield of triclosan induced by cationic surfactant CTAB.
Chen, J; Qiao, X; Xiao, J; Xie, Q; Xue, W; Yang, X; Zheng, X, 2014
)
2.09
"Triclosan has been used as a broad-spectrum antibacterial agent for over 40 years worldwide. "( Reproductive endocrine-disrupting effects of triclosan: Population exposure, present evidence and potential mechanisms.
Tian, Y; Wang, CF, 2015
)
2.12
"Triclosan has a propensity to adhere to organic carbon in biosolids and biosolid-amended soils."( Human health risk assessment of triclosan in land-applied biosolids.
Capdevielle, M; Mayfield, DB; Slezak, B; Tabony, JA; Verslycke, T, 2016
)
1.44
"Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which leads to the lysis of Mycobacterium tuberculosis. "( Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis.
Freundlich, JS; Gulten, G; Jacobs, WR; Jacobus, DP; Langley, R; Sacchettini, JC; Schiehser, GA; Vilchèze, C; Wang, F, 2009
)
3.24
"Triclosan has been widely used as a disinfectant in human health care products. "( Investigation on metabolism and pharmacokinetics of triclosan in rat plasma by using UPLC-triple quadrupole MS.
Cai, Z; Wu, J; Yue, H, 2009
)
2.05
"Triclosan has broad-spectrum anti-microbial activity against most gram-negative and gram-positive bacteria. "( Occurrence, efficacy, metabolism, and toxicity of triclosan.
Beland, FA; Fang, JL; Harrouk, W; Howard, P; Lumpkins, DL; Stingley, RL, 2010
)
2.06
"Triclosan has been commonly used as an antimicrobial and disinfectant agent. "( Sorption of triclosan onto sediments and its distribution behavior in sediment-water-rhamnolipid systems.
Chen, GR; Guo, YP; Hu, YY; Lin, H; Zhang, XY, 2011
)
2.19
"Triclosan has had widespread use in the general population as an antibacterial and antifungal agent and is commonly found in consumer products such as soaps, deodorants, toothpastes, shaving creams, mouthwashes, and cleaning supplies."( Exposure to triclosan augments the allergic response to ovalbumin in a mouse model of asthma.
Anderson, KL; Anderson, SE; Franko, J; Hubbs, AF; Kashon, ML; Lukomska, E; Meade, BJ, 2013
)
1.49
"Triclosan has activity against many, but not all, types of Gram-positive and Gram-negative bacteria. "( Whither triclosan?
Russell, AD, 2004
)
2.2
"Triclosan, which has recently been demonstrated as a potent antimalarial agent, bound to the enzyme with a binding constant of 1.08x10(5) M(-1)."( Kinetic and structural analysis of the increased affinity of enoyl-ACP (acyl-carrier protein) reductase for triclosan in the presence of NAD+.
Kapoor, M; Mukhi, PL; Suguna, K; Surolia, A; Surolia, N, 2004
)
1.26
"Triclosan has previously been found in human plasma and milk, but neither the primary source of human exposure nor the efficiency of triclosan transfer to human milk is known."( Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products.
Adolfsson-Erici, M; Allmyr, M; McLachlan, MS; Sandborgh-Englund, G, 2006
)
2.5
"Triclosan has previously been shown to be present in human plasma and milk at concentrations that are well correlated to the use of personal care products containing triclosan."( The influence of age and gender on triclosan concentrations in Australian human blood serum.
Adolfsson-Erici, M; Allmyr, M; Harden, F; McLachlan, MS; Mueller, JF; Sandborgh-Englund, G; Toms, LM, 2008
)
1.34
"Triclosan has a relatively rapid clearance from the oral cavity, and attempts have been made to increase its oral retention."( Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer.
Barkvoll, P; Kjaerheim, V; Rölla, G; Skaare, A,
)
1.09
"Triclosan has been incorporated into toothpaste to enhance inhibitory effects on bacterial metabolism in dental plaque. "( The effect of triclosan toothpaste on enamel demineralization in a bacterial demineralization model.
Buijs, JF; ten Cate, JM; van Loveren, C, 2000
)
2.11
"Triclosan has demonstrated immediate, persistent, broad-spectrum antimicrobial effectiveness and utility in clinical health care settings."( Triclosan: a review of effectiveness and safety in health care settings.
Jampani, HB; Jones, RD; Lee, AS; Newman, JL, 2000
)
2.47
"Triclosan mouthrinse has strongest anti-adhesion effect among the three tested agents."( [Effect of a new triclosan-containing mouth rinse on oral infection].
Wu, X; Zhang, T; Zhang, Y, 2001
)
1.37
"Triclosan mouthrinse has continuous disinfecting effect and help control the formation and adhesion of dental plaque."( [Effect of a new triclosan-containing mouth rinse on oral infection].
Wu, X; Zhang, T; Zhang, Y, 2001
)
2.09
"Triclosan has been added to toothpaste formulations, alone or with zinc salts, to reduce plaque regrowth. "( Toothpastes containing 0.3% and 0.5% triclosan. I. Effects on 4-day plaque regrowth.
Addy, M; Jenkins, S; Newcombe, R, 1989
)
1.99

Actions

Triclosan was found to increase estradiol and progesterone secretion after short- and long-term exposure. Triclosan is known to cause severe oxidative stress.

ExcerptReferenceRelevance
"Triclosan also promotes the binding of S."( Triclosan promotes Staphylococcus aureus nasal colonization.
Boles, BR; Ghosh, S; Love, NG; Syed, AK, 2014
)
2.57
"Triclosan is known to cause severe oxidative stress, and although the oxidative damage potential decreased concomitantly with the disappearance of triclosan after a 15 min reaction, the sustained toxicity associated with both membrane and protein stress was likely attributed at least partially to the production of 2,4-dichlorophenol that is known to cause the production of abnormal proteins and affect the cell membrane."( A quantitative toxicogenomics assay reveals the evolution and nature of toxicity during the transformation of environmental pollutants.
Alshawabkeh, AN; Gao, C; Gou, N; Gu, AZ; Lan, J; Yuan, S, 2014
)
1.12
"Triclosan is known to inhibit sulfonation of phenolic xenobiotics and is structurally related to inhibitors of estrogen sulfotransferase, such as polychlorobiphenylols."( Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta.
James, MO; Li, W; Rowland-Faux, L; Summerlot, DP; Wood, CE, 2010
)
2.52
"Triclosan induced an increase in the activity of SOD, but no significant (p>0.05) changes were observed."( Potential biochemical and genetic toxicity of triclosan as an emerging pollutant on earthworms (Eisenia fetida).
Lin, D; Liu, Y; Xie, X; Zhou, Q, 2010
)
1.34
"Triclosan was found to increase estradiol and progesterone secretion after short- and long-term exposure."( The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells.
Honkisz, E; Wojtowicz, AK; Zieba-Przybylska, D, 2012
)
1.46
"Triclosan was used to inhibit specifically Block A, whereas diazepam selectively manipulated flux through Block B."( Metabolic control analysis of developing oilseed rape (Brassica napus cv Westar) embryos shows that lipid assembly exerts significant control over oil accumulation.
Fawcett, T; Guschina, IA; Harwood, JL; O'Hara, P; Quant, PA; Slabas, AR; Tang, M, 2012
)
1.1
"Triclosan is known to inhibit this enzyme effectively."( Structural basis for the variation in triclosan affinity to enoyl reductases.
Kapoor, M; Pidugu, LS; Suguna, K; Surolia, A; Surolia, N, 2004
)
1.32
"Triclosan was able to inhibit the induction of the androgen-responsive LTR-CAT reporter gene in S115 mouse mammary tumour cells by 10(-9) m testosterone and in T47D human breast cancer cells by 10(-8) m testosterone at concentrations of 10(-7) m and 10(-6) m, respectively."( Oestrogenic and androgenic activity of triclosan in breast cancer cells.
Charles, A; Darbre, PD; Gee, RH; Taylor, N, 2008
)
1.34

Treatment

Triclosan (TCS) was treated under hydrothermal conditions at 240 °C for 4 h, either dissolved in aqueous solution or preadsorbed onto activated carbon (AC) Triclosan treatment decreased total serum T(4) and T(3) in pregnant rats and also lowered sex ratio, lowered pup body weights on postnatal day (PND) 20, and delayed VO in offspring.

ExcerptReferenceRelevance
"Only triclosan treatment was able to avoid an increase in bleeding on probing (BOP) throughout the follow-ups (P > 0.05), whereas a significant intensification in BOP was observed from the 14th day in the placebo-treated sites (P < 0.05)."( Impact of a triclosan-containing toothpaste during the progression of experimental peri-implant mucositis: Clinical parameters and local pattern of osteo-immunoinflammatory mediators in peri-implant fluid.
Casarin, RC; Casati, MZ; Cirano, FR; Corrêa, MG; Negri, BM; Pimentel, SP; Ribeiro, FV, 2018
)
1.31
"Triclosan-treated fish at 26 °C were fed untreated pellets for 5 additional weeks."( Accumulation of triclosan from diet and its neuroendocrine effects in Atlantic croaker (Micropogonias undulatus) under two temperature Regimes.
Diamond, SL; Hedrick-Hopper, TL; Koster, LP, 2015
)
1.48
"Triclosan (TCS) was treated under hydrothermal conditions at 240 °C for 4 h, either dissolved in aqueous solution or preadsorbed onto activated carbon (AC). "( Hydrothermal Conversion of Triclosan-The Role of Activated Carbon as Sorbent and Reactant.
Kopinke, FD; Sühnholz, S; Weiner, B, 2017
)
2.19
"Triclosan treatment decreased total serum T(4) and T(3) in pregnant rats and also lowered sex ratio, lowered pup body weights on postnatal day (PND) 20, and delayed VO in offspring."( Maternal exposure to triclosan impairs thyroid homeostasis and female pubertal development in Wistar rat offspring.
Rodríguez, PE; Sanchez, MS, 2010
)
1.4
"Biotreatment of triclosan is mainly performed in conventional activated sludge systems, which, however, are not capable of completely removing this antibacterial agent. "( Biotreatment efficiency, degradation mechanism and bacterial community structure in an immobilized cell bioreactor treating triclosan-rich wastewater.
Melidis, P; Navrozidou, E; Ntougias, S; Remmas, N; Sylaios, G, 2023
)
1.46
"Pre-treatment with triclosan before SLS exposure had a slight effect whereas treatment after exposure showed a significant effect."( Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure.
Barkvoll, P; Rølla, G, 1994
)
2.05
"Pretreatment with triclosan potentiated the toxicity of a subsequent exposure of SLS to the S-G cells; a similar pretreatment of the GF fibroblasts with triclosan had no effect on a subsequent challenge with SLS."( Sodium lauryl sulfate and triclosan: in vitro cytotoxicity studies with gingival cells.
Babich, H; Babich, JP, 1997
)
0.92

Toxicity

Triclosan (TCS) has drawn increasing concern due to its potential to exert multiple adverse effects, ranging from endocrine disruption to carcinogenesis. This study aimed to evaluate the influence of different polymer types of MPs including polyethylene (PE), polypropylene (PP), and polyvinyl chloride (PVC) on the adsorption, accumulation, and toxic effects of triclosan in zebrafish.

ExcerptReferenceRelevance
" The LD50 values of Irgasan DP300, II, III and IV were 1,090, 710, 650 and 430 mg/kg, respectively."( Acute toxicity, percutaneous absorption and effects on hepatic mixed function oxidase activities of 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan DP300) and its chlorinated derivatives.
Kaneshima, H; Kanetoshi, A; Katsura, E; Miura, T; Ogawa, H; Ohyama, T, 1992
)
0.28
" Based on these studies, triclosan can be considered safe for use in dentifrice and mouthrinse products."( Triclosan: a safety profile.
DeSalva, SJ; Kong, BM; Lin, YJ, 1989
)
2.02
"The acute intraperitoneal LD50 values of hydroxynonachlorodiphenyl ethers (HO-Cl9-DPEs) in mice have been determined."( The acute toxicity of nonachloropredioxin and 3- and 4-hydroxynonachlorodiphenyl ether in mice.
Deinzer, ML; Lorusso, DJ; Miller, TL,
)
0.13
" Over the 6-month observation period, the sodium hexametaphosphate and the marketed control dentifrices were comparable in terms of adverse event type and severity, and no subject discontinued treatment due to an oral soft tissue adverse event."( Anticalculus efficacy and safety of a novel whitening dentifrice containing sodium hexametaphosphate: a controlled six-month clinical trial.
Baker, R; Gerlach, R; Liu, H; Ramsey, L; Segreto, V; Vastola, K, 2002
)
0.31
" Triclosan, a compound used for inhibiting microbial growth, was not toxic to wastewater microorganisms at concentrations less than aqueous solubility."( Aquatic toxicity of triclosan.
Capdevielle, M; Cunningham, V; Inauen, J; Orvos, DR; Rothenstein, A; Versteeg, DJ, 2002
)
1.55
" Comparison between both assays confirmed that Vibrio fischeri is generally more sensitive than autotrophic bacteria, and, if not calibrated, the bioluminescence method tends to overestimate toxic effects on activated sludge biomass."( Comparison of bioluminescence and nitrification inhibition methods for assessing toxicity to municipal activated sludge.
Andreadakis, AD; Kouris, N; Mamais, D; Noutsopoulos, C; Stasinakis, AS, 2008
)
0.35
"Coated polyglactin 910 with tricosan (Vicryl Plus) is safe and satisfactory in surgical practice."( Efficacy of antimicrobial coating suture coated polyglactin 910 with tricosan (Vicryl plus) compared with polyglactin 910 (Vicryl) in reduced surgical site infection of appendicitis, double blind randomized control trial, preliminary safety report.
Mingmalairak, C; Paocharoen, V; Ungbhakorn, P, 2009
)
0.35
" Triclosan can be considered safe for use in hydrophobic creams."( Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
Abdel-Tawab, M; Bastian, B; Doroshyenko, O; Fuhr, U; Meins, J; Queckenberg, C; Tomalik-Scharte, D; Wachall, B, 2010
)
1.53
" Based on these results, exposure to triclosan in consumer products is not expected to cause adverse health effects in children or adults who use these products as intended."( Triclosan: a critical review of the experimental data and development of margins of safety for consumer products.
Borzelleca, JF; Maronpot, RR; Rodricks, JV; Shipp, AM; Swenberg, JA, 2010
)
2.08
" We investigated the toxicological interactions of the most toxic surfactant, docusate sodium, with two chlorinated compounds, triclosan and 2,4,6-trichlorophenol (TCP), in their binary and ternary mixtures using the method of the combination index based on the median-effect equation."( Ecotoxicological assessment of surfactants in the aquatic environment: combined toxicity of docusate sodium with chlorinated pollutants.
Boltes, K; Fernández-Piñas, F; Leganés, F; Petre, A; Rodea-Palomares, I; Rosal, R, 2010
)
0.57
" TCS is highly toxic to algae and exerts reproductive and developmental effects in some fish."( Triclosan: environmental exposure, toxicity and mechanisms of action.
Dann, AB; Hontela, A, 2011
)
1.81
"As a consequence, it can be transformed into potentially more toxic and persistent compounds, such as chlorinated phenols and biphenyl ethers after chlorination, methyl triclosan after biological methylation, and chlorinated dibenzodioxins after photooxidation."( Occurrence and toxicity of antimicrobial triclosan and by-products in the environment.
Bedoux, G; Dupont, V; Le Bot, B; Roig, B; Thomas, O, 2012
)
0.84
" Because TCS is an antimicrobial and is toxic to some aquatic organisms, concern has arisen that TCS may adversely affect soil organisms."( Toxicity and bioaccumulation of biosolids-borne triclosan in terrestrial organisms.
O'Connor, GA; Pannu, MW; Toor, GS, 2012
)
0.63
" In the present study, 48-h paper contact and 28-day spiked soil tests were conducted to examine the toxic effects of TCS on the antioxidative and genetic indices of earthworms (Eisenia fetida)."( Biochemical and genotoxic effect of triclosan on earthworms (Eisenia fetida) using contact and soil tests.
Lin, D; Liu, Y; Xie, X; Zhou, Q, 2012
)
0.65
" As results of toxicity tests, TCS was found to be most strongly toxic for green algae [e."( Ecotoxicity and screening level ecotoxicological risk assessment of five antimicrobial agents: triclosan, triclocarban, resorcinol, phenoxyethanol and p-thymol.
Kagota, K; Kameda, Y; Kimura, K; Morita, J; Nakada, N; Tamura, I; Tatarazako, N; Yamamoto, H; Yasuda, Y; Yoneda, S, 2013
)
0.61
"The toxic effects of triclosan (TCS) on the swordtail fish (Xiphophorus helleri) were assessed based on various biomarkers including enzymatic activities of ethoxyresorufin O-deethylase (EROD), erythromycin N-demethylase (ERND) and glutathione-s-transferase (GST) and mRNA expression levels of CYP1A, CYP3A, glutathione S-transferase (GST) and P-glycoprotein (P-gp)."( Assessment of toxic effects of triclosan on the swordtail fish (Xiphophorus helleri) by a multi-biomarker approach.
An, T; Li, K; Liang, X; Nie, X; Ying, G, 2013
)
0.99
"Triclosan, one of the most widely used disinfectants, has been found to be toxic to animals and human beings."( Photoelectrocatalytic degradation of triclosan on TiO2 nanotube arrays and toxicity change.
Cao, X; Li, T; Liu, G; Liu, H; Tough, R; Wang, Y; Zhang, N, 2013
)
2.11
"Triclosan (TCS) is considered a potent endocrine disruptor that causes reproductive toxicity in non-mammals, but it is still unclear exactly whether TCS has adverse effects on the sperm or reproductive organs in mammals."( Triclosan exhibits a tendency to accumulate in the epididymis and shows sperm toxicity in male Sprague-Dawley rats.
Hui Chen, X; Hyung Kim, T; Lan, Z; Shun Bi, K; Sik Kim, H, 2015
)
3.3
"The toxic effects of different concentrations of Triclosan (TCS) (1-128 μg/L) on Daphnia magna (D."( Toxic effects of triclosan on the detoxification system and breeding of Daphnia magna.
Liao, W; Luo, Y; Nie, XP; Peng, Y; Yang, YF; Ying, GG, 2013
)
0.98
" Afflicted, but safe substances could therefore be lost."( Way forward in case of a false positive in vitro genotoxicity result for a cosmetic substance?
Ates, G; Doktorova, TY; Rogiers, V; Vanhaecke, T; Vinken, M, 2014
)
0.4
" The present study investigates whether exposure of 6 plant species (radish, carrot, soybean, lettuce, spring wheat, and corn) to triclosan or triclocarban derived from biosolids has an adverse effect on seed emergence and/or plant growth parameters."( Toxicity of biosolids-derived triclosan and triclocarban to six crop species.
Lissemore, L; Prosser, RS; Sibley, PK; Solomon, KR, 2014
)
0.9
"Triclosan, an antimicrobial agent commonly used in down-the-drain consumer products, is toxic to freshwater microalgae."( Accounting for dissociation and photolysis: a review of the algal toxicity of triclosan.
Bettles, N; Price, OR; Rendal, C; Roberts, J; van Egmond, R, 2014
)
2.07
"3% triclosan-toothpaste on serious adverse events (SAEs) in patients with cardiovascular disease (CVD)."( The influence of a triclosan toothpaste on adverse events in patients with cardiovascular disease over 5-years.
Carle, AD; Cullinan, MP; Palmer, JE; Seymour, GJ; West, MJ; Westerman, B, 2015
)
1.37
"The information about adverse effects of emerging contaminants on aquatic protozoa is very scarce."( Effects of triclosan and triclocarban on the growth inhibition, cell viability, genotoxicity and multixenobiotic resistance responses of Tetrahymena thermophila.
Ao, J; Bai, Q; Cheng, P; Gao, L; Wang, W; Yuan, T; Zhang, H; Zhou, C, 2015
)
0.81
" Standard laboratory assays have shown that TCS is toxic to aquatic organisms; however, varied environmental conditions could impact this risk."( Developmental Toxicity of Triclosan in the Presence of Dissolved Organic Carbon: Moving Beyond Standard Acute Toxicity Assays to Understand Ecotoxicological Risk.
Carmosini, N; Grandstrand, S; King-Heiden, TC, 2016
)
0.73
" TCS readily bioaccumulates within aquatic organisms, and has been found to be toxic to fish."( Cardiac Toxicity of Triclosan in Developing Zebrafish.
Hess, M; Howard, D; King-Heiden, TC; Miller, K; Saley, A, 2016
)
0.76
" The toxic effects of TCS on temperate standard aquatic test organisms have been widely reported with microalgae being the most sensitive."( Effects of triclosan on aquatic invertebrates in tropics and the influence of pH on its toxicity on microalgae.
Khatikarn, J; Price, OR; Satapornvanit, K; Van den Brink, PJ, 2018
)
0.87
" In addition, 2,4-dichlorophenol and 4-chlorocatechol were less toxic than triclosan to HepG2/vector cells."( Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Beland, FA; Chitranshi, P; Fang, JL; Gamboa da Costa, G; Loukotková, L; Wu, Y; Zhang, J, 2017
)
0.95
" We verified the feasibility of using synchrotron-based Fourier Transform Infrared (SR-FTIR) spectromicroscopy to explore in vivo toxic effects on single living Chlorococcum sp."( Molecular toxicity of triclosan and carbamazepine to green algae Chlorococcum sp.: A single cell view using synchrotron-based Fourier transform infrared spectromicroscopy.
An, C; Chen, X; Huang, G; Liu, X; Weger, H; Xin, X; Yao, Y; Zhang, P, 2017
)
0.77
"Triclosan (5-chloro-2'-(2,4-dichlorophenoxy)phenol), a widely used antibacterial agent, exerts adverse effects on the organism of mammals."( Mechanism of triclosan toxicity: Mitochondrial dysfunction including complex II inhibition, superoxide release and uncoupling of oxidative phosphorylation.
Belosludtsev, KN; Kruglov, AG; Teplova, VV, 2017
)
2.27
" Higher PAH, fragrance compounds, and triclosan concentrations were found in sewage sludge from urban areas compared with rural regions, and the urban sludge was also more toxic than the rural sludge."( Loading and removal of PAHs, fragrance compounds, triclosan and toxicity by composting process from sewage sludge.
Kindaichi, T; Nakashima, K; Nakazato, A; Ohashi, A; Ozaki, N, 2017
)
0.98
" Some are highly toxic to algae, including antifoulants, herbicides, and fungicides."( Mixture toxicity of five biocides with dissimilar modes of action on the growth and photosystem II efficiency of Chlamydomonas reinhardtii.
de Almeida, ACG; Langford, K; Petersen, K; Thomas, KV; Tollefsen, KE, 2017
)
0.46
" The microalgal growth inhibition assay confirmed absence of toxic effects of triclosan on Chlorella sp."( Toxicity assessment of pesticide triclosan by aquatic organisms and degradation studies.
Cakir, DN; Çelik, HS; Özdemir, C; Taştan, BE; Tekinay, T, 2017
)
0.96
" Results from this study showed that triclosan was toxic to Cyclotella sp."( Biouptake, toxicity and biotransformation of triclosan in diatom Cyclotella sp. and the influence of humic acid.
Bao, L; Ding, T; Gan, J; Li, J; Lin, K; Yang, B; Yang, M, 2018
)
1.01
" Generally, TCS was more toxic to the four aquatic organisms in acidic medium."( The pH-dependent toxicity of triclosan to five aquatic organisms (Daphnia magna, Photobacterium phosphoreum, Danio rerio, Limnodrilus hoffmeisteri, and Carassius auratus).
Ajarem, J; Allam, AA; Chen, J; Li, C; Qu, R; Wang, Z; Zhang, S, 2018
)
0.77
" In the single-substance tests, TCC was about 30 times more toxic than TCS when considering effects on growth and concerning reproduction, TCC was about 50 times more toxic than TCS."( The toxicity of a mixture of two antiseptics, triclosan and triclocarban, on reproduction and growth of the nematode Caenorhabditis elegans.
Spann, N; Vingskes, AK, 2018
)
0.74
" These results demonstrate the application of FTIR spectroscopy to sediment toxicity testing of chemicals to benthic invertebrates with biochemical alterations as endpoints that are more sensitive than standard toxic endpoints (e."( Insights into the sediment toxicity of personal care products to freshwater oligochaete worms using Fourier transform infrared spectroscopy.
Hu, LX; Pan, CG; Peng, FJ; Van den Brink, PJ; Ying, GG, 2019
)
0.51
" In this article, we carried out a literature review of recent studies on the toxic effects of TCS from different aspects at the molecular, cell, tissue, organ, and individual level."( Research Progress on Toxic Effects and Water Quality Criteria of Triclosan.
Fan, J; Liu, P; Wang, P; Wang, S; Yan, Z; Zhang, T; Zheng, X, 2019
)
0.75
" Recent studies showed that TCS can easily migrate into the human brain and animal tissues and cause adverse changes in various target organs."( Neurobehavioral toxicity of triclosan in mice.
Esfahani, ML; Hosseini, SM; Rahimi, A; Tabari, SA, 2019
)
0.81
" elegans were monitored for a better interpretation of toxic effects."( Metabolomics and phenotype assessment reveal cellular toxicity of triclosan in Caenorhabditis elegans.
Kim, HM; Kwon, SW; Long, NP; Nguyen, HT; Yoon, SJ, 2019
)
0.75
" The sludge utilization for fertilizers on agricultural land would pose the risk of causing adverse effects on plant growth and yield by TCS."( Salicylic acid application alleviates the adverse effects of triclosan stress in tobacco plants through the improvement of plant photosynthesis and enhancing antioxidant system.
Guan, C; Ji, J; Jin, C; Li, Q; Wang, C; Wang, G; Wu, H; Zhang, Y, 2020
)
0.8
" In order to investigate the mechanisms of toxic action and the efflux pumps involved in their detoxication, we used a strategy with batteries of Schizosaccharomyces pombe yeast strains, either defective in cell signalling, in detoxification pumps, or in cell surveillance mechanisms."( Investigation of mechanisms of toxicity and exclusion by transporters of the preservatives triclosan and propylparaben using batteries of Schizosaccharomyces pombe strains.
Álvarez-Herrera, C; Maisanaba, S; Repetto, G, 2020
)
0.78
" Traditionally, the adverse effects of TCS and its by-products have been evaluated by examining the phenotypic output relevant to predicting acute toxicity rather than studying the perturbation of biological pathways."( The toxic effect of triclosan and methyl-triclosan on biological pathways revealed by metabolomics and gene expression in zebrafish embryos.
Bae, S; Fu, J; Gong, Z; Tan, YXR, 2020
)
0.88
" However, an important criterion for the assessment of AOPs and their operation conditions could be the potential formation of new toxic secondary products, such as polychlorinated dibenzo-p-dioxins and furans (PCDD/Fs), especially when emerging pollutants are present in the media."( Potential formation of PCDD/Fs in triclosan wastewater treatment: An overall toxicity assessment under a life cycle approach.
Aldaco, R; Irabien, A; Laso, J; Margallo, M; Ortiz, I; San-Román, MF; Schröder, S; Solá-Gutiérrez, C; Vázquez-Rowe, I, 2020
)
0.84
"Triclosan (TCS), an antimicrobial agent widely used in personal care products and ubiquitously exists in environment, has drawn increasing concern due to its potential to exert multiple adverse effects, ranging from endocrine disruption to carcinogenesis."( Characterization of covalent protein modification by triclosan in vivo and in vitro via three-dimensional liquid chromatography-mass spectrometry: New insight into its adverse effects.
Bai, LP; Guo, MQ; Li, N; Liu, M; Sun, B; Wu, JL; Zhang, M; Zhang, Y; Zheng, Z; Zhuo, Y, 2020
)
2.25
"The proliferation and possible adverse effects of emerging contaminants such as pharmaceutical and personal care products (PPCPs) in waters and the environment is a cause for increasing concern."( Bacterial ecotoxicity and shifts in bacterial communities associated with the removal of ibuprofen, diclofenac and triclosan in biopurification systems.
Aguilar-Romero, I; Romero, E; van Dillewijn, P; Wittich, RM, 2020
)
0.77
"05 mg/L) of triclosan, a highly toxic and persistent biocide used in personal care products."( Biomarkers for the toxicity of sublethal concentrations of triclosan to the early life stages of carps.
Bhardwaj, R; Dar, OI; Kaur, A; Sharma, A; Sharma, S; Singh, K, 2020
)
1.18
" PCPs are biologically active substances that can exert an adverse effect on the ecology and food safety."( Occurrence and Safety Evaluation of Antimicrobial Compounds Triclosan and Triclocarban in Water and Fishes of the Multitrophic Niche of River Torsa, India.
Aftabuddin, M; Bandyopadhyay, S; Das Sarkar, S; Das, BK; Kumari, K; Nag, SK; Saha, K, 2020
)
0.8
" This study aimed to evaluate the influence of different polymer types of MPs including polyethylene (PE), polypropylene (PP), and polyvinyl chloride (PVC) on the adsorption, accumulation, and toxic effects of triclosan (TCS) in zebrafish."( The influence of different polymer types of microplastics on adsorption, accumulation, and toxicity of triclosan in zebrafish.
Sheng, C; Zhang, S; Zhang, Y, 2021
)
1.02
"Triclosan (TCS) has attracted increasing concern due to its ubiquitous occurrence in aquatic environments as well as its potential adverse effects on human health."( Toxicity evaluation and by-products identification of triclosan ozonation and chlorination.
Li, L, 2021
)
2.31
"Triclosan (TCS), an emergent pollutant, is raising a global concern due to its toxic effects on organisms and aquatic ecosystems."( Biomarkers-based assessment of triclosan toxicity in aquatic environment: A mechanistic review.
Bera, KK; Bhushan Kumar, C; Karmakar, S; Kumar, K; Kumar, S; Paul, T; Shukla, SP, 2021
)
2.35
" It is reported exposure to triclosan can cause serious toxic effects on aquatic animals."( Long-term exposure to environmental relevant triclosan induces reproductive toxicity on adult zebrafish and its potential mechanism.
Han, P; He, J; Qiao, Y; Qu, J; Wang, J; Wang, X, 2022
)
1.28
" Herein, we evaluated the toxic effects of TCS on the development of cartilage and osteogenesis in 5-dpf zebrafish."( Toxicity mechanisms regulating bone differentiation and development defects following abnormal expressions of miR-30c targeted by triclosan in zebrafish.
Ai, W; Li, X; Wang, D; Wang, H; Wang, W; Wang, X, 2022
)
0.93
" The present study further widens our insights into the adverse effects of TCS."( Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders.
Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023
)
1.24
" Accumulating evidence suggests that TCS is considered as a novel endocrine disruptor and may have potential unfavorable effects on human health, but studies on the toxic effect mediated by TCS exposure as well as its underlying mechanisms of action are relatively sparse."( Adverse effects of triclosan exposure on health and potential molecular mechanisms.
Chen, X; Liu, C; Mou, L; Qu, J; Wu, L, 2023
)
1.24
" Results showed that AgNPs was toxic to Euglena sp."( Individual and combined toxicity of silver nanoparticles and triclosan or galaxolide in the freshwater algae Euglena sp.
Ding, T; Li, J; Lin, S; Wei, L; Yue, Z, 2023
)
1.15
" In this study, we investigated the toxic effects of TCS exposure (1."( MiR-133b as a crucial regulator of TCS-induced cardiotoxicity via activating β-adrenergic receptor signaling pathway in zebrafish embryos.
Qian, Q; Wan, X; Wang, H; Yan, J, 2023
)
0.91

Pharmacokinetics

The aim of the present study was to obtain information on baseline levels of triclosan in plasma and urine. Plasma samples from SD rats collected after the oral administration of 5 mg/kg tricrosan were analyzed by ultra performance liquid chromatography.

ExcerptReferenceRelevance
" The aim of the present study was to (1) obtain information on baseline levels of triclosan in plasma and urine, and (2) study the pharmacokinetic pattern of triclosan after a single-dose intake."( Pharmacokinetics of triclosan following oral ingestion in humans.
Adolfsson-Erici, M; Ekstrand, J; Odham, G; Sandborgh-Englund, G, 2006
)
0.88
" Plasma samples from SD rats collected after the oral administration of 5 mg/kg triclosan were analyzed by ultra performance liquid chromatography (UPLC)-triple quadrupole mass spectrometry (TQMS) to support the pharmacokinetic study of triclosan."( Investigation on metabolism and pharmacokinetics of triclosan in rat plasma by using UPLC-triple quadrupole MS.
Cai, Z; Wu, J; Yue, H, 2009
)
0.83

Compound-Compound Interactions

The objective of this study was to investigate the antibacterial effects on a cariogenic biofilm of a bioactive glass. Dispersive liquid-liquid microextraction combined with capillary zone electrophoresis-UV detection was developed for analyzing triclosan (TCS) and bisphenol A (BPA)

ExcerptReferenceRelevance
"In this study, dispersive liquid-liquid microextraction (DLLME) combined with ultra-high-pressure liquid chromatography (UHPLC)-tunable ultraviolet detection (TUV), has been developed for pre-concentration and determination of triclosan (TCS), triclocarban (TCC) and methyl-triclosan (M-TCS) in aqueous samples."( Determination of triclosan, triclocarban and methyl-triclosan in aqueous samples by dispersive liquid-liquid microextraction combined with rapid liquid chromatography.
Cao, XL; Guo, JH; Li, XH; Li, Y; Wang, XZ; Xu, XB, 2009
)
0.88
" Subsequently, we examined triclosan in combination with bisphenol-A (BPA), which also can disrupt implantation."( Disruption of blastocyst implantation by triclosan in mice: impacts of repeated and acute doses and combination with bisphenol-A.
Crawford, BR; Decatanzaro, D, 2012
)
0.94
"Dispersive liquid-liquid microextraction combined with capillary zone electrophoresis-UV detection was developed for analyzing triclosan (TCS) and bisphenol A (BPA) in water, beverage, and urine samples."( Separation and determination of triclosan and bisphenol A in water, beverage, and urine samples by dispersive liquid-liquid microextraction combined with capillary zone electrophoresis-UV detection.
Liu, H; Wang, H; Wang, W; Wang, X; Zhang, A; Zhang, M,
)
0.62
"The objective of this study was to investigate the antibacterial effects on a cariogenic biofilm of a bioactive glass (BAG) combined with either sodium fluoride (NaF) or triclosan (TCS)."( Antimicrobial effects of a bioactive glass combined with fluoride or triclosan on Streptococcus mutans biofilm.
Chen, YM; Shi, SY; Smales, RJ; Wang, MT; Wu, Q; Xu, YT, 2015
)
0.85
" A possible degradation pathway of TCS was investigated according to the detected intermediates, which were identified by liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) combined with theoretical calculation of Gaussian 09 program."( Degradation of triclosan in aqueous solution by dielectric barrier discharge plasma combined with activated carbon fibers.
Feng, J; He, D; Sun, Y; Wang, J; Xin, L, 2016
)
0.79
" To increase its yield of arachidonic acid, heavy ion beam irradiation mutagenesis of Mortierella alpina was carried out in combination with triclosan and octyl gallate treatment."( Heavy ion mutagenesis combined with triclosan screening provides a new strategy for improving the arachidonic acid yield in Mortierella alpina.
Cui, Q; Feng, Y; Li, X; Lu, D; Song, X; Zhang, H, 2018
)
0.96

Bioavailability

differences in respiration inhibition between soils at equivalent dose were inversely correlated with organic matter and clay content. This suggested that triclosan bioavailability was different in these strains.

ExcerptReferenceRelevance
"3% triclosan/PVM/MA copolymer/NaF test dentifrice provided effective delivery and bioavailability of the antiplaque agent, triclosan."( Salivary and plaque triclosan levels after brushing with a 0.3% triclosan/copolymer/NaF dentifrice.
Afflitto, J; Fakhry-Smith, S; Gaffar, A, 1989
)
1.22
" These included fluoride bioavailability tests, enamel lesion de- and remineralisation studies ('pH-cycling') and in situ caries studies."( The caries preventive effect of a fluoride dentifrice containing Triclosan and zinc citrate, a compilation of in vitro and in situ studies.
ten Cate, JM, 1993
)
0.52
" The absorption rate was determined in rats by histopathology at 7, 28, 56, 63, 70, and 77 days post-implantation."( Physical and functional comparison of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan) with Coated VICRYL* Suture (coated polyglactin 910 suture).
Jacinto, G; Scalzo, H; Storch, M; Van Lue, S, 2002
)
0.52
" Results from both a bioavailability assay and gas chromatography mass spectrometry analyses, revealed that only trace amounts of triclosan desorbed from the plastic."( Effects of triclosan incorporation into ABS plastic on biofilm communities.
Hay, AG; Junker, LM, 2004
)
0.92
" This suggested that triclosan bioavailability was different in these strains."( Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa.
Escalada, MG; Harwood, JL; Maillard, JY; Ochs, D, 2005
)
2.09
" The next step in optimization of the pharmacophore for preclinical evaluation is modification of the B ring to increase the bioavailability to that required for oral delivery."( Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.
amEnde, CW; Amin, AG; Boyne, ME; Chatterjee, D; Gruppo, V; Heaslip, D; Lenaerts, A; Lu, H; Slayden, RA; Sullivan, TJ; Tonge, PJ, 2007
)
0.34
" To investigate algal sensitivity to triclosan in more detail, bioavailability was considered by investigating suspended and attached living algae."( What contributes to the sensitivity of microalgae to triclosan?
Altenburger, R; Franz, S; Heilmeier, H; Schmitt-Jansen, M, 2008
)
0.87
" However, mineral-facilitated TCS polymerization may reduce its mobility and bioavailability in soils."( Transformation of Triclosan by Fe(III)-saturated montmorillonite.
Gwaltney, SR; Liyanapatirana, C; Xia, K, 2010
)
0.69
" Differences in respiration inhibition between soils at equivalent dose were inversely correlated with organic matter and clay content, suggesting that the bioavailability of triclosan might have been reduced by sorption to organic carbon or by physical protection in micropores."( Effects of triclosan on soil microbial respiration.
Butler, E; Ritz, K; Sakrabani, R; van Egmond, R; Whelan, MJ, 2011
)
0.95
" However, these data also suggest substantially reduced bioavailability of TCC in biosolids-amended soils compared with HOC partitioning theory."( Persistence of triclocarban and triclosan in soils after land application of biosolids and bioaccumulation in Eisenia foetida.
Chalew, TE; Halden, RU; Higgins, CP; Hundal, LS; Paesani, ZJ, 2011
)
0.65
" It is important to determine the bioavailability of EEDCs in soil to inform risk assessment concerning their environmental presence; Eisenia fetida (earthworms) are typically used in traditional in vivo bioavailability experiments."( Development of an in vitro thin-film solid-phase microextraction method to determine the bioavailability of xenoestrogens in soil.
Engler, KN; Lemley, AT, 2013
)
0.39
" The concentrations determined by this biomimetic method were compared with the bioavailability of TCS, determined by its accumulation in the roots of wheat plants grown in the same soil-biosolid systems."( New biomimetic approach to determine the bioavailability of triclosan in soils and its validation with the wheat plant uptake bioassay.
Ahumada, I; Fuentes, E; Jachero, L; Richter, P, 2015
)
0.66
" For example, we would predict that sorption to dissolved organic carbon (DOC) in natural surface waters would reduce the bioavailability and, therefore, toxicity of TCS."( Developmental Toxicity of Triclosan in the Presence of Dissolved Organic Carbon: Moving Beyond Standard Acute Toxicity Assays to Understand Ecotoxicological Risk.
Carmosini, N; Grandstrand, S; King-Heiden, TC, 2016
)
0.73
"Regulatory ecotoxicology testing rarely accounts for the influence of natural water chemistry on the bioavailability and toxicity of a chemical."( The impact of natural and anthropogenic Dissolved Organic Carbon (DOC), and pH on the toxicity of triclosan to the crustacean Gammarus pulex (L.).
Comber, SDW; Hutchinson, TH; Rowett, CJ, 2016
)
0.65
" The general aim of this study was to evaluate the effects of biosolid application on EE2 and TCS adsorption and bioavailability in soils through testing with wheat plants."( Effects of applying biosolids to soils on the adsorption and bioavailability of 17α-ethinylestradiol and triclosan in wheat plants.
Ahumada, I; Ascar, L; Brown, S; Cantarero, R; Richter, P, 2017
)
0.67
", aging) which may impact the bioavailability and, thus, ultimate toxicity of the chemical."( Using laboratory-generated biosolids to evaluate the microbial ecotoxicity of triclosan in a simulated land application scenario.
Gardner, CM; Gunsch, CK; Holzem, RM; Stapleton, HM, 2018
)
0.71
" Compound 12g with MIC values of 5 μg/ml as a representative may possess better oral bioavailability and indicated high permeability by the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB)."( Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T, 2018
)
0.48
" Moreover, when the embryos were exposed to a mix of TCS and MTCS, TCS dominated the mixture's effect on biological pathways because the concentration ratio within the mixture, which mimics environmental ratio of 10 TCS : 1 MTCS, leads to high bioavailability of TCS."( Assessment of the effect of methyl-triclosan and its mixture with triclosan on developing zebrafish (Danio rerio) embryos using mass spectrometry-based metabolomics.
Bae, S; Fu, J; Gong, Z, 2019
)
0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"According to ISO 17402:2008 more knowledge is needed on processes controlling bioavailability of organic species so as to close the still existing gap between chemical measurements and biological effects."( In-vitro prediction of the membranotropic action of emerging organic contaminants using a liposome-based multidisciplinary approach.
Adrover, M; Frontera, A; Miró, M; Oliver, M; Ortega-Castro, J, 2020
)
0.56
"Surface-active substances may enhance the bioavailability of certain pollutants by modifying the permeability of cell membranes."( The role of PFOS on triclosan toxicity to two model freshwater organisms.
Beltrán, EM; Fernández Torija, C; García Hortigüela, P; González-Doncel, M; López Arévalo, M; Pablos, MV, 2020
)
0.88
" Among these pollutants, the surface-active substances have been suggested to enhance the bioavailability of other ECs."( The effect of PFOs on the uptake and translocation of emerging contaminants by crops cultivated under soil and soilless conditions.
Beltrán, EM; Fernández-Torija, C; García-Hortigüela, P; González-Doncel, M; Pablos, MV; Porcel, MÁ, 2021
)
0.62
" The analysis presented provides a framework to interpret future antiseptic monitoring results, including monitoring parameters and modeling approaches to address bioavailability of the chemicals of interest."( Ecological Risk Analysis for Benzalkonium Chloride, Benzethonium Chloride, and Chloroxylenol in US Disinfecting and Sanitizing Products.
Bock, M; Brown, L; Fetters, K; Fuchsman, P; Henning, M; Mrdjen, I; O'Connor, A; Stanton, K, 2022
)
0.72
"Toxicity of silver nanoparticles (AgNPs) at environmentally relevant concentrations has been received an increasing attention, and their influence on the bioavailability of personal care products has been seldom studied."( The combined toxicity of silver nanoparticles and typical personal care products in diatom Navicula sp.
Ding, T; Lin, S; Wei, L; Yue, Z; Zhang, L, 2023
)
0.91

Dosage Studied

Triclosan is a suitable antibacterial candidate for the bone tissue engineering and medical applications since the real dosage of triclosan stays at ca. 0.1%.

ExcerptRelevanceReference
" Pharmacokinetic data demonstrate that approximately 30% of the zinc and Triclosan dosed is retained immediately after brushing."( Zinc citrate/Triclosan: a new anti-plaque system for the control of plaque and the prevention of gingivitis: short-term clinical and mode of action studies.
Cummins, D, 1991
)
0.88
" Unfortunately, there have been few dose-response studies for chlorhexidine mouthrinses and for these, only limited details are published."( Dose response of chlorhexidine against plaque and comparison with triclosan.
Addy, M; Jenkins, S; Newcombe, RG, 1994
)
0.53
" Extending the dose-response study to higher concentrations is considered impractical if not unjustifiable, because of potential harmful local side-effects and compliance difficulties."( A dose-response study of triclosan mouthrinses on plaque regrowth.
Addy, M; Jenkins, S; Newcombe, RJ, 1993
)
0.59
" Following a baseline plaque examination and complete plaque removal at the start of the first 4-day treatment period, subjects initiated a twice-daily supervised dosing regimen, during which they rinsed with their first assigned dentifrice in slurry form while refraining from tooth-brushing and all other oral hygiene procedures."( Plaque regrowth effects of a triclosan/pyrophosphate dentifrice in a 4-day non-brushing model.
Beiswanger, BB; Bollmer, BW; Court, LK; Crisanti, MM; Majeti, S; Mau, MS; McClanahan, SF; McClary, JM, 2000
)
0.6
" Safety factors calculated from repeated daily dosing studies ranged from 1,000 to 25,000 times the no-observed-effect levels."( Chemistry and safety of triclosan, and its use as an antimicrobial coating on Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan).
Barbolt, TA, 2002
)
0.62
"Recent concern that the increased use of triclosan (TCS) in consumer products may contribute to the emergence of antibiotic resistance has led us to examine the effects of TCS dosing on domestic-drain biofilm microcosms."( Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility.
Bartolo, RG; Catrenich, CE; Charbonneau, D; Gilbert, P; Ledder, RG; McBain, AJ; Price, BB, 2003
)
0.86
"Adhesive hydrogel patches containing Triclosan (TS) were prepared as an anti-acne dosage form."( Hydrogel patches containing triclosan for acne treatment.
Hwang, SJ; Kim, JC; Lee, TW, 2003
)
0.89
" In the F(1) generations, although the hatching of embryos in the 20 microg/l treatment showed adverse effects, there was no dose-response relationship between hatchability and TCS treatment levels."( Effects of triclosan on the early life stages and reproduction of medaka Oryzias latipes and induction of hepatic vitellogenin.
Arizono, K; Hirano, M; Ishibashi, H; Ishibashi, Y; Matsumura, N; Matsuoka, M; Shiratsuchi, H; Takao, Y, 2004
)
0.71
" Initial rates of protein aggregation at different inhibitor concentrations follow a monoexponential dose-response curve from which inhibition parameters are calculated."( Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors.
Arsequell, G; Dolado, I; Nieto, J; Planas, A; Saraiva, MJ; Valencia, G,
)
0.13
" The broad set of reproduction toxicity tests of triclosan includes a 2-generation study in the rat, in which there was considerable exposure of dams and pups to triclosan throughout fetal development and up to sexual maturity in the F2 generation, and a further study in which pups of dosed dams were followed to weaning."( Risk assessment of triclosan [Irgasan] in human breast milk.
Dayan, AD, 2007
)
0.92
"5 mg/L of DOC, and approximately 58% triclosan depletion for dosage of 6 mg/L(1."( Kinetics of triclosan oxidation by aqueous ozone and consequent loss of antibacterial activity: relevance to municipal wastewater ozonation.
Dodd, MC; Omil, F; Suarez, S; von Gunten, U, 2007
)
0.99
"01) following a single dosing and also on repeated dosing in MDFRs."( Evaluation of the specificity and effectiveness of selected oral hygiene actives in salivary biofilm microcosms.
DeVizio, W; Ledder, RG; McBain, AJ; Sreenivasan, PK, 2010
)
0.36
" Soils were dosed and later redosed with four nominal triclosan concentrations, and respiration rates were measured over time."( Effects of triclosan on soil microbial respiration.
Butler, E; Ritz, K; Sakrabani, R; van Egmond, R; Whelan, MJ, 2011
)
1.01
" The toxicity tests showed that Fe(VI) itself dosed in the reaction did not inhibit green algae growth."( Oxidation of triclosan by ferrate: reaction kinetics, products identification and toxicity evaluation.
Fang, YX; Nghiem, LD; Yang, B; Ying, GG; Zhang, LJ; Zhao, JL, 2011
)
0.74
" Our primary objective was to investigate the dose-response of nitrate intake on nitric oxide status and nitrate reduction in the mouth."( Nitrate causes a dose-dependent augmentation of nitric oxide status in healthy women.
Bondonno, CP; Considine, MJ; Croft, KD; Hodgson, JM; Puddey, IB; Ward, NC; Yang, X, 2012
)
0.38
" Each soil type was dosed and subsequently re-dosed 6 weeks later with triclosan at five nominal concentrations in microcosms (10, 100, 500, 1000 mg kg(-1) and a zero-dose control)."( The effect of triclosan on microbial community structure in three soils.
Butler, E; Ritz, K; Sakrabani, R; van Egmond, R; Whelan, MJ, 2012
)
0.97
" Since an optimal study design for testing potential developmental neurotoxicants in rats, should include exposure during both the pre- and postnatal periods of brain development, we suggest that in the case of triclosan, direct dosing of pups may be the best way to obtain that goal."( Triclosan exposure reduces thyroxine levels in pregnant and lactating rat dams and in directly exposed offspring.
Axelstad, M; Boberg, J; Christiansen, S; Hass, U; Vinggaard, AM, 2013
)
2.02
" These eruptions seem to be reduced when dosed in combination with dabrafenib."( Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth, R; Clements, A; Fernandez-Peñas, P; Kefford, R; Liu, M; Long, GV; Nguyen, B; Uribe, P, 2014
)
0.4
" In addition, they bound in the ways of intercalation, intercalation-adsorption or adsorption, which relied on the dosage of the surfactant."( Microwave-assisted modification on montmorillonite with ester-containing Gemini surfactant and its adsorption behavior for triclosan.
Liu, B; Lu, J; Sun, R; Wang, X; Xie, Y; Yang, B, 2014
)
0.61
" This composite is a suitable antibacterial candidate for the bone tissue engineering and medical applications since the real dosage of triclosan stays at ca."( Investigating composite systems based on poly L-lactide and poly L-lactide/triclosan nanoparticles for tissue engineering and medical applications.
Davachi, SM; Kaffashi, B; Torabinejad, B; Zamanian, A; Ziaeirad, Z, 2016
)
0.87
" However, such dosage of TCS exposure resulted in lipid droplet accumulation in the yolk sac, which might due to the deregulated mRNA expression level of beta-oxidation transcripts."( Triclosan (TCS) exposure impairs lipid metabolism in zebrafish embryos.
Ho, JCH; Hsiao, CD; Kawakami, K; Tse, WKF, 2016
)
1.88
" Reaction conditions such as pH, H2O2 concentration and enzyme dosage were found to have a strong influence on the removal efficiency of TCS."( Removal of triclosan via peroxidases-mediated reactions in water: Reaction kinetics, products and detoxification.
Gao, S; Ji, Y; Li, J; Mao, L; Peng, J; Shi, H; Zhang, Y, 2016
)
0.82
" Results showed that (1) isoniazid and triclosan have positive effects on improving DHA level of cells; (2) mutants from irradiation dosage of 120Gy yielded more DHA compared with cells from 40Gy, 80Gy treatment and wild type; (3) DHA contents of mutants pre-selected by inhibitors of enoyl-ACP reductase of Type II FAS pathway (isoniazid and triclosan)at 4°C, were significantly higher than that of wild type; (4) compared to the wild type, the DHA productivity and yield of a mutant (T-99) obtained from Aurantiochytrium sp."( A new strategy for strain improvement of Aurantiochytrium sp. based on heavy-ions mutagenesis and synergistic effects of cold stress and inhibitors of enoyl-ACP reductase.
Cheng, YR; Cui, GZ; Cui, Q; Song, X; Sun, ZJ, 2016
)
0.7
" Restricted cubic spline analysis was performed to help assess linearity and shape of any dose-response relationships."( Associations between maternal triclosan concentrations in early pregnancy and gestational diabetes mellitus, impaired glucose tolerance, gestational weight gain and fetal markers of metabolic function.
Arbuckle, TE; Ashley-Martin, J; Bouchard, MF; Dodds, L; Ettinger, AS; Fisher, M; Fraser, WD; Monnier, P; Morisset, AS; Shapiro, GD, 2018
)
0.77
"To elucidate the underlying roles of miRNAs and the MAPK pathway in TCS-mediated repression of testicular steroidogenesis, Sprague-Dawley male rats were dosed daily with TCS for 31 days, and TM3 cells were exposed to TCS for 24 h after the pretreatments with the activator of JNK, Nur77 siRNA, or recombinant lentivirus vector for Nur77."( Triclosan Suppresses Testicular Steroidogenesis via the miR-6321/JNK/ Nur77 Cascade.
Ha, M; Li, L; Liu, C; Zhang, P, 2018
)
1.92
" The Parameters or inputs used for optimization are pH, time (days), agitation (rpm) and sorbent dosage (μg/L)."( Isolation and identification of Pseudomonas from wastewater, its immobilization in cellulose biopolymer and performance in degrading Triclosan.
Devatha, CP; Pavithra, N, 2019
)
0.72
" Integrating nonspecific apical and endocrine-specific mechanistic endpoints, results of a MEOGRT can be used, with other data, in a weight-of-evidence evaluation to establish a dose-response relationship for risk assessment and identify potential causal relationships between an endocrine mode of action and adverse effects."( Medaka (Oryzias latipes) Multigeneration Test with Triclosan.
Capdevielle, M; Gallagher, S; Mihaich, E; Urbach-Ross, D; Wolf, J, 2019
)
0.77
"5 ng/mL) was associated with a 23% of reduction in fecundability and there tended to be a dose-response pattern."( Triclosan and Female Reproductive Health: A Preconceptional Cohort Study.
Cheng, W; Gan, Y; Huo, X; Ouyang, F; Tian, Y; Wang, B; Wang, W; Zhang, J; Zhao, S; Zhou, W; Zhu, W, 2019
)
1.96
" The assays were carried out in a pilot AS reactor operating for two-weeks under continuous dosage of pollutants."( Enzyme response of activated sludge to a mixture of emerging contaminants in continuous exposure.
Amariei, G; Boltes, K; Leton, P; Rosal, R, 2020
)
0.56
" Male C57BL/6 mice were orally exposed to TCS at the dosage of 10 mg/kg/d for 13 weeks."( Integrated Proteomics and Metabolomics Assessment Indicated Metabolic Alterations in Hypothalamus of Mice Exposed to Triclosan.
Cai, Z; Cao, G; Chen, X; Huang, J; Huang, W; Song, Y; Xie, P; Zhu, L, 2021
)
0.83
" Enzymatic hydrolysis of the samples was optimized based on enzyme dosage and incubation time."( Simultaneous determination of triclosan, triclocarban, triclocarban metabolites and byproducts in urine and serum by ultra-high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Cai, Z; Liu, Z; Luo, Q; Zhang, H; Zhou, Y, 2021
)
0.91
" The dosage of 20% (w/w) was the most efficient one and the ultimate concentrations of TCS were decreased by 76."( Coordination of bacterial biomarkers with the dominant microbes enhances triclosan biodegradation in soil amended with food waste compost and cow dung compost.
Dang, Q; Gong, T; He, X; Tan, W; Xi, B; Yang, T; Zhao, X, 2022
)
0.95
" Overall, exposure to BPA increased the odds of having endometriosis, and there appeared to be a dose-response relationship."( Association of environmental phenols with endometriosis and uterine leiomyoma: An analysis of NHANES, 2003-2006.
Eata, V; Lee, AW, 2022
)
0.72
" Our novel findings reveal the health risks of exposure to low-level PCPs mixtures and further point out the overall dose-response relationship between DNA oxidative damage and PCP mixtures."( Assessment of health risk and dose-effect of DNA oxidative damage for the thirty chemicals mixture of parabens, triclosan, benzophenones, and phthalate esters.
Chen, C; Deng, Q; Dong, G; Hou, M; Huang, H; Liao, Q; Lv, Y; Ma, X; Peng, J; Wei, Q; Xiao, Y; Xing, X; Zeng, X; Zhang, X; Zhang, Z; Zheng, J; Zhu, X, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
fungicideA substance used to destroy fungal pests.
EC 1.5.1.3 (dihydrofolate reductase) inhibitorAn EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitorAn EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of enoyl-[acyl-carrier-protein] reductase (NADH), EC 1.3.1.9.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
persistent organic pollutantAny environmental contaminant that is resistant to environmental degradation through photolytic, biological or chemical processes. Such substances can have significant impact on health and the environment, as they persist in the environment, bioaccumulate in animal tissue and so biomagnify in food chains.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (97)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
acetylcholinesteraseHomo sapiens (human)Potency39.09740.002541.796015,848.9004AID1347397; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency40.69133.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency22.58960.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency59.66490.173734.304761.8120AID1346859; AID1346924
Fumarate hydrataseHomo sapiens (human)Potency63.09570.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency59.66490.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency19.89800.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency32.26660.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency0.19950.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency22.22340.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency17.78280.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency55.75950.013326.981070.7614AID1346978
PINK1Homo sapiens (human)Potency28.18382.818418.895944.6684AID624263
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency65.65280.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency46.41530.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency28.33210.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.73860.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency28.80410.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.38140.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency26.36430.000817.505159.3239AID1159527; AID1159531; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.42650.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.35540.375827.485161.6524AID588526; AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency22.95420.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency41.69150.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency3.47300.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency8.37020.00108.379861.1304AID1645840
polyproteinZika virusPotency63.09570.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency28.18380.819914.830644.6684AID624263
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.64240.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.85590.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency39.56590.023723.228263.5986AID743222; AID743223
caspase-3Homo sapiens (human)Potency55.75950.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency23.10930.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency47.85070.000723.06741,258.9301AID651777; AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency17.63270.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency49.69570.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency52.50310.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency33.18860.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency34.559419.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency27.87450.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency51.71020.039147.5451146.8240AID1224845
Caspase-7Cricetulus griseus (Chinese hamster)Potency62.56320.006723.496068.5896AID1346980
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency7.94330.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency44.66840.010039.53711,122.0200AID588547
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency35.48133.548119.542744.6684AID743266
caspase-3Cricetulus griseus (Chinese hamster)Potency62.56320.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency19.91350.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency34.66500.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.40240.000627.21521,122.0200AID651741; AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency63.09570.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency16.75430.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency56.23411.584919.626463.0957AID651644
lamin isoform A-delta10Homo sapiens (human)Potency0.03160.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.84490.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency18.83100.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.47300.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency50.14060.002319.595674.0614AID651631; AID651743; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.84490.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency11.22020.56239.398525.1189AID652106
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency10.00000.009610.525035.4813AID1479145
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.47300.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency8.83730.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency8.83730.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.47300.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
Chain C, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
Chain A, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
Chain C, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
Chain A, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
Chain C, enoyl-acyl carrier reductasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.05000.05000.05000.0500AID977610
3-oxoacyl-[acyl-carrier-protein] synthase 3 Escherichia coliIC50 (µMol)850.00002.10004.20006.3000AID1639213
TransthyretinHomo sapiens (human)IC50 (µMol)53.50000.16004.292110.0000AID303082
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)0.58500.00011.68479.3200AID67363; AID67372
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12IC50 (µMol)2.95790.00501.576510.0000AID1796221; AID1796223; AID1796225; AID302095; AID67361; AID67365; AID710149; AID751284
DNA gyrase subunit AEscherichia coli K-12IC50 (µMol)1,000.00000.02390.56295.2300AID1639212
DNA gyrase subunit BEscherichia coli K-12IC50 (µMol)1,000.00000.00500.43985.2300AID1639212
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)75.00000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)75.00000.00022.45859.9600AID1805801
Endoplasmic reticulum chaperone BiPHomo sapiens (human)IC50 (µMol)100.00000.80007.02509.1000AID1590351
Carbonyl reductase [NADPH] 1Homo sapiens (human)IC50 (µMol)0.40000.40002.03003.7800AID347259
Carbonyl reductase [NADPH] 1Homo sapiens (human)Ki0.06000.06001.12503.4300AID347259
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIHaemophilus influenzae Rd KW20IC50 (µMol)7.64250.07000.19000.4300AID1796219; AID1796221
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIBacillus subtilis subsp. subtilis str. 168IC50 (µMol)0.50000.50000.50000.5000AID331275
Enoyl-[acyl-carrier-protein] reductase [NADH]Mycobacterium tuberculosis H37RvIC50 (µMol)2.87120.03002.286410.0000AID1053502; AID1164296; AID1352684; AID1496039; AID1639206; AID1679086; AID1797491; AID361126
Enoyl-[acyl-carrier-protein] reductase [NADH]Mycobacterium tuberculosis H37RvKi0.21000.20000.21000.2200AID1352684; AID1352707; AID1797492; AID319627
Enoyl-[acyl-carrier-protein] reductase [NADH] Francisella tularensis subsp. tularensis SCHU S4IC50 (µMol)4.33000.05001.91256.0000AID756993; AID756994; AID756995; AID756996; AID756997
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabIStaphylococcus aureus subsp. aureus MRSA252IC50 (µMol)2.60490.02900.46411.1000AID1250831; AID1796219; AID1796221; AID1796223; AID1796225; AID218918; AID67363; AID67368; AID67372; AID710143
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabIStaphylococcus aureus subsp. aureus MRSA252Ki0.00000.00000.00950.0189AID1799923
Enoyl-acyl carrier reductaseToxoplasma gondiiIC50 (µMol)0.01670.01500.01670.0200AID509520; AID741090; AID753504
Enoyl-acyl-carrier protein reductase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.08720.06601.549910.0000AID257396; AID263605; AID288442; AID326161; AID406448; AID426407; AID611702; AID638541
Enoyl-acyl-carrier protein reductase Plasmodium falciparum (malaria parasite P. falciparum)Ki0.05540.00000.57785.5000AID277588; AID277589; AID277590; AID277591; AID277592; AID277593; AID277594; AID277595; AID277596; AID277597; AID277598; AID277599; AID277600; AID277601; AID277602; AID288443; AID426408
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RepressorStenotrophomonas maltophiliaKd0.63000.63000.63000.6300AID977611
TransthyretinHomo sapiens (human)Kd144.00000.00301.348210.0000AID303083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC507.84700.19503.667918.6960AID540270
twin arginine protein translocation system - TatA proteinEscherichia coli str. K-12 substr. MG1655AC501.06000.707010.915145.8560AID504941
heat shock protein 90, putativePlasmodium falciparum 3D7AC507.54400.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (336)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein homotetramerizationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
biotin biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
response to antibioticEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit AEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit AEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
response to antibioticDNA gyrase subunit AEscherichia coli K-12
chromosome organizationDNA gyrase subunit AEscherichia coli K-12
negative regulation of DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit BEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit BEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit BEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
response to antibioticDNA gyrase subunit BEscherichia coli K-12
chromosome organizationDNA gyrase subunit BEscherichia coli K-12
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
ER overload responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cerebellum structural organizationEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cerebellar Purkinje cell layer developmentEndoplasmic reticulum chaperone BiPHomo sapiens (human)
substantia nigra developmentEndoplasmic reticulum chaperone BiPHomo sapiens (human)
positive regulation of cell migrationEndoplasmic reticulum chaperone BiPHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum unfolded protein responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
post-translational protein targeting to membrane, translocationEndoplasmic reticulum chaperone BiPHomo sapiens (human)
negative regulation of protein-containing complex assemblyEndoplasmic reticulum chaperone BiPHomo sapiens (human)
positive regulation of protein ubiquitinationEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein folding in endoplasmic reticulumEndoplasmic reticulum chaperone BiPHomo sapiens (human)
response to endoplasmic reticulum stressEndoplasmic reticulum chaperone BiPHomo sapiens (human)
maintenance of protein localization in endoplasmic reticulumEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ERAD pathwayEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cellular response to glucose starvationEndoplasmic reticulum chaperone BiPHomo sapiens (human)
negative regulation of apoptotic processEndoplasmic reticulum chaperone BiPHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEndoplasmic reticulum chaperone BiPHomo sapiens (human)
regulation of protein folding in endoplasmic reticulumEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cellular response to interleukin-4Endoplasmic reticulum chaperone BiPHomo sapiens (human)
regulation of ATF6-mediated unfolded protein responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
regulation of IRE1-mediated unfolded protein responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
negative regulation of IRE1-mediated unfolded protein responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
regulation of PERK-mediated unfolded protein responseEndoplasmic reticulum chaperone BiPHomo sapiens (human)
chaperone cofactor-dependent protein refoldingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein refoldingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
xenobiotic metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
glucocorticoid metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
cyclooxygenase pathwayCarbonyl reductase [NADPH] 1Homo sapiens (human)
epithelial cell differentiationCarbonyl reductase [NADPH] 1Homo sapiens (human)
vitamin K metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (121)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADH) activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
oxidoreductase activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
identical protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
NADH bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
DNA bindingDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit AEscherichia coli K-12
protein bindingDNA gyrase subunit AEscherichia coli K-12
ATP bindingDNA gyrase subunit AEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit AEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit AEscherichia coli K-12
identical protein bindingDNA gyrase subunit AEscherichia coli K-12
DNA bindingDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit BEscherichia coli K-12
protein bindingDNA gyrase subunit BEscherichia coli K-12
ATP bindingDNA gyrase subunit BEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit BEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit BEscherichia coli K-12
metal ion bindingDNA gyrase subunit BEscherichia coli K-12
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
calcium ion bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ATP bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ATP hydrolysis activityEndoplasmic reticulum chaperone BiPHomo sapiens (human)
enzyme bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein domain specific bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ubiquitin protein ligase bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ribosome bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cadherin bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
unfolded protein bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein-folding chaperone bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
misfolded protein bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
ATP-dependent protein folding chaperoneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein folding chaperoneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
heat shock protein bindingEndoplasmic reticulum chaperone BiPHomo sapiens (human)
carbonyl reductase (NADPH) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorCarbonyl reductase [NADPH] 1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorCarbonyl reductase [NADPH] 1Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
prostaglandin-E2 9-reductase activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
S-nitrosoglutathione reductase (NADPH) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (78)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
membraneEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein-containing complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
catalytic complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
chromosomeDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
cytosolDNA gyrase subunit AEscherichia coli K-12
membraneDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit AEscherichia coli K-12
chromosomeDNA gyrase subunit BEscherichia coli K-12
cytoplasmDNA gyrase subunit BEscherichia coli K-12
cytosolDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit BEscherichia coli K-12
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
COP9 signalosomeEndoplasmic reticulum chaperone BiPHomo sapiens (human)
nucleusEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cytoplasmEndoplasmic reticulum chaperone BiPHomo sapiens (human)
mitochondrionEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulumEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum membraneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cytosolEndoplasmic reticulum chaperone BiPHomo sapiens (human)
plasma membraneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
focal adhesionEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cell surfaceEndoplasmic reticulum chaperone BiPHomo sapiens (human)
membraneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
midbodyEndoplasmic reticulum chaperone BiPHomo sapiens (human)
melanosomeEndoplasmic reticulum chaperone BiPHomo sapiens (human)
intracellular membrane-bounded organelleEndoplasmic reticulum chaperone BiPHomo sapiens (human)
extracellular exosomeEndoplasmic reticulum chaperone BiPHomo sapiens (human)
protein-containing complexEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum chaperone complexEndoplasmic reticulum chaperone BiPHomo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cytoplasmEndoplasmic reticulum chaperone BiPHomo sapiens (human)
nucleusEndoplasmic reticulum chaperone BiPHomo sapiens (human)
membraneEndoplasmic reticulum chaperone BiPHomo sapiens (human)
cytosolCarbonyl reductase [NADPH] 1Homo sapiens (human)
extracellular exosomeCarbonyl reductase [NADPH] 1Homo sapiens (human)
extracellular vesicleCarbonyl reductase [NADPH] 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (503)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID406448Inhibition of Plasmodium falciparum recombinant FabI2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID1503432Selectivity index, ratio of LC50 for cytotoxicity in human U937 cells to EC50 for antileishmanial activity against GFP-tagged Leishmania panamensis MHOM/CO/87/UA140 intracellular amastigotes infected in human U937 cells2017European journal of medicinal chemistry, Dec-01, Volume: 141Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID452744Antibacterial activity against Escherichia coli MG16552010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID297872Inhibition of Escherichia coli FabI2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
AID519131Effect on viable cells in urine at time of catheter blockage in Bladder model inoculated with Proteus mirabilis M 55 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID564987Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1738820Inhibition of recombinant Mycobacterium tuberculosis His6-tagged InHA expressed in Escherichia coli BL21 using trans-2-dodecenoyl-Coenzyme A as substrate at 50 uM relative to control2020European journal of medicinal chemistry, Aug-01, Volume: 199Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
AID1682385Antimicrobial activity against Escherichia coli W3110 imp4213 assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID1322944Antimycobacterial activity against LuxABCDE expressing Mycobacterium marinum measured after 48 hrs by luminescence based serial dilution assay2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
AID297875Antibacterial activity against Staphylococcus aureus ATCC 292132007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
AID1606672Binding affinity to hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) assessed as increase the melting temperature at 0.5 mM in presence of 1 mM NAD+ by differential scanning fluorimetry2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID1532353Antibacterial activity against Escherichia coli 700728 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1682392Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID541032Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID1639211Cytotoxicity against HEK293 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID1532365Antibacterial activity against Serratia marcescens OCC 217 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID198308Antibacterial activity against Streptococcus pneumoniae 16292003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID1532385Antibacterial activity against Streptococcus pneumoniae 6305 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID257395Inhibition of drug-resistant Plasmodium falciparum Dd2 after 72 hrs2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.
AID277599Inhibition of Plasmodium falciparum ENR in presence of EGC2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID774993Cytotoxicity against human HCT116 cells after 4 days by WST-1 assay2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis.
AID277601Inhibition of Plasmodium falciparum ENR in presence of quercetin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID496241Antibacterial activity against Escherichia coli W3110 containing empty vector pBluescript at 37 deg C2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID646863Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID347256Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADP+2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID452745Antibacterial activity against Escherichia coli M152010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID1532368Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID710149Inhibition of Escherichia coli FabI using crotonoyl-CoA as substrate preincubated for 90 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID646865Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID509521Antiparasitic activity against Toxoplasma gondii infected in HFF after 24 hrs by [3H]uracil incorporation assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.
AID638541Inhibition of Plasmodium falciparum enoyl-ACP reductase assessed as oxidation of NADH to NAD+ after 10 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Methylenebissantin: a rare methylene-bridged bisflavonoid from Dodonaea viscosa which inhibits Plasmodium falciparum enoyl-ACP reductase.
AID1532399Antibacterial activity against Salmonella enterica subspecies enterica serotype Virchow NCTC 5742 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID277592Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of butein2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID331277Antibacterial activity against Bacillus anthracis dANR2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
AID710143Inhibition of Staphylococcus aureus recombinant FabI using trans-2-octenoyl N-acetylcysteamine thioester as substrate preincubated for 60 mins2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID1532380Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID207541Minimum concentration required for the inhibition of Staphylococcus aureus was determined.2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID360362Antimalarial activity after 48 hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID1250832Antibacterial activity against Staphylococcus aureus incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
AID519134Effect on rate of catheter encrustations in Bladder model inoculated with Proteus mirabilis M 55 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID496250Antibacterial activity against Pseudomonas aeruginosa PA0170 containing fabV gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID277600Inhibition of Plasmodium falciparum ENR in presence of ECG2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID1532387Antibacterial activity against Streptococcus pyogenes ATCC 19615 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID771675Antiplasmodial activity against asexual blood stage form of Plasmodium falciparum assessed as growth inhibition after 72 hrs by [3H]-hypoxanthine incorporation assay2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
AID426408Inhibition of Plasmodium falciparum enoyl-acyl carrier protein reductase expressed in Escherichia coli BL21(DE3) by spectrophotometry2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.
AID532766Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method in presence of chlorpromzine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID278584Reduced apicoplast genome copy number in Plasmodium falciparum FCK2 after 96 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID710142Cytotoxicity against human HepG2 cells2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID1733035Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID284547Inhibition of Escherichia coli DH5-alpha His tagged Fab12007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
AID347252Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in absence of cofactor2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID103344Antibacterial activity against Moraxella catarrhalis2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID646860Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis 81388 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID277589Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of ECG2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID555390Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.01 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID519136Effect on pH of residual urine at time of catheter blockage in Bladder model inoculated with Proteus mirabilis M 48 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1639207Antitubercular activity against Mycobacterium tuberculosis measured after 48 hrs by luminescence based serial dilution method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID751289Inhibition of Plasmodium falciparum FabI using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID1164296Inhibition of Mycobacterium tuberculosis InhA using dodecyl coA as substrate by LC-MS/MS analysis2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID1672291Antifungal activity against Candida tropicalis assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID490662Antibacterial activity against Streptococcus sanguinis ATCC 10556 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID646842Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID278576Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID756993Inhibition of Francisella tularensis SCHU S4 FabI F203L mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID1532391Antibacterial activity against Salmonella enterica subspecies enterica serotype Dublin OCC 627 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532398Antibacterial activity against Salmonella enterica subspecies enterica serotype typhimurium ATCC 14028 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID197883Antibacterial activity against Staphylococcus aureus WCUH292003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID1532378Antibacterial activity against Staphylococcus aureus OCC 106 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID618840Antimicrobial activity against methicillin-resistant Staphylococcus aureus using tryptone soy broth in presence of bovine serum albumin2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
The impact of fatty acids on the antibacterial properties of N-thiolated β-lactams.
AID1532386Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID555362Effect on growth in Staphylococcus aureus FRI-1187 at 0.05 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID288442Inhibition of Plasmodium falciparum recombinant enoyl ACP reductase expressed in BL21 (DE3) cells2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.
AID756992Selectivity ratio of IC50 for C-terminal His6-tagged wild type Francisella tularensis SCHU S4 FabI to IC50 for Francisella tularensis SCHU S4 FabI R96G mutant2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID278583Reduced apicoplast genome copy number in Plasmodium falciparum FCK2 after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID1532393Antibacterial activity against Salmonella enterica subspecies enterica serotype Indiana OCC 597 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532345Antibacterial activity against Cronobacter sakazakii 29544 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID532762Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method in presence of chlorpromazine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1639209Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 measured after 48 hrs2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID555358Effect on growth in Staphylococcus aureus MN8 at 0.01 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID496245Antibacterial activity against Escherichia coli MG1655 containing empty vector pBluescript assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID541030Induction of apoptosis in bovine BL3 cells assessed as late apoptotic cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID741090Inhibition of Toxoplasma gondii enoyl reductase assessed as conversion of trans-2-acyl-ACP to acyl-ACP2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
AID496247Antibacterial activity against Escherichia coli MG1655 pZL17 expressing Pseudomonas aeruginosa fabI gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID710148Antibacterial activity against Staphylococcus aureus CIP54.146 after 18 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID408581Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCK22008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents.
AID646849Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID302093Inhibition of Streptococcus pneumoniae enoyl-ACP reductase FabK2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
AID67371Inhibitory activity against Enoyl-ACP reductase FabI in Haemophilus influenzae2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID555389Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.05 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID564977Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID646846Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID519133Effect on rate of catheter encrustations in Bladder model inoculated with Proteus mirabilis M 48 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1352685Antimycobacterial activity against Mycobacterium tuberculosis2018European journal of medicinal chemistry, Feb-25, Volume: 146An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
AID519108Antibacterial activity against Proteus mirabilis M 44 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1714447Inhibition of Mycobacterium tuberculosis InhA assessed as effect on NADH oxidation incubated for 10 mins by spectrophotometry2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.
AID284548Antimicrobial activity against Staphylococcus aureus ATCC 292132007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
AID1061850Antibacterial activity against Bacillus cereus KCTC 16612014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
AID646858Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1532390Antibacterial activity against Salmonella enterica subspecies enterica serotype Arizonae OCC 706 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID646847Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID277598Inhibition of Plasmodium falciparum ENR in presence of EGCG2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID697038Inhibition of goose isopygial gland FASN2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID496242Antibacterial activity against Escherichia coli W3110 containing pZL19 expressing sEscherichia coli fabI gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID519115Antibacterial activity against Proteus mirabilis NP37 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID263605Inhibition of Plasmodium falciparum ENR enzymatic activity2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
AID519120Antibacterial activity against Proteus mirabilis M 12 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID303081Inhibition of transthyretin amyloidosis assessed as fibril formation at 21.6 uM at pH 4.4 relative to control2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID646871Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID83663Minimum concentration required for the inhibition of Haemophilus influenzae was determined.2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID360363Antimalarial activity after 96 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID1532364Antibacterial activity against Citrobacter freundii 8090 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1060594Inhibition of Mycobacterium tuberculosis recombinant His6x-tagged InhA expressed in Escherichia coli BL21 at 50 uM2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
AID638436Antitubercular activity against Mycobacterium tuberculosis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as anti-tubercular agents.
AID67366In vitro antibacterial activity against Escherichia coli FabI2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID360364Antimalarial activity after 48 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID1733038Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia at 7 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1061853Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 35052014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
AID1532361Antibacterial activity against Proteus vulgaris OCC 195 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID496258Inhibition of wild type Pseudomonas aeruginosa ENR assessed as reduction of [1-14C]acetate incorporation into phospholipids2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID490763Antibacterial activity against Porphyromonas gingivalis ATCC 33277 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID497755Apparent half-life of the terminal disposition phase half life in percutaneously dosed healthy human at 1166 mg2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
AID771682Inhibition of recombinant Plasmodium falciparum FabI using crotonoyl-CoA as substrate assessed as consumption of NADH after 10 mins2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
AID1326369Antibacterial activity against Bacillus subtilis ATCC 47096 after 16 to 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.
AID1326385Antibacterial activity against Bacillus subtilis P10A derived after 10 passage in presence of JBIR-100 after 16 to 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.
AID406451Inhibition of Plasmodium falciparum recombinant FabI A217V mutant2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID519112Antibacterial activity against Proteus mirabilis M 19 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID277602Inhibition of Plasmodium falciparum ENR in presence of butein2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID278591Inhibition of fatty acid biosynthesis in Plasmodium falciparum FCK2 as decreased [1,2-14C]acetate uptake at 10 uM after 2 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID611702Inhibition of Plasmodium falciparum Enoyl-ACP reductase using crotonyl-CoA as substrate peincubated for 5 mins measured after 10 mins of substrate addition by UV-vis spectrophotometry2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Isoflavone dimers and other bioactive constituents from the figs of Ficus mucuso.
AID347253Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADP+2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID519107Antibacterial activity against Proteus mirabilis B2 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID496249Antibacterial activity against Pseudomonas aeruginosa PA01 assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID1532351Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID277588Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGCG2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID490660Antibacterial activity against Streptococcus mutans ATCC 25175 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID774994Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 21 days by micro-broth dilution method2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis.
AID277593Inhibition of Plasmodium falciparum ENR in presence of EGCG by dilution assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID1352707Uncompetitive inhibition of Mycobacterium tuberculosis InhA using trans-2-dodecenoyl-CoA as substrate in presence of NADH2018European journal of medicinal chemistry, Feb-25, Volume: 146An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
AID360366Antimalarial activity after 96hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID1061854Antibacterial activity against Staphylococcus aureus RN42202014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
AID646855Antibacterial activity against Acinetobacter baumannii 63169 isolate CAN-ICU after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1682396Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 pCA24N fabI F203L mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID646854Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID496389Antibacterial activity against Pseudomonas aeruginosa PA0272 containing fabI assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID519122Antibacterial activity against Proteus mirabilis NP55 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1639210Antimicrobial activity against Pseudomonas aeruginosa ATCC 27583 measured after 48 hrs by p-iodonitrotetrazolium violet dye based serial dilution test2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID710147Antibacterial activity against Escherichia coli C7 after 18 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID1225719Inhibition of Mycobacterium tuberculosis recombinant InhA assessed as enzyme activity measured as NADH oxidation using 2-trans-decenyl CoA as substrate at 50 uM by TECAN spectrophotometer analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
AID541029Induction of apoptosis in bovine BL3 cells assessed as viable cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID1682388Antimicrobial activity against Escherichia coli W3110 imp4213 expressing pCA24N-fabI mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID519135Effect on pH of residual urine at time of catheter blockage in Bladder model inoculated with wild-type Proteus mirabilis B22008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID71605Ionisation constant for the compound2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID564969Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID71603In vitro inhibitory activity against wild-type intestinal Fatty acid-binding protein (FabI) of Escherichia coli expressed as K12004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID1532363Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID257394Inhibition of drug-sensitive Plasmodium falciparum 3D7 after 72 hrs2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.
AID1532383Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID361126inhibition of Mycobacterium tuberculosis InhA after 20 mins by fluorometric assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Agonodepsides a and B: two new depsides from a filamentous fungus F7524.
AID1682397Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 pCA24N fabI F204V mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID1672290Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID1322946Antivirulence activity against Mycobacterium marinum assessed as Dictyostelium discoideum phagocytic plaque formation at 10 uM preincubated for 2 to 3 hrs followed by Dictyostelium discoideum addition measured after 5 to 9 days in presence of Klebsiella p2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
AID67370Inhibitory activity against Enoyl-ACP reductase FabI in Escherichia coli2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID347255Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in absence of cofactor2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID751285Inhibition of Staphylococcus aureus FabI using dodecenoyl ACP at pH 7.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID753506Cytotoxicity against HFF after 72 hrs by WST-1 assay2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID630086Inhibition of Mycobacterium tuberculosis InhA using 2-trans-decenoyl-CoA as substrate at 10 uM after 5 mins using by spectrophotometry2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.
AID1532397Antibacterial activity against Salmonella enterica subspecies enterica serotype Pullorum OCC 273 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID646850Antibacterial activity against Escherichia coli isolate CAN-ICU 61714 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID756994Inhibition of Francisella tularensis SCHU S4 FabI R96M mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID1714448Inhibition of Mycobacterium tuberculosis InhA assessed as residual enzyme activity by measuring NADH oxidation at 100 uM incubated for 10 mins by spectrophotometry2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.
AID1532381Antibacterial activity against Staphylococcus epidermidis ATCC 14990 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID67375Inhibitory activity against Enoyl-ACP reductase FabK in Streptococcus pneumoniae2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID406450Inhibition of Plasmodium falciparum FabI assessed as saturated acyl-acyl carrier protein level at 5 uM by MALDI-TOF mass spectrometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID1532347Antibacterial activity against Enterobacter cloacae ATCC 13047 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID277597Inhibition of Plasmodium falciparum ENR in presence of butein by dilution assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID564968Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID496246Antibacterial activity against Escherichia coli MG1655 containing pZL19 expressing Escherichia coli fabI gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID726479Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite growth2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Novel diaryl ureas with efficacy in a mouse model of malaria.
AID1532371Antibacterial activity against Staphylococcus aureus ATCC 6538 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532358Antibacterial activity against Klebsiella aerogenes NCTC 8167 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1726848Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by microdilution method2021RSC medicinal chemistry, Jun-23, Volume: 12, Issue:6
Sulfonium-based liposome-encapsulated antibiotics deliver a synergistic antibacterial activity.
AID519127Effect on catheter blockage in Bladder model inoculated with Proteus mirabilis M 48 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID646869Antibacterial activity against Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID331275Inhibition of Bacillus anthracis Enoyl ACP reductase2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
AID278585Reduced apicoplast DNA/nuclear DNA ratio in Plasmodium falciparum FCK2 at 10 uM after 72 hrs by competitive PCR2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID741094Cytotoxicity against HFF assessed as inhibition of [3H]-thymidine incorporation after 24 hrs by WST-1 assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
AID623302Inhibition of Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21 using trans-2-dodecenoyl-Coenzyme A as substrate at 10 uM by spectrophotometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
AID1060593Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 21 days by micro-broth dilution method2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
AID1532356Antibacterial activity against Escherichia hermannii 33650 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID79400Antibacterial activity against Haemophilus influenzae Q12003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID1738821Inhibition of recombinant Mycobacterium tuberculosis His6-tagged InHA expressed in Escherichia coli BL21 using trans-2-dodecenoyl-Coenzyme A as substrate at 5 uM relative to control2020European journal of medicinal chemistry, Aug-01, Volume: 199Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
AID1679090Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as reduction in microbial growth incubated for 5 days by visual inspection method2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
AID1267223Inhibition of Mycobacterium tuberculosis His6-tagged InhA expressed in Escherichia coli BL21 using trans-2-dodecenoyl-coA as substrate at 50 uM2016European journal of medicinal chemistry, Jan-01, Volume: 107Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.
AID532765Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method in presence of IPTG2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1532372Antibacterial activity against Staphylococcus aureus ATCC 6538P after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1714723Induction of intracellular oxidant species generation in Staphylococcus aureus ATCC 25923 by DCFH-DA dye based fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Allicin-inspired pyridyl disulfides as antimicrobial agents for multidrug-resistant Staphylococcus aureus.
AID326159Antimalarial activity against Plasmodium falciparum Dd2 by reduced [3H]hypoxanthine uptake2007The Journal of biological chemistry, Aug-31, Volume: 282, Issue:35
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.
AID1532352Antibacterial activity against Escherichia coli ATCC 35218 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1503433Selectivity index, ratio of LC50 for cytotoxicity in human U937 cells to EC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigotes transfected with beta-galactosidase infected in human U937 cells2017European journal of medicinal chemistry, Dec-01, Volume: 141Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID1060592Cytotoxicity against human GM637 cells after 4 days by WST-1 assay2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
AID277596Inhibition of Plasmodium falciparum ENR in presence of quercetin by dilution assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID1503431Antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigotes transfected with beta-galactosidase infected in human U937 cells incubated for 72 hrs by spectrophotometry2017European journal of medicinal chemistry, Dec-01, Volume: 141Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID490663Antibacterial activity against Fusobacterium nucleatum ATCC 10953 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID1770463Antiplasmodial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID646843Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1682389Antimicrobial activity against Escherichia coli W3110 imp4213 expressing pCA24N-fab/ Y156V mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID1250831Inhibition of Staphylococcus aureus FabI assessed as reduction in inhibition of reduction of trans-2-octenoyl N-acetylcysteamine substrate by spectrophotometry2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
AID646851Antibacterial activity against Escherichia coli isolate CAN-ICU 63074 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID496244Antibacterial activity against Escherichia coli W3110 containing pZL16 expressing sPseudomonas aeruginosa fabV gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID1225686Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth after 5 days by Microplate Alamar Blue Assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Discovery of target based novel pyrrolyl phenoxy derivatives as antimycobacterial agents: an in silico approach.
AID519106Antibacterial activity against Escherichia coli 10418 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID756995Inhibition of Francisella tularensis SCHU S4 FabI R96G mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID490661Antibacterial activity against Actinomyces viscosus ATCC 15987 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID1714722Induction of intracellular oxidant species generation in Staphylococcus aureus ATCC 25923 after 1 hr by colorimetric based NBT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Allicin-inspired pyridyl disulfides as antimicrobial agents for multidrug-resistant Staphylococcus aureus.
AID753502Antiplasmodial activity against blood stage of drug-resistant Plasmodium falciparum TM91C2352013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID1532384Antibacterial activity against Streptococcus agalactiae OCC 182 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID519252Antibacterial activity against Proteus mirabilis M 26 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID555357Effect on growth in Staphylococcus aureus MN8 at 0.05 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID741095Antiparasitic activity against Toxoplasma gondii type 1 RH expressing YFP infected in HFF assessed as inhibition of [3H]-uracil incorporation after 72 hrs by liquid scintillation counting2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
AID67369In vitro antibacterial activity against Staphylococcus aureus FabI2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID738390Antibacterial activity against Escherichia coli ATCC 8099 after 24 hrs by NCCLS method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Efficient synthesis and antimicrobial activity of some novel S-β-d-glucosides of 5-aryl-1,2,4-triazole-3-thiones derivatives.
AID1503429Cytotoxicity in human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID1532354Antibacterial activity against Escherichia coli NCTC 13216 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1352684Inhibition of Mycobacterium tuberculosis InhA2018European journal of medicinal chemistry, Feb-25, Volume: 146An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
AID751284Inhibition of Escherichia coli FabI using 2-dodecenoyl-CoA as substrate at pH 82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID1590351Inhibition of GRP78 (26 to 636 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 cells pre-incubated for 10 mins before FITC-NRLLLTG fluorescent peptide addition in presence of 20 uM ADP followed by further incubation for 2 hrs by fluoresc2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
A high throughput substrate binding assay reveals hexachlorophene as an inhibitor of the ER-resident HSP70 chaperone GRP78.
AID496256Inhibition of Pseudomonas aeruginosa PAO272 fabI assessed as reduction of Enoyl-[acyl-carrier-protein] reductase activity at 15 ug/ml2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID519128Effect on catheter blockage in Bladder model inoculated with Proteus mirabilis M 55 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1181176Antimicrobial activity against Mycobacterium tuberculosis H37Rv over-expressing InhA cells assessed as upshift of MIC relative to wild type2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID774992Cytotoxicity against human GM637 cells after 4 days by WST-1 assay2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis.
AID1532366Antibacterial activity against Bacillus cereus ATCC 14579 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1322945Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth measured after 24 hrs using p-iodonitrotetrazolium violet by broth dilution method2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
AID1682393Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 pCA24N mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID738389Antifungal activity against Monilia albican ATCC 10231 after 24 to 72 hrs by NCCLS method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Efficient synthesis and antimicrobial activity of some novel S-β-d-glucosides of 5-aryl-1,2,4-triazole-3-thiones derivatives.
AID360365Antimalarial activity after 48 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID519130Effect on viable cells in urine at time of catheter blockage in Bladder model inoculated with Proteus mirabilis M 48 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1532357Antibacterial activity against Hafnia alvei 13337 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID519117Antibacterial activity against Proteus mirabilis M 29 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID64381Antibacterial activity against Enterococcus faecalis I2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID1060595Cytotoxicity against human HCT116 cells after 4 days by WST-1 assay2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
AID302095Inhibition of Escherichia coli enoyl-ACP reductase FabI2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
AID69489Minimum inhibitory concentration against Escherichia coli was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID1679086Inhibition of Mycobacterium tuberculosis InhA using DD-CoA as substrate2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.
AID67363Evaluated for inhibition of enoyl acyl carrier protein reductase (FabI) in Staphylococcus aureus.2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
AID541028Induction of apoptosis in bovine BL3 cells assessed as early apoptotic cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID741093Inhibition of Toxoplasma gondii enoyl reductase assessed as conversion of trans-2-acyl-ACP to acyl-ACP at 1 uM2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
AID1532395Antibacterial activity against Salmonella enterica subspecies enterica serotype Nottingham NCTC 7832 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID738391Antibacterial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by NCCLS method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Efficient synthesis and antimicrobial activity of some novel S-β-d-glucosides of 5-aryl-1,2,4-triazole-3-thiones derivatives.
AID532763Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method in presence of chlorpromazine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID618841Antimicrobial activity against methicillin-resistant Staphylococcus aureus using tryptone soy broth in presence of oleic acid2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
The impact of fatty acids on the antibacterial properties of N-thiolated β-lactams.
AID496259Inhibition of Pseudomonas aeruginosa PA0170 fabV assessed as reduction of [1-14C]acetate incorporation into phospholipids2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID263603Antimalarial activity against Plasmodium falciparum 3D72006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
AID771679Antiplasmodial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 assessed as growth inhibition after 24 hrs by [3H]-hypoxanthine incorporation assay2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
AID527266Inhibition of Plasmodium falciparum FabI by spectrophotometric analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID519123Antibacterial activity against Proteus mirabilis M 35 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID67361Evaluated for inhibition of enoyl acyl carrier protein reductase (FabI) in Escherichia coli.2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
AID1060920Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay2014European journal of medicinal chemistry, Jan, Volume: 71Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
AID1733036Selective index, ratio of CC50 for African green monkey Vero cells to IC50 for plasmodium falciparum2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1532373Antibacterial activity against Staphylococcus aureus ATCC 9144 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532367Antibacterial activity against Bacillus subtilis NCTC 10073 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1639208Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 measured after 48 hrs2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID496254Inhibition of Pseudomonas aeruginosa PA0170 fabV assessed as reduction of Enoyl-[acyl-carrier-protein] reductase activity at 15 ug/ml2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID1532382Antibacterial activity against Staphylococcus haemolyticus OCC 2223 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID64079Antibacterial activity against Escherichia coli 120AcrAB-2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID646845Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID285179Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 1333 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1532359Antibacterial activity against Klebsiella pneumoniae ATCC 10031 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1053502Inhibition of wild type Mycobacterium tuberculosis inhA2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID218916Concentration required for the 50% inhibition of enoyl-ACP reductase from Haemophilus influenzae was determined; NT means not tested2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID347259Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1326386Antibacterial activity against Bacillus subtilis P10B derived after 10 passage in presence of JBIR-100 after 16 to 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.
AID1682387Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI G93V mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID753505Inhibition of Toxoplasma gondii enoyl acyl-carrier protein reductase at 1 uM2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID1736275Inhibition of wild type InhA in Mycobacterium tuberculosis H37Rv using trans-2-dodecenoyl-coenzyme A as substrate at 50 uM2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
AID1532375Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID532580Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID497753Absorption in in percutaneously dosed healthy human at 1166 mg2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
AID278577Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID406449Antiparasitic activity against Plasmodium falciparum in RBCs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID408580Antibacterial activity against wild type Escherichia coli K12 after 12 hrs by microdilution method2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents.
AID303085Inhibition of transthyretin fibril formation at pH 4.4 at 50 uM2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID756989Cytotoxicity against mouse Neuro2a cells assessed as cell survival after 72 hrs by CellTiter-96 aqueous one solution assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID496252Inhibition of Pseudomonas aeruginosa fabI activity assessed as conversion of 3-hydroxydecanoyl-ACP to trans-2-decenoyl-ACP at 10 ug/ml in presence of 2.5 M urea2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID452742Antibacterial activity against Escherichia coli M15 containing pQE30 expression vector2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID1532374Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID347257Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADPH2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID67368Antibacterial activity against Staphylococcus aureus FabI2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID1532343Antibacterial activity against Aeromonas hydrophila OCC 778 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID490762Antibacterial activity against Prevotella intermedia ATCC 25611 after 48 hrs by broth microdilution method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens.
AID509520Inhibition of Toxoplasma gondii enoyl reductase2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.
AID1532379Antibacterial activity against Staphylococcus epidermidis 155 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1682386Antimicrobial activity against Escherichia coli W3110 imp4213 expressing pCA24N mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID519118Antibacterial activity against Proteus mirabilis M 31 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID496248Antibacterial activity against Escherichia coli MG1655 pZL16 expressing Pseudomonas aeruginosa fabV gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID419344Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 weeks2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives.
AID288443Inhibition of Plasmodium falciparum recombinant enoyl ACP reductase expressed in BL21 (DE3) cells with respect to crotonyl CoA2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.
AID751286Inhibition of Mycobacterium tuberculosis FabI using 2-dodecenoyl-CoA as substrate at pH 6.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID555394Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1187 at 0.05 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1532370Antibacterial activity against Enterococcus faecium ATCC 19434 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532392Antibacterial activity against Salmonella enterica subspecies enterica serotype Enteritidis 13076 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID646859Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1532348Antibacterial activity against Escherichia coli ATCC 8739 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID297873Inhibition of Streptococcus pneumoniae FabK2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
AID646872Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1733042Antimalarial activity against ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM assessed as time taken for recrudescence by measuring parasitemia at 7 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID646867Antibacterial activity against Escherichia coli isolate CAN-ICU 63074 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID532573Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID741096Antiparasitic activity against Toxoplasma gondii infected in BALB/c mouse assessed as reduction of parasite burden at 25 mg/kg, ip qd for 5 days2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
AID519109Antibacterial activity against Proteus mirabilis M 48 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID309298Inhibition of Plasmodium falciparum FabI2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID519125Antibacterial activity against Proteus mirabilis M 42 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1532396Antibacterial activity against Salmonella enterica subspecies enterica serotype Poona NCTC 4840 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532394Antibacterial activity against Salmonella enterica subspecies enterica serotype Infantis OCC 2133 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID496255Inhibition of wild type Pseudomonas aeruginosa ENR at 15 ug/ml2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID756997Inhibition of C-terminal His6-tagged wild type Francisella tularensis SCHU S4 FabI expressed in Escherichia coli BL21 (DE3) using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID646848Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID67372Inhibitory activity against Enoyl-ACP reductase FabI in Staphylococcus aureus2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID555361Effect on growth in Staphylococcus aureus FRI-1187 at 0.50 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555393Induction of toxin TSST-1 production in Staphylococcus aureus FRI-1187 at 0.50 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID263604Antimalarial activity against Plasmodium falciparum Dd22006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
AID519114Antibacterial activity against Proteus mirabilis M 23 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID519137Effect on pH of residual urine at time of catheter blockage in Bladder model inoculated with Proteus mirabilis M 55 mutant2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID756990Cytotoxicity against human 786-O cells assessed as cell survival after 72 hrs by CellTiter-96 aqueous one solution assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID497752Excretion in in percutaneously dosed healthy human urine at 1166 mg up to 48 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
AID1532346Antibacterial activity against Enterobacter aerogenes ATCC 13048 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1682394Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 pCA24N fabI mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID646856Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID303087Inhibition of transthyretin fibril formation assessed as turbidity at 21.6 uM at pH 4.4 after 3 hrs2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID564971Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID756996Inhibition of Francisella tularensis SCHU S4 FabI F93V mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID1532389Antibacterial activity against Salmonella enterica subspecies enterica serotype Abony NCTC 6017 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1639213Inhibition of Escherichia coli KAS3 expressed in Escherichia coli BL21(DE3)2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID646866Antibacterial activity against Escherichia coli isolate CAN-ICU 61714 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1639212Inhibition of Escherichia coli DNA gyrase assessed as reduction in enzyme-mediated supercoiling of relaxed pBR322 DNA measured after 60 mins by electrophoresis method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID1682391Antimicrobial activity against Escherichia coli W3110 imp4213 expressing pCA24N-fab F204V mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID564970Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID564982Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID618842Antimicrobial activity against methicillin-resistant Staphylococcus aureus using tryptone soy broth in presence of tween-802011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
The impact of fatty acids on the antibacterial properties of N-thiolated β-lactams.
AID218918Concentration required for the 50% inhibition of enoyl-ACP reductase from Staphylococcus aureus was determined.2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID497754Time to reach maximum urine excretion rate in percutaneously dosed healthy human at 1166 mg2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
AID1532360Antibacterial activity against Proteus mirabilis ATCC 12453 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID710145Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID1326387Antibacterial activity against Bacillus subtilis P10C derived after 10 passage in presence of JBIR-100 after 16 to 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.
AID771676Inhibition of Plasmodium falciparum FabI using crotonoyl-CoA as substrate by UV-Vis spectrophotometric analysis in presence of NADH2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
AID1250833Antibacterial activity against methicillin-resistant Staphylococcus aureus incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
AID277590Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGC2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID519129Effect on viable cells in urine at time of catheter blockage in Bladder model inoculated with wild-type Proteus mirabilis B22008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID361262Inhibition of fatty acid synthesis in Plasmodium falciparum FCK2 trophozoites at 10 uM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID541027Antiproliferative activity against Theileria parva-induced proliferation of bovine BL3 cells assessed as inhibition of [3H]thymidine uptake after 32 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID726480Antimalarial activity against Plasmodium falciparum Dd2 assessed as inhibition of parasite growth2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Novel diaryl ureas with efficacy in a mouse model of malaria.
AID1682406Antibacterial activity against Escherichia coli BW25113 assessed as effect on growth rate per hour at 0.128 uM incubated for 24 hrs by microplate reader2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID1532377Antibacterial activity against Staphylococcus aureus OCC 104 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1532388Antibacterial activity against Streptococcus viridans OCC 234 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID347254Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADPH2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID753503Antiplasmodial activity against blood stage of drug-sensitive Plasmodium falciparum D62013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID452746Antibacterial activity against fabI-overexpressing Escherichia coli M152010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID67367In vitro antibacterial activity against Moraxella catarrhalis 1502 FabI2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID753504Inhibition of Toxoplasma gondii enoyl acyl-carrier protein reductase2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID360367Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
AID406452Inhibition of Plasmodium falciparum FabI A217V mutant assessed as saturated acyl-acyl carrier protein level at 5 uM by MALDI-TOF mass spectrometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID519132Effect on rate of catheter encrustations in Bladder model inoculated with wild-type Proteus mirabilis B22008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1672289Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID564972Antimicrobial activity against Mycobacterium bovis BCG by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID623304Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by twofold dilution method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
AID419343Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 1 ug/ml after 6 weeks2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives.
AID303083Binding affinity to transthyretin at pH 4.42007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID519121Antibacterial activity against Proteus mirabilis M 17 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1187053Inhibition of Plasmodium falciparum FabI2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes.
AID496243Antibacterial activity against Escherichia coli W3110 containing pZL17 expressing Pseudomonas aeruginosa fabI gene assessed as microbial growth inhibition2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID1053501Antitubercular activity against Mycobacterium tuberculosis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID1532362Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID646853Antibacterial activity against Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID646864Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1672292Antifungal activity against Candida albicans assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID541031Induction of apoptosis in bovine BL3 cells assessed as necrotic after 24 hrs by annexin V/propidium iodide staining-based FACS analysis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Theileria apicoplast as a target for chemotherapy.
AID302094Antibacterial activity against Streptococcus pneumoniae KU197 mutant by broth microdilution method2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
AID67373Concentration required for the 50% inhibition of Enoyl-ACP reductase from Streptococcus pneumoniae was determined.2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID646861Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1739640Inhibition of Mycobacterium tuberculosis His6-tagged MabA expressed in Escherichia coli BL21 (DE3) assessed as reduction in HBCoA formation up to 100 uM using AcAcCoA as substrate preincubated for 10 to 30 mins followed by substrate and NADPH addition and2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
AID426407Inhibition of Plasmodium falciparum enoyl-acyl carrier protein reductase2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.
AID1733046Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia pretreated with dihydroartemisinin for 6 hrs followed by treated at 7 uM for 48 hrs by Quiescen2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID303082Inhibition of transthyretin fibril formation at pH 4.42007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID408582Stability at -10 to 40 degC after 24 hrs by FPLC assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Design, synthesis, and application of novel triclosan prodrugs as potential antimalarial and antibacterial agents.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1682390Antimicrobial activity against Escherichia coli W3110 imp4213 expressing pCA24N-fab F203L mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID646852Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1532369Antibacterial activity against Enterococcus faecalis ATCC 33186 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID319627Inhibition of Mycobacterium tuberculosis H37RV InhA2008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
AID1322943Inhibition of recombinant Mycobacterium tuberculosis InhA expressed in Escherichia coli Rosetta (DE3) pLysS using 2-trans-decenoyl-N-acetylcyste-amine as substrate in presence of NADH by spectrophotometric method2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
AID1532355Antibacterial activity against Escherichia coli OCC 122 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID618839Antimicrobial activity against methicillin-resistant Staphylococcus aureus using tryptone soy broth2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
The impact of fatty acids on the antibacterial properties of N-thiolated β-lactams.
AID1315572Inhibition of His6-tagged recombinant Mycobacterium tuberculosis InhA expressed in protease-deficient Escherichia coli (BL21) using trans-2-dodecenoyl-coenzyme A as substrate assessed as NADH oxidation at 50 uM relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.
AID519111Antibacterial activity against Proteus mirabilis NP14 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1496039Inhibition of Mycobacterium tuberculosis InhA using trans-2-decenoyl-N-acetylcysteamine as substrate preincubated for 1 hr followed by substrate addition measured every 30 secs for 5 mins2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID646844Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis 81388 after 24 hrs by macrobroth dilution method2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID1532350Antibacterial activity against Escherichia coli ATCC 11775 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1733034Antimalarial activity against artemisinin-sensitive Plasmodium falciparum F32-TEM by SYBR green dye based fluorescence assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID496253Inhibition of Pseudomonas aeruginosa fabV activity assessed as conversion of 3-hydroxydecanoyl-ACP to trans-2-decenoyl-ACP at 1000 ug/ml in presence of 2.5 M urea2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID277595Inhibition of Plasmodium falciparum ENR in presence of ECG by dilution assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID257396Inhibition of PfENR enzymatic activity2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.
AID753507Antiparasitic activity against tachyzoite of Toxoplasma gondii RH expressing yellow fluorescent protein infected in human foreskin fibroblasts after 72 hrs by bacterial beta-galactosidase reporter gene assay2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
AID519110Antibacterial activity against Proteus mirabilis M 55 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID1639206Inhibition of recombinant Mycobacterium tuberculosis InhA expressed in Escherichia coli Rosette(DE3) pLysS using trans-2-decenoyl-N-acetylcysteamine as substrate by spectrophotometric method2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
AID1532344Antibacterial activity against Citrobacter freundii OCC 851 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID509522Toxicity to HFF2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.
AID1435642Inhibition of Mycobacterium tuberculosis His6-tagged wild type InhA expressed in Escherichia coli BL21 at 50 uM using DDCoA as substrate relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.
AID326160Antimalarial activity against Plasmodium falciparum 3D7 by reduced [3H]hypoxanthine uptake2007The Journal of biological chemistry, Aug-31, Volume: 282, Issue:35
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.
AID646868Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID743656Antibacterial activity against Escherichia coli EB2120 conditional lolA strain with lolA deletion and complementing copy placed at araBAD locus at 1 to 256 ug/mL after 18 hrs in presence of 0.00002 to 0.2% of arabinose2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA.
AID1061852Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 31672014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
AID1503430Antileishmanial activity against GFP-tagged Leishmania panamensis MHOM/CO/87/UA140 intracellular amastigotes infected in human U937 cells incubated for 72 hrs by flow cytometry2017European journal of medicinal chemistry, Dec-01, Volume: 141Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID326161Inhibition of Plasmodium falciparum ENR2007The Journal of biological chemistry, Aug-31, Volume: 282, Issue:35
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.
AID303080Inhibition of transthyretin amyloidosis assessed as fibril formation at 7.2 uM at pH 4.4 relative to control2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID127507Antibacterial activity against Moraxella catarrhalis 15022001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
AID519124Antibacterial activity against Proteus mirabilis M 40 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID303088Stabilization of urea-induced transthyretin dissociation at 21.6 uM at pH 7.2 after 1 hr relative to control2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
AID519126Effect on catheter blockage in Bladder model inoculated with wild-type Proteus mirabilis B22008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID710144Antibacterial activity against Streptococcus pneumoniae D39 after 18 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
AID206881Antibacterial activity against Staphylococcus aureus Oxford.2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
AID67365Antibacterial activity against Escherichia coli FabI2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID646862Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID519119Antibacterial activity against Proteus mirabilis NP43 after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID519113Antibacterial activity against Proteus mirabilis M 21 mutant after 18 hrs by Etest method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reduced Susceptibility of Proteus mirabilis to triclosan.
AID756991Selectivity ratio of IC50 for C-terminal His6-tagged wild type Francisella tularensis SCHU S4 FabI to IC50 for Francisella tularensis SCHU S4 FabI R96M mutant2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
AID1532349Antibacterial activity against Escherichia coli ATCC 10536 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID277591Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of quercetin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID277594Inhibition of Plasmodium falciparum ENR in presence of EGC by dilution assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
AID1682395Antimicrobial activity against Escherichia coli W3110 imp4213 expressing fabI392 pCA24N fabI Y156V mutant assessed as absence of growth2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
AID532764Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID611703Inhibition of Plasmodium falciparum Enoyl-ACP reductase using crotonyl-CoA as substrate at 0.05 mM peincubated for 5 mins measured after 10 mins of substrate addition by UV-vis spectrophotometry2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Isoflavone dimers and other bioactive constituents from the figs of Ficus mucuso.
AID1532376Antibacterial activity against Staphylococcus aureus NCTC 13758 after 18 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and antibacterial profiles of targeted triclosan derivatives.
AID1714449Inhibition of Mycobacterium tuberculosis InhA2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.
AID496257Inhibition of Pseudomonas aeruginosa PAO272 fabI assessed as reduction of [1-14C]acetate incorporation into phospholipids2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
AID646870Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002The Journal of biological chemistry, Apr-12, Volume: 277, Issue:15
Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1796223Enzyme Inhibition Assay from Article 10.1016/s0960-894x(01)00404-8: \\1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).\\2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
AID1799921Fabl Assay from Article 10.1111/cbdd.12118: \\Design, Synthesis, Structural Characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-Ray Diffraction and Evaluation of a New Class of Phenylaminoacetic Acid Benzylidene Hydrazines as pfENR Inhibitors.\\2013Chemical biology & drug design, Jun, Volume: 81, Issue:6
Design, synthesis, structural characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-ray diffraction and evaluation of a new class of phenylaminoacetic acid benzylidene hydrazines as pfENR inhibitors.
AID1799923Thermal Shift Assay from Article 10.1021/bi400413c: \\Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex.\\2013Biochemistry, Jun-18, Volume: 52, Issue:24
Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
AID1799428Enzyme Inhibition Assay from Article 10.1021/cb800306y: \\Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.\\2009ACS chemical biology, Mar-20, Volume: 4, Issue:3
Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
AID1796221Enzyme Inhibition Assay from Article 10.1021/jm0204035: \\Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.\\2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
AID1802645Inhibition Kinetics Assay from Article 10.1021/acs.biochem.6b01048: \\Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.\\2017Biochemistry, 04-04, Volume: 56, Issue:13
Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
AID1796225Enzyme Inhibition Assay from Article 10.1016/s0960-894x(01)00405-x: \\Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.\\2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
AID1797491Enoyl-CoA Reductase Inhibition Assay from Article 10.1021/cb0500042: \\High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.\\2006ACS chemical biology, Feb-17, Volume: 1, Issue:1
High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1796219Enzyme Inhibition Assay from Article 10.1021/jm020050+: \\Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).\\2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
AID1798551PfENR Enzymatic Inhibition Assay from Article 10.1074/jbc.M701813200: \\X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.\\2007The Journal of biological chemistry, Aug-31, Volume: 282, Issue:35
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.
AID1799429Enzyme Inhibition Assay from Article 10.1021/cb800306y: \\Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.\\2009ACS chemical biology, Mar-20, Volume: 4, Issue:3
Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
AID1800410TgENR Inhibition Assay from Article 10.1021/bi400945y: \\Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.\\2013Biochemistry, Dec-23, Volume: 52, Issue:51
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
AID1797492Measurement of Inhibition Constants from Article 10.1021/cb0500042: \\High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.\\2006ACS chemical biology, Feb-17, Volume: 1, Issue:1
High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2014The Journal of biological chemistry, Nov-28, Volume: 289, Issue:48
Crystal structure of the human fatty acid synthase enoyl-acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011PLoS pathogens, Jun, Volume: 7, Issue:6
The binding of triclosan to SmeT, the repressor of the multidrug efflux pump SmeDEF, induces antibiotic resistance in Stenotrophomonas maltophilia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,260)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990521 (15.98)18.7374
1990's200 (6.13)18.2507
2000's652 (20.00)29.6817
2010's1363 (41.81)24.3611
2020's524 (16.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.89 (24.57)
Research Supply Index8.23 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index142.60 (26.88)
Search Engine Supply Index2.24 (0.95)

This Compound (70.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials379 (11.24%)5.53%
Reviews175 (5.19%)6.00%
Case Studies24 (0.71%)4.05%
Observational7 (0.21%)0.25%
Other2,788 (82.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (58)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Triclosan Coated Suture Wound Closure for Peripheral Vascular Surgery: a Prospective Multicenter Study [NCT01101789]276 participants (Actual)Interventional2010-04-30Completed
Triclosan-coated Sutures in Cardiac Surgery:Effects on Leg Wound Infections and Costs [NCT01212315]Phase 4392 participants (Actual)Interventional2009-03-31Completed
Effect of a Triclosan Containing Dentifrice on Oral Bacteria and Postoperative Complications Following Third Molar Surgery [NCT01292343]141 participants (Actual)Interventional2008-02-29Completed
Incisional Surgical Site Infection and Fascial Dehiscence After Abdominal Fascial Closure With Triclosan-Coated Barbed Suture vs Polydioxanone Suture After Emergency Exploratory Laparotomy: A Randomized Control Trial [NCT06043414]250 participants (Anticipated)Interventional2024-01-01Not yet recruiting
To Access the Effects of Mucositis in Adults With Dental Implants [NCT01072201]Phase 360 participants (Actual)Interventional2007-06-30Completed
The Clinical Study of the Microbial Colonization of Chronic Keratinized Hand Eczema and the Change of Microbial Colonization After External Using of Halometasone Triclosan Cream [NCT03246776]Phase 480 participants (Actual)Interventional2017-08-20Completed
Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families. A Controlled and Randomized Clinical Trial. [NCT03642353]Phase 440 participants (Actual)Interventional2016-01-30Completed
Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis: Clinical Parameters and Local Pattern of Osteo-immunoinflammatory Mediators in Peri-implant Fluid [NCT03145610]22 participants (Actual)Interventional2013-06-01Completed
Efficacy of a Triclosan Formulation to Control the Initial Subgingival Biofilm Formation [NCT02192060]28 participants (Actual)Interventional2013-05-31Completed
Clinical Study to Evaluate Dental Plaque [NCT00758290]Phase 323 participants (Actual)Interventional2008-05-31Completed
Suture of the Abdominal Wall With Triclosan-coated Polydioxanone Barbed Suture vs Triclosan-coated Polydioxanone Monofilament vs Polydioxanone Monofilament in Emergency Surgery [NCT03763279]Phase 3150 participants (Actual)Interventional2018-11-30Completed
Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis [NCT00926328]Phase 3120 participants (Actual)Interventional2007-06-30Completed
Evaluating Commercial Anti-Plaque Products and Oral Rinse [NCT01014143]Phase 226 participants (Actual)Interventional2007-08-31Completed
Periodontal Disease and Cardiovascular Disease [NCT00763165]Phase 3438 participants (Actual)Interventional2000-11-30Active, not recruiting
Train New Examiners Via Modified Gingival Margin Plaque [NCT00758563]Phase 315 participants (Actual)Interventional2008-03-31Completed
Effect of a Triclosan-containing Toothpaste as a Preventive Strategy of Peri-implant Experimental Mucositis in Cigarette Smokers: Clinical and Osteo-immunoinflammatory Response in a Randomized Crossover Study. [NCT03241407]26 participants (Actual)Interventional2013-07-01Completed
Effects of a Toothpaste Containing 0.3% Triclosan in the Maintenance Phase of Peri-implantitis Treatment. [NCT03191721]Phase 3102 participants (Actual)Interventional2010-06-30Completed
Training and Calibration of Dental Examiners [NCT00765167]Phase 318 participants (Actual)Interventional2007-11-30Completed
Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers [NCT02670135]Phase 4303 participants (Actual)Interventional2015-06-30Completed
Compare the Results of Antimicrobial to Conventional Suture Materials in Patients Receiving Primary Total Knee Replacement: A Prospective Double-blinded Randomized Controlled Trial [NCT02533492]Phase 4102 participants (Actual)Interventional2011-06-30Completed
The Efficacy of a Toothpaste to Reduce Sensitivity [NCT00763269]Phase 3626 participants (Actual)Interventional2008-09-30Completed
Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery [NCT00768222]Phase 4101 participants (Actual)Interventional2008-10-31Completed
Clinical Study to Compare Dental Plaque Control [NCT00758394]Phase 329 participants (Actual)Interventional2007-09-30Completed
The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics [NCT00763256]Phase 333 participants (Actual)Interventional2006-05-31Completed
The Effect of Periodontal Treatment and the Use of a Triclosan/Copolymer/Fluoride Toothpaste on Glycaemic Control in Diabetics. [NCT00762762]Phase 360 participants (Actual)Interventional2006-03-31Completed
Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons [NCT00631566]550 participants (Actual)Interventional2007-05-31Completed
Investigation of Dental Plaque and Gingival Index [NCT00759031]Phase 319 participants (Actual)Interventional2008-02-29Completed
"The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection Prospective, Randomized, Controlled, Double Blind, Multi-centre Study." [NCT01019447]Phase 4701 participants (Actual)Interventional2009-11-30Completed
The Influence of Periodontal Treatment on Gingival Inflammatory Response of the Type II Diabetic Patient [NCT01881074]74 participants (Actual)Observational2012-06-30Completed
[NCT02018289]Phase 3106 participants (Actual)Interventional2007-10-31Completed
Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery [NCT01869257]Phase 3279 participants (Actual)Interventional2009-05-31Completed
Triclosan-antibacterial Sutures Efficacy on the Incidence of Surgical Site Infection in Clean-contaminated Wounds; Multi-center, Double Blind, Randomized Study [NCT04256824]Phase 4430 participants (Anticipated)Interventional2020-02-05Recruiting
Antibacterial-coated Sutures at Time of Cesarean [NCT03386240]Phase 43,374 participants (Anticipated)Interventional2018-01-09Recruiting
Efficacy of Salivary Bacteria and Post Brushing [NCT00981825]Phase 322 participants (Actual)Interventional2007-10-31Completed
Effect on Bacterial Glycolytic Acid Formation on Plaque [NCT00762450]Phase 36 participants (Actual)Interventional2008-04-30Completed
Compare Anti-inflammatory Dentifrices [NCT00762528]Phase 449 participants (Actual)Interventional2009-02-28Completed
Compare the Clinical Efficacy of Prototype Toothpastes [NCT00926029]Phase 398 participants (Actual)Interventional2008-01-31Completed
Evaluate Clinical Research From Commerical Oral Care Products [NCT00759187]Phase 325 participants (Actual)Interventional2008-01-31Completed
Clinical Study to Examine Brushing on Dental Implants [NCT00762619]Phase 3105 participants (Actual)Interventional2007-04-30Completed
Development of Clinical Method to Triclosan Retention in Plaque Following Brushing [NCT00762853]Phase 320 participants (Actual)Interventional2008-05-31Completed
Effect on the Reduction of Bacterial Load in Surgical Antisepsis of Hands After Washing With Triclosan 0.5% Compared to Propan-1-ol 60% Used as Reference Disinfectant [NCT04538365]Phase 424 participants (Actual)Interventional2020-10-01Completed
Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes [NCT00762515]Phase 344 participants (Actual)Interventional2008-02-29Completed
The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis. [NCT02193165]Phase 3120 participants (Actual)Interventional2014-07-31Completed
Triclosan, Triclocarban, and the Microbiota [NCT01509976]20 participants (Actual)Interventional2011-07-01Completed
Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70% [NCT01762904]Phase 3135 participants (Actual)Interventional2013-01-31Completed
Stanford's Outcomes Research in Kids (STORK) [NCT01442701]361 participants (Actual)Observational2011-11-17Completed
Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing. [NCT00966953]Phase 325 participants (Actual)Interventional2007-10-31Completed
The Clinical Investigation of Colgate Total Toothpaste as Compared to Crest Pro-Health Toothpaste and Crest Pro-Health Mouthwash, and Crest Cavity Protection Toothpaste and Crest Fluoride Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical St [NCT02360995]Phase 4129 participants (Actual)Interventional2014-06-30Completed
Collection of Gingival Crevicular Fluid From Periodontitis Patients [NCT00763048]Phase 339 participants (Actual)Interventional2008-03-31Completed
Investigate Oral Bacteria in Adult Population [NCT00762177]Phase 324 participants (Actual)Interventional2008-05-31Completed
Evaluate Inflammation Caused by Gingivitis in Adults [NCT00941668]Phase 449 participants (Actual)Interventional2007-01-31Completed
Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse [NCT01024738]Phase 322 participants (Actual)Interventional2008-03-31Completed
Triclosan-antibacterial Sutures Impact on the Incidence of Surgical Site Infection in Laparoscopic Sleeve Gastrectomy, Laparoscopic Appendectomy or Laparoscopic Cholecystectomy; Multi-center, Double-blind, Randomized Study. [NCT04255927]Phase 4912 participants (Actual)Interventional2020-02-05Completed
Compare the Clinical Efficacy of Prototype Toothpastes. [NCT00761930]Phase 3103 participants (Actual)Interventional2008-03-31Completed
Effectiveness of Triclosan Coated VICRYLMONOCRYL Sutures in Preventing Leg Wound Infection Compared to POLYSORB BIOSYN Sutures in Patients After Coronary Bypass Surgery- a Randomized Controlled Trial [NCT01457859]Phase 4410 participants (Anticipated)Interventional2011-10-31Not yet recruiting
Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model [NCT01799226]32 participants (Actual)Interventional2013-03-31Completed
Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice. [NCT05105139]90 participants (Actual)Observational2021-11-29Completed
Clinical Efficacy in Reducing Established Dental Plaque and Gingivitis of a Toothpaste Containing 0.3% Triclosan, 2% Copolymer / Sodium Fluoride and a Manual Toothbrush as Compared to an Oral Hygiene Multi-component Regimen Encompassing the Use of a Manua [NCT02366689]Phase 4179 participants (Actual)Interventional2014-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00631566 (2) [back to overview]To Determine the Prevalence and Incidence of MRSA Colonization of the Nares, Throat, Perirectal, Axilla, and Groin Areas Among HIV Infected Patients and to Study Changes in the Colonization Rates Over Time.
NCT00631566 (2) [back to overview]The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization
NCT00758290 (1) [back to overview]Dental Plaque Index
NCT00758394 (1) [back to overview]Dental Plaque Index
NCT00758563 (1) [back to overview]Mean Gingival Plaque Units
NCT00759031 (1) [back to overview]Gingival Margin Plaque Index
NCT00759187 (1) [back to overview]Dental Plaque Index
NCT00761930 (3) [back to overview]Gingivitis Score
NCT00761930 (3) [back to overview]Dental Plaque
NCT00761930 (3) [back to overview]Bleeding Index (EIBI)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Sulfur Bacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Tongue(Total Anaerobic)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Fusobacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Actinomyces)
NCT00762177 (24) [back to overview]Antimicrobial Species in Tongue(Sulfur Bacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Oral Streptococci)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Total Anaerobic)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Actinomyces)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Fusobacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Veillonella)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Total Anaerobic)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Oral Streptococci)
NCT00762177 (24) [back to overview]Antimicrobial Species in Tongue(Fusobacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Tongue(Oral Streptococci)
NCT00762177 (24) [back to overview]Antimicrobial Species in Plaque(Sulfur Bacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species in Tongue(Veillonella)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Actinomyces)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Fusobacteria)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Oral Streptococci)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Total Anaerobic)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Veillonella)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Tongue(Actinomycetes)
NCT00762177 (24) [back to overview]Antimicrobial Species in Saliva(Veillonella)
NCT00762177 (24) [back to overview]Antimicrobial Species on the Cheek(Sulfur Bacteria)
NCT00762450 (1) [back to overview]ph of Dental Plaque After Sucrose Challenge
NCT00762515 (2) [back to overview]Control Gingivitis in Adults
NCT00762515 (2) [back to overview]Control Established Plaque in Adults
NCT00762528 (8) [back to overview]Bleeding on Probing (BOP)
NCT00762528 (8) [back to overview]Gingival Index (GI)
NCT00762528 (8) [back to overview]8-iso-prostaglandinF2α (8-iso-PGF2α)
NCT00762528 (8) [back to overview]Prostaglandin E2 (PGE2)
NCT00762528 (8) [back to overview]Nuclear Factor Kappa B Ligand (RANK-L)
NCT00762528 (8) [back to overview]Interleukin - 1 Beta (IL-ß)
NCT00762528 (8) [back to overview]Interleukin-6 (IL-6)
NCT00762528 (8) [back to overview]Dental Plaque Index (PI)
NCT00762619 (68) [back to overview]P.Intermedia (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]P.Intermedia (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]P.Intermedia (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]P.Intermedia (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]A.Actinomycetemcomitans (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant
NCT00762619 (68) [back to overview]A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant
NCT00762619 (68) [back to overview]A.Actinomycetemcomitans (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]C.Rectus (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]C.Rectus (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]C.Rectus (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]C.Rectus (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Streptococci (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]E.Corrodens (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]E.Corrodens (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]E.Corrodens (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]E.Corrodens (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]E.Saburreum (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]E.Saburreum (DNA Probe Analysis) - Dental Implant
NCT00762619 (68) [back to overview]E.Saburreum (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]E.Saburreum (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]F.Nucleatum (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]F.Nucleatum (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]F.Nucleatum (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]F.Nucleatum (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth
NCT00762619 (68) [back to overview]Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth
NCT00762619 (68) [back to overview]Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants
NCT00762619 (68) [back to overview]Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants
NCT00762619 (68) [back to overview]Löe-Silness Gingival Index Score (GI) - Natural Teeth
NCT00762619 (68) [back to overview]Löe-Silness Gingival Index Score (GI) - Natural Teeth
NCT00762619 (68) [back to overview]Löe-Silness Gingival Index Score (GI)- Dental Implants
NCT00762619 (68) [back to overview]Löe-Silness Gingival Index Score (GI)- Dental Implants
NCT00762619 (68) [back to overview]Mombelli Plaque Index (mPI) for Dental Implants
NCT00762619 (68) [back to overview]Mombelli Plaque Index (mPI) for Dental Implants
NCT00762619 (68) [back to overview]Mombelli Plaque Index (mPI) for Natural Teeth
NCT00762619 (68) [back to overview]Mombelli Plaque Index (mPI) for Natural Teeth
NCT00762619 (68) [back to overview]Neissera sp. (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]Neissera sp. (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]Neissera sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Neissera sp. (DNA Probe Analysis) Natural Teeth
NCT00762619 (68) [back to overview]P.Gingivalis (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]P.Gingivalis (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Veillonella sp.(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Veillonella sp.(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Veillonella sp.(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]Veillonella sp.(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]T.Forsythia (DNA Probe Analysis)-Natural Teeth
NCT00762619 (68) [back to overview]T.Forsythia (DNA Probe Analysis)- Natural Teeth
NCT00762619 (68) [back to overview]Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]T.Forsythia (DNA Probe Analysis)- Dental Implants
NCT00762619 (68) [back to overview]T.Forsythia (DNA Probe Analysis)- Dental Implants
NCT00762619 (68) [back to overview]Streptococci (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Streptococci (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Streptococci (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]P.Melaninogenica (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]P.Melaninogenica (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]P.Gingivalis (DNA Probe Analysis) - Natural Teeth
NCT00762619 (68) [back to overview]P.Melaninogenica (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]P.Melaninogenica (DNA Probe Analysis) - Dental Implants
NCT00762619 (68) [back to overview]P.Gingivalis (DNA Probe Analysis) - Dental Implants
NCT00762762 (6) [back to overview]IL-6 (Interleukin - 6)
NCT00762762 (6) [back to overview]High Sensitivity CRP (C-Reactive Protein)
NCT00762762 (6) [back to overview]HbA1c Levels in Blood
NCT00762762 (6) [back to overview]HbA1c Levels in Blood
NCT00762762 (6) [back to overview]C-Peptide
NCT00762762 (6) [back to overview]TNF-α (Tumor Necrosis Factor - Alpha)
NCT00762853 (1) [back to overview]Triclosan Concentration in Dental Plaque
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Lysine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Phenylalanine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Putrescine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Xanthine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Cadaverine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Choline)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Hypoxanthine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Inosine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Isoleucine)
NCT00763048 (10) [back to overview]Metabolite Associated With Inflammation (Leucine)
NCT00763256 (5) [back to overview]C-Peptide
NCT00763256 (5) [back to overview]Gingivitis Score (GI)
NCT00763256 (5) [back to overview]P. Gingivalis
NCT00763256 (5) [back to overview]High Sensitivity CRP (C-Reactive Protein)
NCT00763256 (5) [back to overview]HbA1c Levels in Blood
NCT00763269 (4) [back to overview]Air Blast Hypersensitivity (8 Week)
NCT00763269 (4) [back to overview]Air Blast Hypersensitivity (4 Week)
NCT00763269 (4) [back to overview]Hypersensitivity Tactile(Yeaple Probe)
NCT00763269 (4) [back to overview]Hypersensitivity Tactile (Yeaple Probe)
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Surgical Site Infection Score on Modified ASEPSIS Scale
NCT00768222 (9) [back to overview]Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)
NCT00768222 (9) [back to overview]Mean Cosmetic Outcome Score on Modified Hollander Scale
NCT00768222 (9) [back to overview]Mean Cosmetic Outcome Score on Modified Hollander Scale
NCT00926029 (2) [back to overview]Plaque Index
NCT00926029 (2) [back to overview]Gingivitis Index
NCT00926328 (2) [back to overview]Gingivitis Index
NCT00926328 (2) [back to overview]Plaque Index
NCT00941668 (2) [back to overview]Level of Gingival Crevicular Fluid Interleukin - 6(GCF IL-6) at 2 Hours
NCT00941668 (2) [back to overview]Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours
NCT00966953 (1) [back to overview]Plaque Index
NCT00981825 (1) [back to overview]CFU (Colony Forming Units)
NCT01014143 (1) [back to overview]Plaque Index
NCT01024738 (1) [back to overview]Plaque Index
NCT01072201 (3) [back to overview]Mean Pocket Depth
NCT01072201 (3) [back to overview]Mean Percentage of Plaque Scores
NCT01072201 (3) [back to overview]Bleeding on Probing
NCT01762904 (4) [back to overview]Detect Presence of Allergy or Skin Reaction by the Antiseptic Application
NCT01762904 (4) [back to overview]Evaluate the Effect on the Skin Flora Application Process of Antiseptics by Sterile Swab
NCT01762904 (4) [back to overview]Evaluate the Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Administered Topically
NCT01762904 (4) [back to overview]Evaluate the Residual Effect of Triclosan 1% / Isopropyl Alcohol 70% Administered Topically.
NCT01799226 (2) [back to overview]Change From Baseline in Gingival Index (Loe & Silness 1963) to Day 35
NCT01799226 (2) [back to overview]Change From Baseline in Plaque Index (Silness & Loe 1964) to Day 35
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Gingivitis Scores

To Determine the Prevalence and Incidence of MRSA Colonization of the Nares, Throat, Perirectal, Axilla, and Groin Areas Among HIV Infected Patients and to Study Changes in the Colonization Rates Over Time.

(NCT00631566)
Timeframe: Every 6 months

,,
InterventionParticipants (Count of Participants)
NaresThroatPerirectalGroinAxilla
Mupirocin/Hexachlorophene Group17NANANANA
No MRSA Colonization00000
Placebo Group18NANANANA

[back to top]

The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization

MRSA colonization at 6-months post-randomization (NCT00631566)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Mupirocin/Hexachlorophene Group12
Placebo Group14
No MRSA Colonization0

[back to top]

Dental Plaque Index

Plaque units measured on a scale between 0 to 5. No plaque=0;5=2/3 of tooth covered in plaque (NCT00758290)
Timeframe: 4 Day

InterventionUnits on a scale (Mean)
Fluoride/Triclosan2.48
Triclosan/Fluoride2.42

[back to top]

Dental Plaque Index

plaque units measured on a scale between 0 to 5. 0 = No plaque; 5 = 2/3 of Tooth covered in plaque. (NCT00758394)
Timeframe: 4-Day

InterventionUnits on a scale (Mean)
Fluoride - A3.12
Fluoride/Triclosan - B2.90
Triclosan/Fluoride/Arginine2.92
Triclosan/Fluoride/Cavistat2.94

[back to top]

Mean Gingival Plaque Units

Scale 0 to 100% of tooth gingival margin covered by plaque. (0=no plaque, 100%=100% of the tooth's gingival margin is covered in plaque). (NCT00758563)
Timeframe: 1 day

InterventionUnits on a scale (Mean)
Fluoride13.38
Triclosan14.29

[back to top]

Gingival Margin Plaque Index

Scale 0 to 100% of tooth gingival margin covered by plaque. (0=no plaque, 100%=100% of the tooth's gingival margin is covered in plaque). The lower the score less dental plaque is present along the gum line and therefore the better the performance of the study treatment. (NCT00759031)
Timeframe: 1 day

InterventionUnits on a scale (Mean)
Fluoride15.4
Triclosan + Fluoride12.81

[back to top]

Dental Plaque Index

Scale 0 to 5 (zero= no plaque to 5 = plaque covering 2/3 or more of the crown of the tooth) (NCT00759187)
Timeframe: 4-Day

InterventionUnits on a scale (Mean)
Fluoride2.79
Fluoride/Triclosan2.82
Chlorhexidine Gluconate1.99

[back to top]

Gingivitis Score

"Gingivitis score (GI)= Units on a scale 0 to 3 (0 = no inflammation,~1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding. GI scored=sum of GI scores divided by the number of sites (gingival gum line around the tooth)scored." (NCT00761930)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
A- Placebo Comparator0.942
B - Active Comparator0.722
C - Experimental Toothpaste0.705

[back to top]

Dental Plaque

Quigley Hein Method: Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth. Plaque score= sum of all scores divided by the number of sites (teeth) scored. (NCT00761930)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
A- Placebo Comparator2.273
B - Active Comparator1.806
C - Experimental Toothpaste2.041

[back to top]

Bleeding Index (EIBI)

Eastman Interdental Bleeding Index Scores (EIBI) measures the number of interdental spaces that bleed, divided by number of interdental spaces studied to yield a score with a minimum of O and a maximum of 1 (0=no bleeding & 1= bleeding) The number of spots between teeth that bleed are divided by number of spots between teeth that are scored and may be expressed as a percent when multiplied by 100. (NCT00761930)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
A- Placebo Comparator0.325
B - Active Comparator0.164
C - Experimental Toothpaste0.141

[back to top]

Antimicrobial Species in Saliva(Sulfur Bacteria)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.1213
Active Comparator0.1556
Experimental-0.603

[back to top]

Antimicrobial Species in Tongue(Total Anaerobic)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0445
Active Comparator0.2691
Experimental0.0926

[back to top]

Antimicrobial Species in Plaque(Fusobacteria)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.2973
Active Comparator0.2703
Experimental-0.0095

[back to top]

Antimicrobial Species in Plaque(Actinomyces)

After 14 days of study product use, dental plaque was scraped from the subject's teeth. The plaque was placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo Toothpaste0.023
Active Comparator0.3881
Experimental0.0538

[back to top]

Antimicrobial Species in Tongue(Sulfur Bacteria)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.083
Active Comparator0.2065
Experimental-0.0248

[back to top]

Antimicrobial Species in Saliva(Oral Streptococci)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0436
Active Comparator0.1445
Experimental0.087

[back to top]

Antimicrobial Species in Saliva(Total Anaerobic)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0247
Active Comparator0.1505
Experimental0.05

[back to top]

Antimicrobial Species in Saliva(Actinomyces)

Saliva was collected, after 14 days of product use, by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.016
Active Comparator0.3209
Experimental0.1116

[back to top]

Antimicrobial Species in Saliva(Fusobacteria)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0096
Active Comparator0.194
Experimental0.0539

[back to top]

Antimicrobial Species in Plaque(Veillonella)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.0007
Active Comparator0.3658
Experimental0.0316

[back to top]

Antimicrobial Species in Plaque(Total Anaerobic)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0629
Active Comparator0.312
Experimental0.0762

[back to top]

Antimicrobial Species in Plaque(Oral Streptococci)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0848
Active Comparator0.2593
Experimental-0.0096

[back to top]

Antimicrobial Species in Tongue(Fusobacteria)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0742
Active Comparator0.377
Experimental0.1668

[back to top]

Antimicrobial Species in Tongue(Oral Streptococci)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.1284
Active Comparator0.2233
Experimental0.0525

[back to top]

Antimicrobial Species in Plaque(Sulfur Bacteria)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.0174
Active Comparator0.3083
Experimental-0.0416

[back to top]

Antimicrobial Species in Tongue(Veillonella)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.002
Active Comparator0.2724
Experimental-0.0424

[back to top]

Antimicrobial Species on the Cheek(Actinomyces)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.0099
Active Comparator0.2949
Experimental-0.1875

[back to top]

Antimicrobial Species on the Cheek(Fusobacteria)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0319
Active Comparator0.1887
Experimental0.111

[back to top]

Antimicrobial Species on the Cheek(Oral Streptococci)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.0126
Active Comparator0.2088
Experimental-0.0251

[back to top]

Antimicrobial Species on the Cheek(Total Anaerobic)

After 14 day of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0551
Active Comparator0.2009
Experimental-0.0531

[back to top]

Antimicrobial Species on the Cheek(Veillonella)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0732
Active Comparator0.2579
Experimental-0.0676

[back to top]

Antimicrobial Species on the Tongue(Actinomycetes)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.0132
Active Comparator0.2612
Experimental-0.0536

[back to top]

Antimicrobial Species in Saliva(Veillonella)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on veillonella Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo0.0167
Active Comparator0.3062
Experimental0.0901

[back to top]

Antimicrobial Species on the Cheek(Sulfur Bacteria)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar. (NCT00762177)
Timeframe: 14 days

Interventionlog CFU (Colony forming units) (Log Mean)
Placebo-0.1788
Active Comparator0.2036
Experimental-0.0815

[back to top]

ph of Dental Plaque After Sucrose Challenge

Panelists rinsed with toothpaste slurry (2 grams of toothpaste dissolved in 10 ml of water) waited 20 minutes and then rinsed with a 10% sucrose solution. Sucrose challenge is used to change the ph in the mouth and help determine if the toothpastes used in this study and control dental plaque growth. (NCT00762450)
Timeframe: 1 week

Interventionph of dental plaque (Mean)
Active Comparator4.88
Placebo - Silica Control5.04
Experimental Toothpaste4.98

[back to top]

Control Gingivitis in Adults

Gingivitis Index (GI) is described as Units on a scale 0 to 3 (0 = no inflammation,1 = Mild inflammation - slight change in color and little change in texture 2 = Moderate inflammation - moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding. GI score = Sum of all scores divided by the number of sites (teeth scored). (NCT00762515)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
A -Placebo Comparator0.54
B- Active Comparator0.63

[back to top]

Control Established Plaque in Adults

Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth. Total Plaque score=sum of all scores divided by the number of sites (teeth) scored. (NCT00762515)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
A -Placebo Comparator2.42
B- Active Comparator2.45

[back to top]

Bleeding on Probing (BOP)

Presence or absence of bleeding to manual probing as a dichotomous variable as follows: 0 = No bleeding within 10 seconds after probing, 1 = Bleeding within 10 seconds after probing. (NCT00762528)
Timeframe: 29 days

InterventionUnits on a scale (Mean)
Total Toothpaste0.24
Fluoride Toothpaste0.26

[back to top]

Gingival Index (GI)

"Gingival Index(GI)recorded on scale of 0-3 detailed below:~0=normal gingiva, 1=Mild inflammation(slight change in color, slight edema)no bleeding on palpation,2=Moderate inflammation(redness,edema,glazing)bleeding upon probing, 3=Severe inflammation(marked redness,edema)ulceration & tendency to spontaneously bleed" (NCT00762528)
Timeframe: 29 days

Interventionunits on a scale (Mean)
Total Toothpaste1.04
Fluoride Toothpaste1.01

[back to top]

8-iso-prostaglandinF2α (8-iso-PGF2α)

Inflammatory biomarker found in gingival crevicular fluid (GCF). Presence in GCF may indicate tissue damage as seen in periodontal disease. All GCF samples are collected onto filter paper strips (Pro Flow, Inc.) and the volume determined by Periotron 8000. Samples were placed in cryovial and labelled, then place into liquid nitrogen and stored at -180°C until analysis. (NCT00762528)
Timeframe: 29 days

Interventionpg/µl (Log Mean)
Total Toothpaste14.2
Fluoride Toothpaste15.2

[back to top]

Prostaglandin E2 (PGE2)

Inflammatory biomarker found in gingival crevicular fluid (GCF). Higher Levels found in GCF may be a factor in tissue destruction as seen in periodontal disease. All GCF samples are collected onto filter paper strips (Pro Flow, Inc.) and the volume determined by Periotron 8000. Samples were placed in cryovial and labelled, then place into liquid nitrogen and stored at -180°C until analysis. (NCT00762528)
Timeframe: 29 days

Interventionpg/µl (Log Mean)
Total Toothpaste5.8
Fluoride Toothpaste5.2

[back to top]

Nuclear Factor Kappa B Ligand (RANK-L)

Receptor activator found in gingival crevicular fluid (GCF). Presence in GCF may indicate tissue damage as seen in periodontal disease. All GCF samples are collected onto filter paper strips (Pro Flow, Inc.) and the volume determined by Periotron 8000. Samples were placed in cryovial and labelled, then place into liquid nitrogen and stored at -180°C until analysis. (NCT00762528)
Timeframe: 29 days

Interventionpg/µl (Log Mean)
Total Toothpaste4.5
Fluoride Toothpaste4.4

[back to top]

Interleukin - 1 Beta (IL-ß)

Inflammatory biomarkers found in gingival crevicular fluid (GCF) that may be a factor in oral tissue destruction as seen in periodontal disease. All GCF samples are collected onto filter paper strips (Pro Flow, Inc.) and the volume determined by Periotron 8000. Samples were placed in cryovial and labelled, then place into liquid nitrogen and stored at -180°C until analysis. (NCT00762528)
Timeframe: 29 days

Interventionpg/µl (Log Mean)
Total Toothpaste6.9
Fluoride Toothpaste6.6

[back to top]

Interleukin-6 (IL-6)

Inflammatory biomarker found in gingival crevicular fluid (GCF). Higher Levels found in GCF may be a factor in tissue destruction as seen in periodontal disease. All GCF samples are collected onto filter paper strips (Pro Flow, Inc.) and the volume determined by Periotron 8000. Samples were placed in cryovial and labelled, then place into liquid nitrogen and stored at -180°C until analysis. (NCT00762528)
Timeframe: 29 days

Interventionpg/µl (Log Mean)
Total Toothpaste2.8
Fluoride Toothpaste2.7

[back to top]

Dental Plaque Index (PI)

measurement of supragingival dental plaque on scale of 0-3. 0=No plaque in gingival area,1=a film of plaque adhering to the free gingival margin and the adjacent tooth,2=Moderate accumulation of soft deposits within the gingival pocket and on the gingival margin and/or adjacent tooth-visible by the naked eye, 3=Abundance of soft matter within the gingival pocket and/or gingival margin and adjacent tooth surfaces. (NCT00762528)
Timeframe: 29 days

InterventionUnits on a scale (Mean)
Total Toothpaste1.69
Fluoride Toothpaste1.65

[back to top]

P.Intermedia (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.007
B - Positive Control3.803

[back to top]

P.Intermedia (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.091
B - Positive Control3.853

[back to top]

P.Intermedia (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.329
B - Positive Control3.803

[back to top]

P.Intermedia (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.544
B - Positive Control3.853

[back to top]

A.Actinomycetemcomitans (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are Least means square (LSM)determined by baseline adjusted means including Standard Error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (Colony Forming Units) (Least Squares Mean)
A - Fluoride Only Control6.269
B - Positive Control5.002

[back to top]

A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implant. Data point is Least means square (LSM) determined by baseline adjusted means including Standard Error of Means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.814
B - Positive Control4.446

[back to top]

A.Actinomycetemcomitans (DNA Probe Analysis)- Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implant. Data point is Least means square (LSM) determined by baseline adjusted means including Standard Error of Means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.664
B - Positive Control4.339

[back to top]

A.Actinomycetemcomitans (DNA Probe Analysis)- Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data point is Least means square (LSM) determined by baseline adjusted means including Standard Error of Means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.201
B - Positive Control4.669

[back to top]

C.Rectus (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.46
B - Positive Control3.015

[back to top]

C.Rectus (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.318
B - Positive Control2.758

[back to top]

C.Rectus (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.69
B - Positive Control3.322

[back to top]

C.Rectus (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.578
B - Positive Control2.798

[back to top]

Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.391
B - Positive Control4.243

[back to top]

Capnocytophaga sp. (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.356
B - Positive Control4.268

[back to top]

Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.676
B - Positive Control4.526

[back to top]

Streptococci (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means )SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5
B - Positive Control3.263

[back to top]

E.Corrodens (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM)determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.21
B - Positive Control5.639

[back to top]

E.Corrodens (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM)determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.242
B - Positive Control5.482

[back to top]

E.Corrodens (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM)determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.47
B - Positive Control5.822

[back to top]

E.Corrodens (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM)determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.417
B - Positive Control5.682

[back to top]

E.Saburreum (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.012
B - Positive Control3.861

[back to top]

E.Saburreum (DNA Probe Analysis) - Dental Implant

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.733
B - Positive Control3.372

[back to top]

E.Saburreum (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.229
B - Positive Control4.385

[back to top]

E.Saburreum (DNA Probe Analysis)- Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM)detemined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.079
B - Positive Control3.571

[back to top]

F.Nucleatum (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM)determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.89
B - Positive Control3.637

[back to top]

F.Nucleatum (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM)determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.602
B - Positive Control2.425

[back to top]

F.Nucleatum (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error of means (SEM) (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.243
B - Positive Control3.405

[back to top]

F.Nucleatum (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM)determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.337
B - Positive Control4.403

[back to top]

Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth

Sulcus bleeding index for teeth is explained here. Gums around teeth are scored:0 = gingiva of normal texture & color, no bleeding;1 = gingiva normal, bleeds on probing;2 = bleeding on probing,change in color, no oedema; 3 = bleeding on probing,change in color, slight oedema;4 = bleeding on probing, change in color, obvious oedema;5=bleeding on probing, spontaneous bleeding, change in color, marked oedema. (NCT00762619)
Timeframe: 3 months

InterventionUnits on a scale (Mean)
A - Fluoride Control0.77
B - Postive Control0.51

[back to top]

Gingival Bleeding on Probing (BOP) Using Sulcus Bleeding Index for Teeth

Sulcus bleeding index for teeth is explained here. Gums around teeth are scored:0 = gingiva of normal texture & color, no bleeding;1 = gingiva normal, bleeds on probing;2 = bleeding on probing,change in color, no oedema;3 = bleeding on probing,change in color, slight oedema;4 = bleeding on probing,change in color, obvious oedema;5 = bleeding on probing, spontaneous bleeding,change in color,marked oedema. (NCT00762619)
Timeframe: 6 months

InterventionUnits on a scale (Mean)
A - Fluoride Control0.877
B - Postive Control0.53

[back to top]

Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants

Gingival bleeding on probing (BOP) using the modified sulcus bleeding index for implants. Scale equals 0 = No bleeding when periodontal probe is passed along the gingival margin;1 = Isolated bleeding spots visible;2 = Blood forms a confluent red line on the gingival margin;3 = Heavy or profuse bleeding. (NCT00762619)
Timeframe: 3 months

InterventionUnits on a scale (Mean)
A - Fluoride Control0.65
B - Postive Control0.48

[back to top]

Gingival Bleeding on Probing (BOP) Using the Modified Sulcus Bleeding Index for Implants

Gingival bleeding on probing (BOP) using the modified sulcus bleeding index for implants. Scale equals 0 = No bleeding when periodontal probe is passed along the gingival margin;1 = Isolated bleeding spots visible;2 = Blood forms a confluent red line on the gingival margin;3 = Heavy or profuse bleeding. (NCT00762619)
Timeframe: 6 months

InterventionUnits on a scale (Mean)
A - Fluoride Control0.81
B - Postive Control0.45

[back to top]

Löe-Silness Gingival Index Score (GI) - Natural Teeth

Gingivitis score(GI) is defined: 0 = Absence of inflammation,1 = Mild inflammation-slight change in color and little change in texture,2 = Moderate inflammation-moderate glazing,redness,edema & hypertrophy,3 = Severe inflammation-marked redness and hypertrophy tendency for spontaneous bleeding. Each tooth is scored on 6 surfaces:mesio-facial;2)mid-facial;3)disto-facial;4)mesio-lingual;5)mid-lingualand 6)disto-lingual. A whole mouth score = adding all the GI scores & dividing by the total of number of sites scored. 3rd molars and teeth with restorations or crowns will be excluded. (NCT00762619)
Timeframe: 3 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.3
B - Postive Control1.17

[back to top]

Löe-Silness Gingival Index Score (GI) - Natural Teeth

Gingivitis score(GI) is defined: 0 = Absence of inflammation,1 = Mild inflammation-slight change in color and little change in texture,2 = Moderate inflammation-moderate glazing,redness,edema & hypertrophy,3 = Severe inflammation-marked redness and hypertrophy tendency for spontaneous bleeding.Each tooth is scored on 6 surfaces:mesio-facial;2)mid-facial;3)disto-facial;4)mesio-lingual;5)mid-lingualand 6)disto-lingual. A whole mouth score = adding all the GI scores & dividing by the total of number of sites scored. 3rd molars and teeth with restorations or crowns will be excluded. (NCT00762619)
Timeframe: 6 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.29
B - Postive Control1.01

[back to top]

Löe-Silness Gingival Index Score (GI)- Dental Implants

Gingivitis Score (GI) is defined: 0 = Absence of inflammation,1 = Mild inflammation-slight change in color and little change in texture,2 = Moderate inflammation-moderate glazing,redness,edema & hypertrophy,3 = Severe inflammation-marked redness and hypertrophy tendency for spontaneous bleeding. Each tooth is scored on 6 surfaces:mesio-facial;2)mid-facial;3)disto-facial;4)mesio-lingual;5)mid-lingualand 6)disto-lingual. A whole mouth score=adding all the GI scores & dividing by the total of number of sites scored. 3rd molars and teeth with restorations or crowns will be excluded. (NCT00762619)
Timeframe: 6 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.24
B - Postive Control0.99

[back to top]

Löe-Silness Gingival Index Score (GI)- Dental Implants

Gingivitis Score (GI) is defined: 0 = Absence of inflammation,1=Mild inflammation-slight change in color and little change in texture,2 = Moderate inflammation-moderate glazing,redness,edema & hypertrophy,3 = Severe inflammation-marked redness and hypertrophy tendency for spontaneous bleeding. Each tooth is scored on 6 surfaces:mesio-facial;2)mid-facial;3)disto-facial;4)mesio-lingual;5)mid-lingualand 6)disto-lingual. A whole mouth score=adding all the GI scores & dividing by the total of number of sites scored. 3rd molars and teeth with restorations or crowns will be excluded. (NCT00762619)
Timeframe: 3 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.27
B - Postive Control1.12

[back to top]

Mombelli Plaque Index (mPI) for Dental Implants

"Modified Plaque Index (mPI) is a dental plaque scale as follows 0 = No plaque,~1 = Separate flecks of plaque at the cervical margin;2 = Plaque can be seen by naked eye.3 = Abundance of soft matter. The lower the number the less plaque is present on the tooth." (NCT00762619)
Timeframe: 3 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.62
B - Postive Control1.35

[back to top]

Mombelli Plaque Index (mPI) for Dental Implants

"Modified Plaque Index (mPI) is a dental plaque scale as follows 0 = No plaque,~1 = Separate flecks of plaque at the cervical margin;2 = Plaque can be seen by naked eye.3 = Abundance of soft matter. The lower the number the less plaque is present on the tooth." (NCT00762619)
Timeframe: 6 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.71
B - Postive Control1.45

[back to top]

Mombelli Plaque Index (mPI) for Natural Teeth

"Modified Plaque Index (mPI) is a Dental plaque scale as follows 0 = No plaque,~1 = Separate flecks of plaque at the cervical margin;2 = Plaque can be seen by naked eye.3 = Abundance of soft matter. The lower the number the less plaque is present on the tooth." (NCT00762619)
Timeframe: 6 months

Interventionunits on a scale (Mean)
A - Fluoride Control2.05
B - Postive Control1.73

[back to top]

Mombelli Plaque Index (mPI) for Natural Teeth

"Modified Plaque Index (mPI)is a Dental plaque scale as follows 0 = No plaque,~1 = Separate flecks of plaque at the cervical margin;2 = Plaque can be seen by naked eye.3 = Abundance of soft matter. The lower the number the less plaque is present on the tooth." (NCT00762619)
Timeframe: 3 months

Interventionunits on a scale (Mean)
A - Fluoride Control1.96
B - Postive Control1.82

[back to top]

Neissera sp. (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.405
B - Positive Control3.955

[back to top]

Neissera sp. (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.585
B - Positive Control4.415

[back to top]

Neissera sp. (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.638
B - Positive Control4.508

[back to top]

Neissera sp. (DNA Probe Analysis) Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.702
B - Positive Control4.658

[back to top]

P.Gingivalis (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error of means (SEM) (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.562
B - Positive Control4.642

[back to top]

P.Gingivalis (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error of means (SEM) (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.166
B - Positive Control5.183

[back to top]

Veillonella sp.(DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.746
B - Positive Control4.563

[back to top]

Veillonella sp.(DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error (SEM) (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.82
B - Positive Control4.927

[back to top]

Veillonella sp.(DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error (SEM) (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.364
B - Positive Control4.186

[back to top]

Veillonella sp.(DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error (SEM) (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.472
B - Positive Control4.485

[back to top]

T.Forsythia (DNA Probe Analysis)-Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.286
B - Positive Control4.926

[back to top]

T.Forsythia (DNA Probe Analysis)- Natural Teeth

14 microorganisms were identified via DNA probe analysis for both natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.408
B - Positive Control5.143

[back to top]

Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.644
B - Positive Control4.411

[back to top]

T.Forsythia (DNA Probe Analysis)- Dental Implants

14 microorganisms were identified via DNA probe analysis for both Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.08
B - Positive Control4.633

[back to top]

T.Forsythia (DNA Probe Analysis)- Dental Implants

14 microorganisms were identified via DNA probe analysis for both Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.19
B - Positive Control4.628

[back to top]

Streptococci (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means )SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.995
B - Positive Control4.495

[back to top]

Streptococci (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.867
B - Positive Control4.109

[back to top]

Streptococci (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means )SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.665
B - Positive Control2.404

[back to top]

Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.511
B - Positive Control5.237

[back to top]

Solobacterium (S.Moorei)(DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.081
B - Positive Control4.487

[back to top]

Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.046
B - Positive Control3.899

[back to top]

Solobacterium (S.Moorei)(DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.767
B - Positive Control4.701

[back to top]

P.Melaninogenica (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.066
B - Positive Control3.935

[back to top]

P.Melaninogenica (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for both natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.062
B - Positive Control3.691

[back to top]

P.Gingivalis (DNA Probe Analysis) - Natural Teeth

14 microorganisms were identified via DNA probe analysis for natural teeth. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM) (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control6.071
B - Positive Control4.951

[back to top]

P.Melaninogenica (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 6 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.387
B - Positive Control3.155

[back to top]

P.Melaninogenica (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) determined by using baseline adjusted means including standard error of means (SEM). (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control4.406
B - Positive Control3.363

[back to top]

P.Gingivalis (DNA Probe Analysis) - Dental Implants

14 microorganisms were identified via DNA probe analysis for Dental Implants. Data points are least means square (LSM) detemined by using baseline adjusted means including standard error of means (SEM) (NCT00762619)
Timeframe: 3 months

InterventionLog cfu (colony forming units) (Least Squares Mean)
A - Fluoride Only Control5.784
B - Positive Control4.926

[back to top]

IL-6 (Interleukin - 6)

Levels of Interleukin - 6 (GCF IL-6) found in blood drawn from subjects. Indication of systemic inflammation in the body.(weight in picograms) (NCT00762762)
Timeframe: 12 months

Interventionpg/ml (Mean)
Active Comparator1.93
Placebo Comparator2.89

[back to top]

High Sensitivity CRP (C-Reactive Protein)

CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. (NCT00762762)
Timeframe: 12 months

Interventionµg/ml (Mean)
Active Comparator14.94
Placebo Comparator10.76

[back to top]

HbA1c Levels in Blood

Blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). This test measures the glycated hemoglobin in the blood. (NCT00762762)
Timeframe: 12 months

Interventionpercentage of HbA1c levels in blood (Mean)
Triclosan/Copolymer/Fluoride Toothpaste11.42
Fluoride Mouthrinse10.81

[back to top]

HbA1c Levels in Blood

Blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). This test measures the glycated hemoglobin in the blood. (NCT00762762)
Timeframe: 12 months

Interventionpercentage of HbA1c levels (Mean)
Active Comparator11.42
Placebo Comparator10.81

[back to top]

C-Peptide

C-Peptide levels in blood indicate whether or not a person is producing insulin (NCT00762762)
Timeframe: 12 months

Interventionng/ml (Mean)
Active Comparator5.39
Placebo Comparator4.61

[back to top]

TNF-α (Tumor Necrosis Factor - Alpha)

Blood drawn from subjects to determine the level of TNF-α (Tumor necrosis factor - alpha). TNF-α is a pleiotropic inflammatory cytokine involved in systemic inflammation. (NCT00762762)
Timeframe: 12 months

Interventionpg/ml (Mean)
Active Comparator4.13
Placebo Comparator3.50

[back to top]

Triclosan Concentration in Dental Plaque

Triclosan is analyzed by gas chromatography (GC) with Atomic Emission Detection (480 nm) and quantitated by determining the ration of the peak height of triclosan to the peak height of an internal standard and relating the result to corresponding ratios of calibration standards. (NCT00762853)
Timeframe: 12 hours

Interventionppm levels of triclosan (Mean)
Fluoride Toothpaste (Placebo)0
Active Toothpaste1.8

[back to top]

Metabolite Associated With Inflammation (Lysine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.063873
B - Active Comparator1.09704

[back to top]

Metabolite Associated With Inflammation (Phenylalanine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.16994
B - Active Comparator1.057373

[back to top]

Metabolite Associated With Inflammation (Putrescine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.050398
B - Active Comparator0.74134

[back to top]

Metabolite Associated With Inflammation (Xanthine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present.Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.05189
B - Active Comparator1.011732

[back to top]

Metabolite Associated With Inflammation (Cadaverine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.119186
B - Active Comparator0.92077

[back to top]

Metabolite Associated With Inflammation (Choline)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.2264
B - Active Comparator1.169513

[back to top]

Metabolite Associated With Inflammation (Hypoxanthine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator0.76984
B - Active Comparator0.701628

[back to top]

Metabolite Associated With Inflammation (Inosine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.11183
B - Active Comparator0.84462

[back to top]

Metabolite Associated With Inflammation (Isoleucine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.20033
B - Active Comparator1.048449

[back to top]

Metabolite Associated With Inflammation (Leucine)

One of 10 inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with inflammation that could lead to gingivitis. The number is a quantitative, normalized ion count from a mass spectral instrument. The lower the number the less inflammation may be present. Data is after 6 weeks use of the study treatment. (NCT00763048)
Timeframe: 6 weeks

Interventionion count (Mean)
A - Control Comparator1.10064
B - Active Comparator1.018989

[back to top]

C-Peptide

C-Peptide levels in blood indicate whether or not a person is producing insulin. This peptide is usually found in equal levels to insulin. C-peptide levels measured as a means of distinguishing type 1 diabetes and type 2 diabetes. Blood is taken from each subject and C-Peptide levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). (NCT00763256)
Timeframe: 12 months

Interventionnmol/L (Mean)
Active Comparator1.20
B - Placebo Comparator1.04

[back to top]

Gingivitis Score (GI)

"Units on a scale 0 to 3 (0 = no inflammation,~1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)" (NCT00763256)
Timeframe: 12 months

InterventionUnits on a scale (Mean)
Active Comparator0.89
B - Placebo Comparator0.88

[back to top]

P. Gingivalis

Subgingival plaque samples were collected from all interproximal (mesial) sites and pooled prior to assessment. The samples will be analysed for the presence of P. gingivalis, using real time PCR to quantitate the numbers of bacteria. P. gingivalis is a non-motile, gram negative, anaerobic, pathogenic bacteria. It is linked to periodontal disease and causes collagen degradation. (NCT00763256)
Timeframe: 12 months

InterventionPg/ng DNA (Median)
Active Comparator209
B - Placebo Comparator22

[back to top]

High Sensitivity CRP (C-Reactive Protein)

CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. Blood is taken from each subject and CRP levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). (NCT00763256)
Timeframe: 12 months

Interventionmg/L (Mean)
Active Comparator6.16
B - Placebo Comparator5.37

[back to top]

HbA1c Levels in Blood

Glycated hemoglobin (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. In this study, blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). (NCT00763256)
Timeframe: 12 months

InterventionPercentage (Mean)
Active Comparator9.47
B - Placebo Comparator10.27

[back to top]

Air Blast Hypersensitivity (8 Week)

"Examiner rates the response to stimulation of hypersensitive teeth using a jet of air (constant stimulus on the basis of duration, pressure, temperature, distance from target). Response is rated based on the Schiff Cold Air Sensitivity Scale.This analog scale scores for the tooth is 0,1,2 or 3:0No subject response to stimulus1responds but will continue2responds and moves or requests discontinuation3Painful response to stimulus, discontinuation requested. The lower the score, the lower the hypersensitivity.Scores per study subject are recorded as mean scores of two hypersensitive teeth." (NCT00763269)
Timeframe: 8 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse0.89
B -Control Toothpaste1.80

[back to top]

Air Blast Hypersensitivity (4 Week)

"Examiner rates the response to stimulation of hypersensitive teeth using a jet of air (constant stimulus on the basis of duration, pressure, temperature, distance from target). Response is rated based on the Schiff Cold Air Sensitivity Scale.This analog scale scores for the tooth is 0,1,2 or 3:0No subject response to stimulus1responds but will continue2responds and moves or requests discontinuation3Painful response to stimulus, discontinuation requested. The lower the score, the lower the hypersensitivity.Scores per study subject are recorded as mean scores of two hypersensitive teeth." (NCT00763269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse1.61
B -Control Toothpaste2.18

[back to top]

Hypersensitivity Tactile(Yeaple Probe)

Measured with an electronic force sensing probe (Yeaple Probe): 10, 20, 30, 40, up to 50 grams of force are applied to hypersensitive tooth until pain elicited. Grams of force needed to elicit pain are recorded as hypersensitivity score for the tooth. For Tactile Hypersensitivity: The higher the score (the more grams of force needed to elicit a response of pain), the lower the hypersensitivity. Hypersensitivity scores on a per study subject basis are recorded as mean scores of two hypersensitive teeth (NCT00763269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse19.81
B -Control Toothpaste13.94

[back to top]

Hypersensitivity Tactile (Yeaple Probe)

Measured with an electronic force sensing probe (Yeaple Probe): 10, 20, 30, 40, up to 50 grams of force are applied to hypersensitive tooth until pain elicited. Grams of force needed to elicit pain are recorded as hypersensitivity score for the tooth. For Tactile Hypersensitivity: The higher the score (the more grams of force needed to elicit a response of pain), the lower the hypersensitivity. Hypersensitivity scores on a per study subject basis are recorded as mean scores of two hypersensitive teeth (NCT00763269)
Timeframe: 8 weeks

InterventionUnits on a scale (Mean)
A-Experimental Toothpatse31.90
B -Control Toothpaste17.28

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 90

Interventionscore on scale (Mean)
Chinese Silk Suture4.3
VICRYL* Plus Suture3.2

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 7

Interventionscore on scale (Mean)
Chinese Silk Suture1.4
VICRYL* Plus Suture0.9

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 5

Interventionscore on scale (Mean)
Chinese Silk Suture1.5
VICRYL* Plus Suture1.2

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 30

Interventionscore on scale (Mean)
Chinese Silk Suture4.6
VICRYL* Plus Suture3.7

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 3

Interventionscore on scale (Mean)
Chinese Silk Suture1.6
VICRYL* Plus Suture1.2

[back to top]

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst) (NCT00768222)
Timeframe: Day 12

Interventionscore on scale (Mean)
Chinese Silk Suture4.6
VICRYL* Plus Suture3.3

[back to top]

Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)

Post-operative cosmetic outcome assessed on surgical site photographs by an independent blinded central assessor using a validated 100 mm visual analog scale, with 0 representing the worst possible scar and 100 representing the best possible scar (NCT00768222)
Timeframe: 30 days (+/- 5) post-operative

Interventionscore on scale (Mean)
Chinese Silk Suture45.4
VICRYL* Plus Suture67.2

[back to top]

Mean Cosmetic Outcome Score on Modified Hollander Scale

Post-operative cosmetic outcome assessed on surgical site by investigator using the modified Hollander Cosmetic Scale (mHCS) with 0 representing worst and 6 representing best, calculated by adding the individual scores on each of 6 categories (step-off borders, contour irregularities, wound margin separation, edge inversion, excessive inflammation, and overall appearance (NCT00768222)
Timeframe: 30 days

Interventionscore on scale (Mean)
Chinese Silk Suture5.0
VICRYL* Plus Suture5.7

[back to top]

Mean Cosmetic Outcome Score on Modified Hollander Scale

Post-operative cosmetic outcome assessed on surgical site by investigator using the modified Hollander Cosmetic Scale (mHCS) with 0 representing worst and 6 representing best, calculated by adding the individual scores on each of 6 categories (step-off borders, contour irregularities, wound margin separation, edge inversion, excessive inflammation, and overall appearance (NCT00768222)
Timeframe: 12 days

Interventionscore on scale (Mean)
Chinese Silk Suture5.2
VICRYL* Plus Suture5.7

[back to top]

Plaque Index

Plaque Index score scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque,3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT00926029)
Timeframe: 6 weeks

InterventionUnits on a scale (Mean)
Placebo Control0.91
Positive Control0.84
Experimental1.77

[back to top]

Gingivitis Index

Gingivitis score- scale 0 to 3 (0 = no inflammation,1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT00926029)
Timeframe: 6 Weeks

InterventionUnits on a scale (Mean)
Placebo Control0.63
Positive Control0.51
Experimental0.98

[back to top]

Gingivitis Index

"Units on a scale 0 to 3 (0 = no inflammation ,~1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing.~3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)" (NCT00926328)
Timeframe: 6 months

InterventionUnits on a scale (Mean)
Experimental Treatment1.00
Placebo Control1.27

[back to top]

Plaque Index

Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT00926328)
Timeframe: 6 Months

InterventionUnits on a scale (Mean)
Experimental Treatment2.22
Placebo Control2.88

[back to top]

Level of Gingival Crevicular Fluid Interleukin - 6(GCF IL-6) at 2 Hours

Levels of Gingival crevicular fluid Interleukin - 6 (GCF IL-6) (weight in micrograms) (NCT00941668)
Timeframe: 4 weeks

InterventionMicrograms (Mean)
Total Toothpaste (Active)12.8
Colgate Cavity Protection (Placebo)21.3

[back to top]

Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours

Levels of Gingival crevicular fluid Interleukin - 1 (GCF IL-1)(weight in micrograms) (NCT00941668)
Timeframe: 4 weeks

InterventionMicrograms (Mean)
Total Toothpaste (Active)492.2
Colgate Cavity Protection (Placebo)326.3

[back to top]

Plaque Index

Plaque score scale: Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT00966953)
Timeframe: 8 weeks

InterventionUnits on a scale (Mean)
Fluoride Only2.45
Total/Whitening2.22
Herbal Extract Toothpaste2.54
Herbal Extract Toothpaste2.56

[back to top]

CFU (Colony Forming Units)

Total number of salivary bacterial colony forming units (lower number = less colonies present) (NCT00981825)
Timeframe: 4 hours

Interventionnumber of colony forming units (Mean)
Fluoride Toothpaste (Control)7.18
Triclosan/Fluoride Toothpaste6.94

[back to top]

Plaque Index

Plaque scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque,3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT01014143)
Timeframe: Four days

InterventionUnits on a scale (Mean)
Fluoride Toothpaste2.63
Total Toothpaste2.65
Chlorhexidine Oral Rinse1.23

[back to top]

Plaque Index

Plaque score is Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT01024738)
Timeframe: 4 Days

InterventionUnits on a scale (Mean)
Fluoride Toothpaste3.31
Total Toothpaste3.31
Chlorhexidine Oral Rinse2.91

[back to top]

Mean Pocket Depth

Measurement scale: 0 millimeter measurement= no pocket depth. 3, 4, 5, & 6 millimeter are indications of deeper Pocket depth. (NCT01072201)
Timeframe: 6 Months

InterventionMillimeters (Mean)
Total Toothpaste4.4
Ultrabrite Toothpaste4.5

[back to top]

Mean Percentage of Plaque Scores

Mean Percentage (%) of dental plaque on all tooth surfaces, including implants and natural teeth. Plaque Scale is 0=no plaque and 1= dental plaque present. Percentage is derived from sum of all plaque scores divided by the number of tooth surfaces scored. (NCT01072201)
Timeframe: 6 Months

Interventionpercentage of dental plaque (Mean)
Total Toothpaste13.2
Ultrabrite Toothpaste16.0

[back to top]

Bleeding on Probing

Percentage of Bleeding Scale: The bleeding sites are identified by either a 0 or 1. (0=no bleeding & 1= bleeding) The number of spots between teeth that bleed are divided by number of spots between teeth that are scored. (NCT01072201)
Timeframe: 6 months

InterventionPercentage of bleeding sites (Mean)
Total Toothpaste53.8
Ultrabrite Toothpaste52.3

[back to top]

Detect Presence of Allergy or Skin Reaction by the Antiseptic Application

"135 units of measurement to test two antiseptics and two controls. Principal unit of measurement: four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites.~All volunteers was provided with a neutral soap without antiseptics for use of two weeks. 2% chlorhexidine in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol, Deionized water redistilled and Scrub the skin without prior application of any substance was tested. We prepared four skin's areas of 25 cm2, two in each forearm. The solution remained on the skin for 60s, 3h and 24h.~Presence of allergy or any skin reaction at 24 hours after the antiseptic application." (NCT01762904)
Timeframe: 24 hours

Interventionparticipants (Median)
Whole Group of 135 Units of Measurement0

[back to top]

Evaluate the Effect on the Skin Flora Application Process of Antiseptics by Sterile Swab

"135 units of measurement to test two controls. Principal unit of measurement: four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites.~All volunteers was provided with a neutral soap without antiseptics for use of two weeks. Deionized water redistilled (Control 2: Control with scrub) and Scrub the skin without prior application of any substance (Control1: Control without scrub) was tested. Were prepared two skin's areas of 25 cm2 randomly selected. The solution remained on the skin for 60s, 3h and 24h.~Cultures was taken with a scrub-cup of 5 cm2 pressed over the skin, added a 3 mL of culture broth. The skin was scrub with a sterile rubber policeman for 1 minute and the procedure conducted once again. Both aliquots came together in a sterile tube, a sample of 50 microliters were spread in a plate containing a neutralizing agar and were incubated at 35°C for 24 h." (NCT01762904)
Timeframe: 24 hrs

Intervention(CFU/cm2) (Median)
Control 1: without scrub 0 hControl 2: scrub with Deionized water redisti 0 hControl 1: without scrub 3 hControl 2: scrub with Deionized water redisti 3 hControl 1: without scrub 24 hControl 2: scrub with Deionized water redisti 24 h
Whole Group of 135 Units of Measurement4802162889628896

[back to top]

Evaluate the Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Administered Topically

"135 determinations to evaluate residual effect of 2% chlorhexidine in 70% isopropyl alcohol.~All volunteers was provided with a neutral soap without antiseptics for use of two weeks. 2% chlorhexidine in 70% isopropyl alcohol was tested. Were prepared the skin area of 25 cm2 randomly selected. The solution remained on the skin for 60s, 3h and 24h, everyone on different days.~Cultures was taken with a scrub-cup of 5 cm2 pressed over the skin, added a 3 mL of culture broth. The skin was scrub with a sterile rubber policeman for 1 minute and the procedure conducted once again. Both aliquots came together in a sterile tube, a sample of 50 microliters were spread in a plate containing a neutralizing agar and were incubated at 35°C for 24 h." (NCT01762904)
Timeframe: 24 hours

Intervention(CFU/cm2) (Median)
0 h3 h24 h
Whole Group of 135 Units of Measurement244824

[back to top]

Evaluate the Residual Effect of Triclosan 1% / Isopropyl Alcohol 70% Administered Topically.

"135 determinations to test 1% triclosan in 70% isopropyl alcohol.~All volunteers was provided with a neutral soap without antiseptics for use of two weeks. 1% triclosan in 70% isopropyl alcohol was tested. Were prepared the skin area of 25 cm2 randomly selected. The solution remained on the skin for 60s, 3h and 24h, everyone on different days.~Cultures was taken with a scrub-cup of 5 cm2 pressed over the skin, added a 3 mL of culture broth. The skin was scrub with a sterile rubber policeman for 1 minute and the procedure conducted once again. Both aliquots came together in a sterile tube, a sample of 50 microliters were spread in a plate containing a neutralizing agar and were incubated at 35°C for 24 h." (NCT01762904)
Timeframe: 24 hours

Intervention(CFU/cm2) (Median)
0 h3 h24 h
Whole Group of 135 Units of Measurement484896

[back to top]

Change From Baseline in Gingival Index (Loe & Silness 1963) to Day 35

Loe & Silness 1963 is a score of 0-3 with 0 = Absence of inflammation, 1 = Mild inflammation, slight change in color and texture, 2 = Moderate inflammation, glazing, redness, edema and hypertrophy, 3 = Severe inflammation, redness and hypertrophy, ulceration. This index was used at days 0, 14, 21 and 35. (NCT01799226)
Timeframe: Baseline to 35 Days

,
Interventionunits on a scale (Mean)
Gingival index BaselineGingival index Day 14Gingival index Day 21Gingival index Day 35
Control Arm0.251.331.560.39
Test Arm0.321.381.520.47

[back to top]

Change From Baseline in Plaque Index (Silness & Loe 1964) to Day 35

Silness & Loe 1964 is a score of 0-3 with 0 = No plaque, 1 = A film of plaque adhering to free gingival margin and adjacent area of tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface, 2 = Moderate accumulation of soft deposits within the gingival pocket, or on the tooth and gingival margin, which can be seen with the naked eye, 3 = Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin. This index was used at days 0, 14, 21 and 35. (NCT01799226)
Timeframe: Baseline to 35 Days

,
Interventionunits on a scale (Mean)
Plaque index BaselinePlaque index Day 14Plaque index Day 21Plaque index Day 35
Control Arm0.371.241.840.45
Test Arm0.441.491.810.57

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Regimen 12.78
Regimen 22.79
Regimen 3 - Control Group3.34

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Regimen 12.42
Regimen 22.59
Regimen 3 - Control Group3.38

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Regimen 13.33
Regimen 23.19
Regimen 3 - Control Group3.31

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Regimen 11.19
Regimen 21.30
Regimen 3 - Control Group1.44

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Regimen 11.03
Regimen 21.21
Regimen 3 - Control Group1.46

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Regimen 11.40
Regimen 21.40
Regimen 3 - Control Group1.44

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Total Toothpaste3.42
Toothpaste + Mouthwash3.69
Control Group3.73

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.05
Toothpaste + Mouthwash1.15
Control Group1.24

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Total Toothpaste3.91
Toothpaste + Mouthwash3.86
Control Group3.84

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Total Toothpaste1.38
Toothpaste + Mouthwash1.35
Control Group1.41

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.05
Toothpaste + Mouthwash1.15
Control Group1.24

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.15
Toothpaste + Mouthwash1.20
Control Group1.30

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Toothpaste2.26
Toothpaste + Mouthwash2.42
Fluoride Only Toothpaste + Mouthwash2.66

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Toothpaste1.84
Toothpaste + Mouthwash1.86
Fluoride Only Toothpaste + Mouthwash2.37

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Toothpaste3.33
Toothpaste + Mouthwash3.22
Fluoride Only Toothpaste + Mouthwash3.34

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Toothpaste1.48
Toothpaste + Mouthwash1.65
Fluoride Only Toothpaste + Mouthwash1.89

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Toothpaste1.17
Toothpaste + Mouthwash1.18
Fluoride Only Toothpaste + Mouthwash1.85

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Toothpaste2.18
Toothpaste + Mouthwash2.17
Fluoride Only Toothpaste + Mouthwash2.22

[back to top]